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Abstract 
Dopamine (DA) is central to movement, reward, learning, sleep, and anxiety. The 
dopamine transporter (DAT) spatially and temporally controls extracellular 
dopamine levels by taking DA back up into the presynaptic neuron following 
evoked release. Multiple lines of evidence from studies using pharmacological 
DAT blockade or genetic DAT deletion demonstrate that DAT availability at the 
plasma membrane is required for maintenance of homeostatic DA levels. 
Therefore, intrinsic mechanisms that regulate the transporter’s availability at the 
plasma membrane may directly impact downstream DA signaling cascades and 
DA-dependent behaviors. Acute, regulated DAT internalization in response to 
protein kinase C (PKC) activation has been well documented, however the 
physiological importance of this mechanism remains untested. Due to DAT’s 
critical role in regulating DA levels, it is essential to understand mechanisms that 
acutely regulate DAT function and surface expression, and further, how these 
mechanisms contribute to DA related behaviors. 
 
DAT has intracellular amino and carboxy termini, which contain domains for 
transporter phosphorylation, recruitment to and from the plasma membrane, and 
sites for protein-protein interactions. To test whether these domains work 
synergistically for DAT function and regulated endocytosis I made DAT/SERT 
chimeras, in which I switched DAT’s amino, carboxy, or both termini with that of 
SERT, a homologous transporter with highly divergent intracellular domains. I 
 	 ix 
demonstrated that DAT’s amino and carboxy termini synergistically contribute to 
substrate and select competitive inhibitor affinities. Additionally, I demonstrated 
that the amino terminus is required for PKC-stimulated DAT endocytosis, and 
that both N- and C-termini are required for downstream Ack1-dependent 
regulation of DAT endocytosis.  
 
To test the physiological importance of PKC-stimulated DAT endocytosis in vivo, 
I knocked down Rin, a GTPase required for PKC-stimulated DAT trafficking. This 
study was the first to achieve AAV-mediated, conditional, and inducible gene 
silencing in neurons. Using this AAV approach, I demonstrated a critical role for 
Rin GTPase signaling and DAT trafficking in both anxiety and locomotor 
response to cocaine. 
 
Taken together, this thesis 1) adds to the understanding of DAT functional and 
endocytic mechanisms and 2) is the first to report the physiological impact of Rin 
signaling and DAT endocytosis in DA behavior.  
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Chapter I 
Introduction 
I.A Dopaminergic Signaling 
Dopamine (DA) is a catecholamine neurotransmitter required for movement, 
reward, learning, motivation, and anxiety (Wise, 2004; Schultz, 2007; Zweifel et 
al., 2011; Russo and Nestler, 2013). DA dysregulation is associated with 
Parkinson’s disease (PD), attention deficit hyperactivity disorder (ADHD), and 
addictive disorders (Iversen and Iversen, 2007; Sulzer, 2011). Therefore, it is 
necessary to understand mechanisms that regulate DA and its associated 
signaling cascades. DA is synthesized from its precursor, tyrosine, through an 
enzymatic pathway that was initially described by Hermann Blaschko in 1939. In 
the first, rate-limiting step, tyrosine hydroxylase (TH) converts tyrosine to L-
DOPA. Next, aromatic L-amino acid decarboxylase converts L-DOPA to 
dopamine (Blaschko, 1952; Molinoff and Axelrod, 1971). DA was originally 
hypothesized to serve solely as a precursor to norepinephrine (NE). However, 
Arvid Carlsson and colleagues discovered that DA is in fact a neurotransmitter 
(Carlsson et al., 1957; Carlsson et al., 1958). They rescued reserpine-induced 
akinesia in mice and rabbits with a L-DOPA treatment. This resulted in an 
increase of DA without concomitant NE increase, demonstrating that DA is in fact 
a neurotransmitter. Carlsson also described DA’s profile throughout the brain and 
showed that it is concentrated in the basal ganglia (Carlsson, 1993).  
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Basal ganglia brain structures include the striatum, pallidum, subthalamic 
nucleus, substantia nigra, and ventral tegmental area (VTA) (Groenewegen, 
2003). The striatum is the largest basal ganglia nucleus, and it is subdivided into 
dorsal (caudate nucleus and putamen) and ventral (nucleus accumbens, NAc) 
regions. The dorsal striatum (DS) primarily receives DAergic innervation from the 
substantia nigra pars compacta (SNc). The SNc to DS pathway (nigrostriatal 
pathway) is commonly associated with motor planning and voluntary movement.  
NAc receives DAergic innervation from the VTA (mesolimbic pathway), and this 
pathway is commonly associated with reward-related learning and motivated 
behavior (Burke et al., 2017).  
 
The striatum is a heterogeneous hub of connections. In addition to DAergic 
inputs from VTA and SNc, it receives glutamatergic inputs from cortical, thalamic, 
and limbic regions (Burke et al., 2017). The principle striatal neurons are the 
medium spiny neurons (MSNs), which make up approximately 95% of total 
striatal neurons. The remaining striatal neurons are GABAergic and cholinergic 
interneurons. The MSNs are classically subdivided into two groups based upon 
the DA receptors they express (D1R vs. D2R) and structures to which they 
project. The D1-like receptors are Gs/olf coupled receptors and include D1 and D5, 
whereas the D2-like receptors are Gi/o coupled and include D2, D3, and D4 
(Gerfen and Surmeier, 2011). In a simplified model of MSN signaling, D1R- 
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expressing MSNs project through the basal ganglia’s “direct pathway” to 
disinhibit thalamic neurons to promote behavior. In contrast, the D2R expressing 
MSNs use the “indirect pathway” to inhibit basal ganglia output nuclei, and 
reduce behavioral output (Graybiel, 2000; Gerfen and Surmeier, 2011).  
 
Dopamine impacts both direct and indirect pathways by modulating MSN 
excitability and synaptic plasticity at glutamatergic terminals. MSNs are quiescent 
without glutamatergic input. DA receptor activation alters voltage-dependent ion 
channel properties in the MSN (Kreitzer and Malenka, 2008; Gerfen and 
Surmeier, 2011). This modulation is slow (order of seconds) compared to fast 
excitatory glutamatergic signaling. Additionally, DA acts upon afferent 
glutamatergic terminals that project to the striatum. D1R activity in glutamatergic 
terminals suppresses excitatory signaling onto the MSN (Nicola et al., 2000). 
Taken together, DA signaling within the striatum is critical to shape excitatory 
input onto MSNs, which signal through both direct and indirect pathways to 
regulate behaviors such as locomotor activity and reward. Therefore, 
mechanisms that alter DA signaling within the synapse can shape excitatory 
signaling at both pre- and post-synaptic sites. DAergic terminals express the 
cocaine- and amphetamine-sensitive DA transporter (DAT), which regulates 
extracellular DA levels through presynaptic reuptake. Here, I provide evidence 
suggesting that DAT is required for DAergic homeostasis. 
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I.B Dopamine transporter (DAT) 
Julius Axelrod first discovered catecholamine reuptake, by observing 
radiolabeled epinephrine and norepinephrine accumulation in rodent tissues 
(Axelrod et al., 1959; Whitby et al., 1961; Iversen, 2000). Snyder and Coyle 
demonstrated that distinct transporters exist for DA (DAT) and NE (NET) (Coyle 
and Snyder, 1969). However, the monoamine transporter field began to 
accelerate greatly when clones were isolated for DAT, NET, and SERT (5HT 
transporter) (Blakely et al., 1991; Giros et al., 1991; Kilty et al., 1991; Pacholczyk 
et al., 1991). DAT, NET, and SERT belong to the Solute Carrier 6 (SLC6) gene 
family, which also includes other Na+/Cl--coupled transporters for GABA and 
glycine, among others (Kristensen et al., 2011). These transporters use Na+ and 
Cl- co-transport down their concentration gradients to drive substrate transport. 
DAT transports DA into the presynaptic neuron using an alternating access 
mechanism, in which DAT cycles between outward facing to an inward facing 
states. DA binds to DAT in the outward facing state, and DAT undergoes 
conformational changes that expose DA to the intracellular milieu where it is 
released. (Forrest and Rudnick, 2009). 
 
SLC6 structural elements include twelve transmembrane spanning domains, a 
large, glycosylated extracellular loop (EL2), and intracellular N- and C-termini. 
While these elements were predicted topologically (Blakely et al., 1991; Kilty et 
al., 1991; Pacholczyk et al., 1991; Chen and Reith, 2000), structures for the 
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bacterial homolog leucine transporter (LeuT) (Yamashita et al., 2005) and 
Drosophila melanogaster DAT (dDAT) (Penmatsa et al., 2013) confirmed these 
findings. Moreover, dDAT structure revealed elements that are specific the 
eukaryotic monoamine transporter, such as a kink in the DAT C-terminus, next to 
the plasma membrane. This kink causes a C-terminal helical structure to create a 
“gate” along the intracellular face. Little is known about the N-terminal structure 
and the distal C-terminal structure due to their highly disordered nature. 
However, it is known that the intracellular N- and C-termini serve as sites for 
multiple posttranslational modifications and protein binding sites, and their 
importance in DAT regulation will be discussed in Chapters II and III. 
 
DAT Proteome 
As stated previously, DAT’s N- and C-termini serve as scaffolds for DAT-
associated proteins. These DAT-associated complexes are critical for regulating 
DAT function. While numerous studies have identified DAT-associated proteins, 
the functional implication resulting from each protein’s association with DAT has 
been characterized to varying extent. Table I-1 summarizes known DAT-
associated proteins, their DAT binding domains, and functional implications for 
the DAT-association. Taken as a whole, it demonstrates that DAT-associated 
molecules are required for membrane targeting, trafficking, and forward/reverse 
DA transport. This suggests that DAT function is tightly regulated through a DAT-
associated complex. Some DAT-associated molecules have been and/or will be 
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discussed further within this introduction including D2R (Bolan et al., 2007; Lee et 
al., 2007), Rin (Navaroli et al., 2011), CaMKIIa (Fog et al., 2006b; Rickhag et al., 
2013a), KOR (Kivell et al., 2014), Gbg (Garcia-Olivares et al., 2013; Garcia-
Olivares et al., 2017), PIP2 (Hamilton et al., 2014; Khelashvili et al., 2015a; 
Khelashvili et al., 2015b; Khelashvili and Weinstein, 2015), Syn1A (Lee et al., 
2004; Binda et al., 2008; Cartier et al., 2015), and Flot-1 (Cremona et al., 2011; 
Sorkina et al., 2013). Given that DAT N- and C-termini serve as sites for multiple 
protein interactions, it raises the hypothesis that these two terminal domains 
collectively create a DAT-binding scaffold. In Chapter III, I report tools for 
investigating DAT-associated proteins to further test how the N- and C-termini 
synergistically create a DAT associated regulatory complex.  
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Table I-1 
DAT-associated proteins/lipids 
Protein 
N-Terminus C-terminus Means of 
discovery 
Functional 
Implication Reference 
Association Residues Association Residues 
                
⍺- synuclein No - Yes 598-620 Y2H, Co-IP, FRET Increased Vmax, Increased AMPH-stimulated efflux Lee 2001, Butler 2015 
14-3-3ζ N.D. - N.D. - Co-IP 
N.D., 14-3-3ζ mice 
have less DAT 
protein 
Ramshaw 
2013 
CaMKII⍺ No* - Yes 612-617 Y2H, Co-IP, GST-pulldown Required for AMPH-stimulated DA efflux, *N-terminus is 
CaMKIIa substrate 
Fog 2006, 
Rickhag 
2013 
Carboxypeptidase 
E No - Yes 583-620 
Y2H, Co-IP, GST-
pulldown Increased Vmax Zhang 2009 
Ctr9 N.D. - Yes 577-579 Y2H, Co-IP, GST-pulldown Increased Vmax 
De Gois 
2015 
D2R Yes1/No2 1-151/-2 No - 
Co-IP, GST-
pulldown1/FlagΔ1-
55 DAT, co-IP2 
Promote DAT PM 
insertion and 
increased DA uptake 
Lee 20071/ 
Bolan 20072 
DJ-1 No - No - Co-IP, GST-pulldown 
Associates with DAT 
IL4, Increased DA 
uptake 
Luk 2015 
Epsin/Eps5 N.D. - N.D. - siRNA screen, Co-IP 
Required for PKC-
stimulated 
internalization 
Sorkina 2006 
Flot-1 N.D. - N.D. - Co-IP 
Required for PKC-
stimulated 
internalization and 
AMPH stimulated 
efflux3/Not required 
for PKC stimulated 
internalization4 
Cremona 
20113/ 
Sorkin 20134 
 
GPR37 N.D. - N.D. - Co-IP reduced Vmax 
Marazziti 
2007 
Gβγ No - Yes 582-596 
Co-IP, GST-
pulldown, Far 
Western 
Reduced Vmax, 
Promotes efflux 
Garcia-
Olivares 
2013, 2017 
Hic5 No - Yes 561-590 Y2H, Co-IP, GST-pulldown Reduced Vmax 
Carneiro 
2002 
KOR N.D. - N.D. - Co-IP, FRET 
Increased Vmax, 
increased surface 
expression 
Kivell 2014 
NEDD4-2 N.D. - N.D. - siRNA screen, Co-IP 
Required for PKC-
stimulated 
internalization 
Sorkina 2006 
Parkin N.D. - Yes - Co-IP/Co-IP, GST-pulldown 
Increased Vmax and 
surface 
expression5/Reduced 
Vmax, competes with ⍺- synuclein for 
binding6 
Jiang 20045/ 
Moszczynska 
20076 
PICK1 No - Yes 617-620 Y2H, Co-IP 
Increased Vmax, 
Required for PM 
insertion 
Torres 2001, 
Madsen 
2012,  
Wu 2017 
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PIP2 Yes 3,5,19,27,35,51 N.D. - 
PIP2 sensor, Co-
IP, GST-
pulldown, 
Molecular 
dynamic 
simulation 
Promotes AMPH-
stimulated DA efflux, 
Reduced AMPH-
stimulated locomotor 
activity in Drosophila 
Hamilton 
2014, 
Khelashvili 
2015 
PKCb N.D. - N.D. - Co-IP 
Increased AMPH-
stimulated efflux, 
Increased Vmax 
Johnson 
2005, Chen 
2009 
Rack1 Yes - N.D. - Y2H - 
Lee 2004, 
Franekova 
2008 
Rin N.D. - Yes 587-596 Y2H, FRET 
Required for PKC-
stimulated 
internalization 
Navaroli 
2011 
Syn1A Yes 1-33 N.D. - Y2H, Co-IP, GST-pulldown 
Reduced Vmax, 
Increased AMPH 
stimulated efflux 
Binda 2008, 
Lee 2004, 
Cervinski 
2010 
Synaptogyrin-3 Yes - No - 
mbSUS, Co-IP, 
FRET, GST-
pulldown 
Increased Vmax Egana 2009 
1,2Discrepancy regarding D2R. 1Finding from Lee et al., 2007. 2Finding from Bolan et al., 2007. 
3,4Discrepancy regarding Flotillin. 3Finding from Cremona et al., 2011. 4Finding from Sorkina et al., 2013. 
5,6Discrepancy regarding Parkin. 5Finding from Jiang et al., 2004. 6Finding from Moszczynska et al., 2007.  
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DAT and psychostimulants 
DAT is the molecular target for psychostimulants and their analogs, therapeutic 
agents, and neurotoxins. Select DAT inhibitors and their respective Ki values are 
listed in Table II-1 (Sweeney et al., 2017). Cocaine was originally described as a 
DA reuptake inhibitor using radioligand binding assays (Ritz et al., 1987). 
Cocaine binds the monoamine transporters, DAT, NET, and SERT, with 
equimolar affinity, and at high doses, cocaine inhibits voltage gated sodium 
channels (Reith et al., 1986). Multiple cocaine analogs have been developed with 
enhanced affinity for specific monoamine transporters. For example, WIN35,428 
( b-CFT) binds DAT with approximately 15x higher potency than cocaine, and it 
displays slight selectivity for DAT and NET over SERT (Ki = 27, 33, and 133nM 
respectively) (Eshleman et al., 1999; Kristensen et al., 2011; Sweeney et al., 
2017).  
 
AMPH is a psychostimulant that disrupts DAT function at numerous levels 
(Sulzer et al., 2005b). First, AMPH is a competitive DAT substrate (Sitte et al., 
1998). It competes with extracellular DA for DAT binding sites, and is then 
translocated in the cytosol. AMPH is also a vesicular monoamine transporter 
(VMAT) substrate and, once in the cytosol, AMPH blocks DA repackaging into 
vesicles. Further, once translocated into vesicles, AMPH serves as a weak base, 
therefore disrupting the proton gradient necessary for DA vesicular reuptake 
(Sulzer and Rayport, 1990; Sulzer et al., 1993; Freyberg et al., 2016). Both direct 
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VMAT blockade and proton gradient disruption result in increased cytosolic DA 
accumulation, which promotes nonvesicular DA release, or efflux, through DAT. 
AMPH transitions DAT from an “efflux reluctant” state to an “efflux willing” state 
without interfering with forward transport mechanisms (Khoshbouei et al., 2004). 
The “willing” state requires AMPH-induced increases in intracellular Na+ and Ca2+ 
(Khoshbouei et al., 2003; Gnegy et al., 2004). Additionally, N-terminal DAT 
phosphorylation is required for AMPH-stimulated efflux (Khoshbouei et al., 2004). 
AMPH promotes active CaMKIIa binding to DAT’s C-terminus, which in turn 
results in phosphorylated N-terminal serines (Fog et al., 2006a; Rickhag et al., 
2013a). Additionally, AMPH-stimulated efflux requires PKCb activity as 
demonstrated with PKCb inhibitors and PKCb-/- mice. (Johnson et al., 2005; 
Zestos et al., 2016). AMPH also elicits DAT internalization in a PKC-independent 
mechanism (Saunders et al., 2000; Boudanova et al., 2008a). The Gnegy group 
reported that upon initial exposure to AMPH (<2min), DAT inserts into the plasma 
membrane; however, following longer treatments with AMPH, (10-30 min), DAT 
sequesters from the plasma membrane through rapid endocytosis (Chen et al., 
2009). Below, I will discuss AMPH-stimulated efflux mechanism in detail in 
addition to regulated DAT endocytic mechanisms.  
 
I.C Dopamine Transporter Endocytic Trafficking 
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Membrane trafficking is a central mechanism that exerts significant control over 
synaptic transmission in the CNS. It is required for signal transduction (Sorkin 
and Von Zastrow, 2002), AMPA receptor turnover and synaptic plasticity 
(Malinow and Malenka, 2002; Bredt and Nicoll, 2003; Kennedy and Ehlers, 
2006), and  synaptic vesicle biogenesis (Hannah et al., 1999; Buckley et al., 
2000). Much like receptors involved in synaptic transmission, DAT undergoes 
regulated trafficking. While we know much about regulated DAT trafficking 
mechanisms, the physiological importance of regulated DAT trafficking remains 
unknown. Here I present what is known about regulated DAT trafficking, and in 
Chapter IV, I will test the physiological importance behind a known trafficking 
mechanism.  
 
Constitutive DAT internalization 
At steady state, DAT internalizes and recycles to the plasma membrane. DAT 
expression in intracellular compartments at steady state was initially observed 
using electron microscopy in SN, VTA, striatum, and NAc (Nirenberg et al., 1996; 
Hersch et al., 1997; Nirenberg et al., 1997b; Nirenberg et al., 1997a). Further 
evidence for constitutive internalization came from Melikian and Buckley, using 
cellular fractionation techniques. They observed that, at steady state, DAT 
localizes to TfR-+ endosomes (Melikian and Buckley, 1999). To test whether 
significant basal DAT trafficking occurs, Loder and Melikian used a reversible 
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biotinylation assay or “internalization assay” to directly measure DAT 
internalization rates following both temperature-dependent recycling blockade 
and pharmacological recycling inhibition (Loder and Melikian, 2003). Basal DAT 
trafficking has since been demonstrated by many other studies in heterologous 
expression systems (Loder and Melikian, 2003; Li et al., 2004; Holton et al., 
2005; Sorkina et al., 2005; Boudanova et al., 2008b; Sorkina et al., 2009; 
Navaroli et al., 2011; Sakrikar et al., 2012; Chen et al., 2013; Gabriel et al., 2013; 
Hong and Amara, 2013; Wu et al., 2015; Vuorenpaa et al., 2016; Wu et al., 
2017), and in ex vivo preparations (Eriksen et al., 2009; Gabriel et al., 2013; 
Hong and Amara, 2013; Block et al., 2015). Hong and Amara, using an antibody 
feeding assay in rat midbrain cultures transduced with DAT, found that DAT 
constitutively internalized and recycled to the plasma membrane (Hong and 
Amara, 2013). However, this study relied upon DAT overexpression, rather than 
endogenously expressed DAT. The Gether group demonstrated constitutive 
endocytosis of endogenously expressed DAT in ventral midbrain cultures, using 
a fluorescent cocaine analog (JHC 1-64) (Eriksen et al., 2009). Additionally, the 
Sorkin group, using a knock-in mouse expressing HA-tagged DAT, reported 
intracellular HA-DAT in ventral midbrain slices (Block et al., 2015), consistent 
with findings from the Gether laboratory (Eriksen et al., 2009). However, little is 
known about constitutive DAT trafficking in striatal nerve terminals. Block et al. 
saw no intracellular DAT populations in striatal slices from HA-DAT knock-in 
mouse (Block et al., 2015). In contrast with these findings, Gabriel et al. reported 
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that recycling blockade and dynamin inhibition in ex vivo striatal slices reduced 
surface DAT populations, showing that DAT internalizes from and recycles to the 
plasma membrane under steady state conditions (Gabriel et al., 2013).  
 
Dopamine Transporter Endocytic Signals 
Canonical endocytic motifs include a dileucine motif ([D/E]XXXLI or DXXLL, 
where D/E is an acidic amino acid, X is any amino acid, L is leucine, and I is 
isoleucine) or a tyrosine-based motif (NPXY where N is asparagine, P is proline, 
X is any amino acid, and Y is tyrosine or YXXf, where f is a bulky hydrophobic 
residue) (Bonifacino and Traub, 2003). DAT has five dileucine-like motifs and two 
tyrosine based motifs; however, these sequences are not required for DAT 
endocytosis (Loland et al., 2002; Granas et al., 2003; Holton et al., 2005). Holton 
el al. used a gain-of-function approach to test whether DAT N- or C-terminus was 
sufficient to drive internalization of endocytic defective reporter proteins. They 
determined that DAT’s C-terminus, and more specifically, a ten amino acid motif, 
FREKLAYAIA (587-596), was necessary and sufficient for both constitutive and 
PKC-stimulated endocytosis. Within the FREKLAYAIA sequence there are 
overlapping sequences that are required for constitutive internalization (LAYAIA) 
and PKC-stimulated internalization (FREK, discussed below). Interestingly, when 
the FREK (587-590) sequence was mutated to alanines, DAT underwent 
enhanced basal endocytosis (Boudanova et al., 2008b). These data suggested 
that DAT endocytic rates are negatively regulated, and that the C-terminus is 
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required for the negative regulatory mechanism. Additional support for a C-
terminal role in negatively regulating DAT endocytosis came from an ADHD 
patient with a C-terminal point mutation distal to the FREKLAYAIA sequence 
(R615C) (Sakrikar et al., 2012). This mutation results in enhanced constitutive 
endocytic rates, consistent with negative regulation at the DAT C-terminus 
(Sakrikar et al., 2012; Wu et al., 2015). The Sorkin laboratory demonstrated that 
DAT’s N-terminus is also required for negatively regulating DAT endocytosis 
(Sorkina et al., 2009). They truncated DAT’s entire N-terminus, and replaced this 
sequence with YFP-tag (D1-65 DAT). Using an antibody-feeding assay, they 
observed that D1-65 DAT underwent enhanced constitutive endocytosis. Further, 
they determined that the most membrane proximal residues (60-65) mediate N-
terminal negative regulation. Whether these N- and C-terminal mechanisms 
function independently from one another or are synergistically required to 
maintain negative endocytic regulation for DAT remains an unanswered question 
in the field, and I will test this question in Chapter III. 
 
Protein Kinase C (PKC) stimulated trafficking 
Initial studies reporting DAT sequestration to intracellular compartments, 
following protein kinase C (PKC) activation, began in the late 1990’s using 
radioligand binding assays (Zhu et al., 1997; Pristupa et al., 1998) and 
immunofluorescently-tagged DAT (Pristupa et al., 1998). These findings, in 
conjunction with reports that both SERT (Qian et al., 1997) and NET 
CHAPTER I 
	 15 
(Apparsundaram et al., 1998) downregulate in response to PKC in a trafficking 
dependent manner, raised the hypothesis that DAT undergoes enhanced 
internalization following PKC activation. Two independent reports in 1999 
demonstrated that DAT rapidly internalizes following PKC activation (Daniels and 
Amara, 1999; Melikian and Buckley, 1999). Melikian and Buckley used a 
biotinylation assay to demonstrate that PKC activation, via treatment with the 
phorbol ester PMA, reduced DAT surface expression (Melikian and Buckley, 
1999). Daniels and Amara also used PMA to activate PKC in cells 
overexpressing GFP-DAT and used immunocytochemistry to identify intracellular 
DAT populations (Daniels and Amara, 1999). Since these original findings, 
investigators have sought out the mechanisms underlying PKC-stimulated DAT 
endocytosis.  
 
The specific PKC isoforms required for PKC-stimulated DAT downregulation 
remains a critical unanswered question in the field. Protein kinase C is a cellular 
kinase that phosphorylates serines and threonines on target proteins. The ten 
PKC isoforms are subdivided into three classes, conventional PKC (cPKC), novel 
PKC (nPKC), and atypical (aPKC) (Steinberg, 2008). PKC a, bI, bII, and g make 
up the cPKC family.  They require Ca2+ and diacylglycerol (DAG) for activation. 
nPKCs (d, e, h, q, and µ) are Ca2+-independent and require only DAG for 
activation. aPKC (z, i, and l) require neither Ca2+ nor DAG for activation. It 
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should be noted that the phorbol ester, PMA, activates only cPKC and nPKC 
isoforms.  
 
Doolen and Zahniser reported that DAT downregulation required only cPKC 
based upon pharmacological inhibition (Doolen and Zahniser, 2002). However, 
this study was conducted Xenopus oocytes, which, presumably do not have the 
molecular factors contained in an intact DA nerve terminal. Fog et al., reported 
that PKCa used the DAT N-terminus as a substrate for phosphorylation (Fog et 
al., 2006b). It is known that PKC activation stimulates DAT phosphorylation; (Huff 
et al., 1997; Vaughan et al., 1997; Foster et al., 2002; Granas et al., 2003; Fog et 
al., 2006a); however, this phosphorylation is not required for PKC-stimulated 
endocytosis. Chen et al. mutated three putative PKC phosphorylation sites on 
DAT (S262, S586, and T613), and this mutant maintained PKC-stimulated 
downregulation (Chang et al., 2001). In addition to those three PKC consensus 
sites, DAT’s distal N-terminus contains five serines (S2, S4, S7, S12, S13) that 
are phosphorylated following PKC activation (Foster et al., 2002). However, the 
Gether group truncated the first 22 DAT residues, and showed that this domain is 
not required for PKC-stimulated DAT internalization either by PMA or activation 
of the Gq-coupled substance P receptor, NK1R (Granas et al., 2003). This finding 
demonstrated that the first 22 DAT residues, including these distal N-terminal 
serines, are not required for PKC stimulated DAT internalization. The 
Fleckenstein group identified PKCbI, bII, and g as DAT-associated in a co-IP from 
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rat striatal synaptosomes, however, they did not follow up on these studies with 
functional data (Hadlock et al., 2011). Work from the Gnegy group demonstrated 
that PKCb is required for DAT plasma membrane insertion rather than 
internalization (Chen et al., 2009; Chen et al., 2013). PKCb is activated by PMA, 
however, it is hypothesized that other PKC isoforms, activated by PMA, drive 
DAT internalization to a greater effect than PKCb DAT insertion, such that the net 
effect is the observed downregulation (Bermingham and Blakely, 2016). Taken 
as a whole, the PKC isoforms required for DAT internalization in terminals 
remains unknown, and in the absence of effective isoform-specific PKC 
activators and inhibitors, this question remains unanswered.  
 
PKC activation causes additional DAT posttranslational modifications. DAT is 
palmitoylated at its membrane-proximal C-terminus (Foster and Vaughan, 2011). 
PKC activation reduces palmitoylated DAT; however, PKC-induced 
palmitoylation reductions do not affect PKC-stimulated DAT endocytosis (Foster 
and Vaughan, 2011; Moritz et al., 2015). Ubiquitination is another PKC-induced 
DAT posttranslational modification. Miranda et al. first reported that PKC 
activation results in DAT ubiquitination at lysines 19, 35, and 599 (Miranda et al., 
2005). However, mutating these three ubiquitination sites did not block PKC-
stimulated DAT endocytosis, suggesting that these three residues, and the 
resulting ubiquitination at these sites, are not required for regulated endocytosis 
(Miranda et al., 2007). However, PKC-mediated endocytosis was blocked when 
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two of these sites, K19 and K35, were mutated in conjunction with an additional, 
putatively non-ubiquitinated lysine, K27 (Miranda et al., 2007). This DAT triple 
mutant (N3K) does not internalize in response to PKC activation. This finding 
correlates DAT ubiquitination with PKC-stimulated endocytosis. However, more 
directly, it demonstrates that lysines 19, 27, and 35 are required for PKC-
stimulated DAT endocytosis.  
 
In addition to three N-terminal lysines, DAT also has C-terminal domains required 
for PKC-stimulated DAT endocytosis. As discussed previously in this chapter, the 
Melikian laboratory showed a non-canonical endocytic motif, FREKLAYAIA, is 
both necessary and sufficient for PKC-stimulated DAT endocytosis (Holton et al., 
2005; Boudanova et al., 2008a). To identify putative DAT interacting proteins 
involved in regulated DAT endocytosis, a yeast 2-hybrid screen was performed 
using FREKLAYAIA as bait. This screen identified the small, neuronal Ras-like 
GTPase, Rin as a DAT binding protein (Navaroli et al., 2011). FRET microscopy 
studies demonstrate that Rin binds directly to DAT, and internalization assays in 
PC12 cells showed that Rin activity is required for PKC-stimulated endocytosis. 
 
Even though Rin binds DAT, and its activity is required for PKC-stimulated 
endocytosis, it is unknown how Rin drives DAT endocytosis. GTP-bound Rin is 
found in complex with Par6 and Cdc42 (Hoshino et al., 2005), which prompted 
the hypothesis that Cdc42 activity is required for regulated DAT endocytosis.  Wu 
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et al. showed that Cdc42 negatively regulates DAT endocytic rates (Wu et al., 
2015). This finding is consistent with the negative regulatory mechanism or 
“endocytic brake” that is associated with DAT’s N- or C-terminus (Boudanova et 
al., 2008b; Sorkina et al., 2009). Cdc42 activates the nonreceptor tyrosine 
kinase, Ack1, which Wu et al. demonstrated negatively regulates DAT 
endocytosis downstream of PKC and Cdc42 activation (Wu et al., 2015). 
Whether Rin sequesters Cdc42 such that it cannot activate Ack1, and therefore, 
cannot serve as a DAT endocytic brake remains untested. Ack1 contains a PPXY 
motif that is required for binding to the E3 ubiquitin ligase, Nedd4-2, and Nedd4-2 
activity downregulates Ack1 expression (Chan et al., 2009). Interestingly, Nedd4-
2, was identified in an siRNA screen as a required molecule for PKC-stimulated 
DAT endocytosis (Sorkina et al., 2006; Vina-Vilaseca and Sorkin, 2010). Whether 
Nedd4-2 mediated Ack1 downregulation is required to drive Ack1-dependent 
DAT endocytosis down stream of PKC activation remains unknown.  
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Figure I-1. PKC stimulated DAT endocytosis. DAT rapidly internalizes and 
displays reduced insertion rates following protein kinase C activation. PKC-
stimulated DAT endocytosis requires Ack1 inactivation, Rin activity, Nedd4-2, 
and Flot1. Future studies are required to test whether these mechanisms are 
distinct or part of a coordinated signaling cascade (Adapted from Wu et al., 
2015).  
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DAT mobility in membrane microdomains 
Multiple reports indicate that DAT localizes to distinct membrane microdomains 
(Adkins et al., 2007; Foster et al., 2008; Hong and Amara, 2010; Cremona et al., 
2011; Navaroli et al., 2011; Rahbek-Clemmensen et al., 2017). Membrane 
microdomains are small, heterogeneous, dynamic domains that can facilitate 
cellular functions by compartmentalizing cellular factors (Simons and Ikonen, 
1997; Pike, 2006). Flotillin (Flot-1) is an integral membrane protein involved in 
signaling, endocytosis, and cytoskeletal interactions (Otto and Nichols, 2011). 
Cremona et al. reported that Flot-1 is required for DAT localization to cholesterol-
rich domains, and that Flot-1 is required for PKC-stimulated DAT internalization 
(Cremona et al., 2011). However, the Sorkin group showed that while Flot-1 is 
required for DAT lateral mobility in the membrane; it is not required for PKC-
stimulated DAT endocytosis (Sorkina et al., 2013). While follow up studies are 
necessary to test whether Flot-1 is in fact required for PKC-stimulated 
endocytosis, Cremona et al.’s findings raise an interesting hypothesis that 
regulated DAT endocytosis requires DAT localization in discrete microdomains. 
In support of this hypothesis, the DAT/Rin interaction is enriched in membrane 
rafts as measured with CTxB labeling (Navaroli et al., 2011). Given that Rin is 
required for DAT internalization following PKC activation, these findings correlate 
DAT membrane localization and PKC-stimulated DAT endocytosis. Further, the 
ADHD associated DAT mutant, R615C, displays altered microdomain localization 
(Sakrikar et al., 2012). R615C is an endocytic gain-of-function mutant, as 
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demonstrated by increased basal internalization rates. Taken together, these 
data correlate R615C’s enhanced basal endocytosis with disrupted plasma 
membrane localization, further supporting the hypothesis that microdomain 
localization is required for regulated DAT endocytosis. 
 
Voltage-dependent DAT internalization 
Consistent with reports that DAT localizes to discrete microdomains, the Gether 
group recently used super-resolution microscopy to demonstrate that DAT 
localizes to cholesterol-rich domains in CAD cells and ex vivo preparations 
(Rahbek-Clemmensen et al., 2017). Further, they showed that DAT microdomain 
localization decreased following NMDA receptor activation, suggesting that DAT 
undergoes activity-dependent lateral diffusion. While this finding does not speak 
to whether DAT internalizes or recycles back to the plasma membrane following 
depolarization, reports from the Khoshbouei group support voltage dependent 
DAT internalization (Richardson et al., 2016). They used TIRF microscopy and 
surface biotinylation approaches to monitor fluorescently-tagged DAT during 
depolarization and hyperpolarization in HEK cells and cultured neurons. They 
observed DAT surface losses in response to depolarization, and enhanced 
surface expression following hyperpolarization. However, it should be noted that 
the only means of membrane depolarization used in this paper was KCl 
treatment. Whether this mechanism holds true under more physiological 
depolarization conditions remains untested.  
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Substrate-Mediated DAT Trafficking 
In addition to constitutive, PKC-stimulated, and voltage-dependent trafficking 
mechanisms, DAT undergoes rapid internalization following substrate 
translocation. As discussed previously, amphetamines are a potent, competitive 
DAT substrate. They increase extracellular levels by competing with DA for 
uptake into the presynaptic terminal, by promoting an “efflux willing” state that 
allows for reverse DA transport through DAT, and they cause rapid DAT 
endocytosis which results in less DAT at the plasma membrane for reuptake 
(Sulzer et al., 2005a). Initial reports, using Flag-DAT in EM4 cells showed that 
AMPH treatment increased intracellular DAT populations (Saunders et al., 2000). 
A surface biotinylation assay confirmed that AMPH-stimulated DAT sequestration 
was due to a loss of surface DAT populations (Kahlig et al., 2004). AMPH-
stimulated DAT internalization is inhibited by pretreatment with cocaine, 
suggesting that this process requires AMPH translocation through DAT to the 
cytosol intracellular AMPH. Consistent with this idea, introducing AMPH via patch 
pipette was sufficient to elicit enhanced DAT endocytosis (Kahlig et al., 2006). 
The Melikian group reported that AMPH-stimulated DAT trafficking uses 
pathways distinct from PKC-stimulated DAT internalization, given that the C-
terminal endocytic motif FREKLAYAIA is not required for AMPH-stimulated DAT 
internalization, and pharmacological PKC blockade did not affect AMPH-
stimulated DAT internalization in PC12 cells (Boudanova et al., 2008a).  
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As stated earlier, AMPH activates CaMKII, which results in CaMKII binding to 
DAT’s C-terminus (Fog et al., 2006a). Additionally, following AMPH exposure, 
CaMKII inactivates Akt, and Akt inactivation is required for DAT internalization 
(Garcia et al., 2005; Wei et al., 2007). These data demonstrate that following 
AMPH treatment, CaMKII’s association with DAT is required for two important 
DAT mechanisms – endocytosis and efflux. Further, these data demonstrate that 
Akt negatively regulates DAT surface expression, and following Akt inactivation, 
DAT rapidly internalizes. The notion of negatively regulating DAT surface 
expression is a recurrent theme within the DAT regulatory field (Boudanova et 
al., 2008b; Sorkina et al., 2009; Wu et al., 2015), suggesting that multiple factors 
stabilize DAT surface populations, and following a stimulus (PKC activation, 
AMPH treatment), an “endocytic brake” is released, allowing for rapid 
internalization. In addition to Akt-dependent AMPH-stimulated endocytosis, the 
Amara group showed that AMPH activates Rho GTPase, and Rho activity is 
required for AMPH-stimulated DAT internalization (Wheeler et al., 2015). 
However, how this Rho-dependent mechanism relates to the Akt-dependent 
mechanism remains unknown.  
 
In addition to AMPH, dopamine, the endogenous DAT substrate, causes DAT 
internalization. Chi and Reith reported dose-dependent DAT surface loss 
following pretreatment with DA. While others report DA-stimulated DAT 
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internalization (Saunders et al., 2000) with 100µM DA, Daniels and Amara saw 
no effect on DAT plasma membrane levels with DA treatment with 10µM DA 
(Daniels and Amara, 1999). The difference in their findings may be due to 
different cellular expression systems, or rather, a reflection of the dose-
dependence of DA-stimulated DAT internalization.  
 
Other DAT Trafficking Mechanisms 
Neurons have other mechanisms for acutely regulating DAT surface expression. 
The autoreceptor, D2R is expressed on DA nerve terminals. Multiple lines of 
evidence suggest that following D2R activation, DAT surface expression 
increases (Bolan et al., 2007; Lee et al., 2007; Chen et al., 2013). Lee et al, used 
Co-IP and GST-tagged N-terminal peptides to show that DAT associates with 
D2R at its N-terminus (Lee et al., 2007). Following D2R activation with 
quinperole, DAT functionally upregulates as measured by increased Vmax, which 
the authors attribute to increased surface expression. It should be noted that 
Bolan et al. also report that D2R activation increases DAT surface expression; 
however, they report that the N-terminus is not required for either DAT/D2R 
complex or for DAT upregulation (Bolan et al., 2007). Bolan et al., further 
demonstrated that D2R-dependent DAT upregulation requires ERK1/2. The 
Gnegy group provided additional support for increased DAT insertion following 
D2R activation (Chen et al., 2013). They treated striatal synaptosomes with 
quinperole, and measured increased DAT surface expression with a surface 
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biotinylation assay (Chen et al., 2013). Chen et al. further demonstrated that 
D2R-mediated DAT surface upregulation requires PKCb, for PKCb-/- mice did not 
display quinperole-induced DAT plasma membrane insertion. D2R is a Gai 
coupled receptor, which raises the question as to whether this mechanism is 
specific to the DAT/D2R interaction or more broadly attributed to Gai signaling 
cascades. Kivell et al. used Co-IP and FRET to show that DAT exists in complex 
with the kappa opioid receptor (KOR) (Kivell et al., 2014). KOR is expressed in 
DAT+ varicosities in the NAc (Svingos et al., 2001), suggesting that KOR 
activation and signaling via Gai cascades, could regulate DAT function and 
surface expression. Like D2R, KOR activation increased DAT function as a result 
of increased DAT surface expression (Kivell et al., 2014). They further reported 
that this increase requires ERK1/2 signaling downstream of KOR activation, 
consistent with the D2R-mediated mechanism reported by Bolan et al.  
 
Zhu et al. reported a novel DAT trafficking mechanism that is GDNF and Vav2 
dependent (Zhu et al., 2015). GDNF signals through the receptor tyrosine kinase, 
Ret. Downstream of Ret activation, Vav2 negatively regulates DAT surface 
expression. Further, they showed that both Ret+/- and Vav2-/- mice have 
increased DAT surface expression, and increased DAT transporter activity. 
Interestingly, this mechanism is specific to the NAc, as Ret+/- and Vav2-/- mice 
show no changes in DAT surface expression or transporter activity in the DS. 
Ret/Vav2 dependent DAT trafficking does not require PKC activity, suggesting a 
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novel mechanism for negatively regulating DAT surface expression.  Cocaine 
increases DAT surface expression (Daws et al., 2002; Little et al., 2002); 
however, in the NAc of Vav2-/- mice, cocaine decreased DAT surface expression. 
Vav2-/- mice are not hyperactive; however, they do not sensitize to the locomotor 
effects of cocaine. This finding is the first to link a DAergic behavior to an acute 
DAT trafficking mechanism. It is known that DAT maintains DAergic 
homeostasis, and DAT trafficking mechanisms regulate DAT availability. 
However, the physiological outcome of DAT trafficking events remains poorly 
understood. This finding in Vav2-/- mice correlates DAT surface expression 
regulation with locomotor sensitization to cocaine, suggesting that other acute 
DAT endocytic mechanisms can have profound consequences on DAergic 
behavior. I will be testing the physiological impact of PKC-stimulated DAT 
endocytosis in Chapter IV.  
 
I.D Animal Models of Dopamine Transporter 
Acute DAT trafficking mechanisms regulate DAT availability at the plasma 
membrane. It is hypothesized that acutely altering DAT availability will impact 
extracellular DA levels, and therefore impact DA signaling cascades; however, 
this hypothesis remains untested. DAT animal models support the hypothesis 
that altered DAT activity will have profound consequences on DAergic pathways 
and behaviors. DAT-/- mice demonstrate that DAT is required for maintaining 
homeostatic DA signaling. DAT-/- mice have increased extracellular DA; however, 
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reduced total DA stores and reduced DA release upon single pulse stimulation 
(Gainetdinov et al., 1998; Jones et al., 1998b; Benoit-Marand et al., 2000). DAT-/- 
mice have less striatal TH, but overall TH mRNA is not reduced. Further, TH 
activity is increased in DAT-/- mice, as indicated by increased L-DOPA levels and 
unchanged L-amino acid decarboxylase levels (Jones et al., 1998a). Additionally, 
D1R and D2R  are downregulated in DAT-/- mice (Giros et al., 1996). Taken as a 
whole, these data demonstrate that DAT is required for maintaining DA 
homeostasis at both pre- and postsynaptic neurons. Behaviorally, the broad 
disruption in DA homeostasis results in hyperactivity. However, DAT-/- mice still 
display conditioned place preference (CPP) to cocaine and self-administer 
cocaine (Rocha et al., 1998; Sora et al., 1998). These surprising results 
suggested that either DAT is not required for cocaine induced reward and 
motivation, or that DAT-/- mice have profound molecular compensation within 
their reward circuitry. A cocaine insensitive DAT KI (DAT-CI) mouse was critical 
in demonstrating that DAT is indeed required for cocaine’s rewarding properties 
(Chen et al., 2006). The Gu group used a chimeric protein approach, swapping 
out mouse DAT (mDAT) sequences with dDAT sequences because dDAT has 
10-fold lower affinity for cocaine than mDAT. This approach revealed three 
residues (L104V, F105C, A109V) required for DAT/cocaine binding (Wu and Gu, 
2003; Chen et al., 2005). DAT-CI mice do not display cocaine-induced 
hyperlocomotion nor CPP to cocaine (Chen et al., 2006). The Gu laboratory used 
the DAT-CI mice to test the minimal DAergic circuitry sufficient for cocaine’s 
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rewarding and locomotor effects (O'Neill et al., 2014; Wu et al., 2014). AAV-
mediated WT DAT delivery to DAT-CI mice in the rostrolateral striatum rescued 
cocaine-induced locomotion, whereas WT DAT expression in the DS and medial 
NAc did not restore cocaine-induced locomotion. Moreover, WT DAT expression 
in each of these brain regions failed to rescue CPP to cocaine (O'Neill et al., 
2014). However, WT DAT injection into ventral midbrain (VTA and SNc), rescued 
cocaine CPP (Wu et al., 2014). Taken together, these data demonstrate not only 
that cocaine’s rewarding properties require DAT, but also that DAT expression in 
both DS and NAc is required for cocaine reward.  
 
I.E DAT mutants in disease states 
As previously stated, DAT functions to clear synaptic DA, and therefore, 
regulates descending DA signaling cascades. DAergic dysfunction is implicated 
in numerous disease states including Parkinson’s Disease (PD), attention deficit 
hyperactivity disorder (ADHD), bipolar disorder (BPD), autism spectrum disorder 
(ASD), schizophrenia, and drug abuse. Therefore, dysfunctional DAT can alter 
synaptic homeostasis, and possibly lead to DA-related disease states. Here, I 
provide description of DAT coding variants associated with multiple DAergic 
disease states, to support the hypothesis that altered DAT function may 
contribute to pathophysiology of DAergic disease states.  
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Dopamine Transporter Deficiency Syndrome 
Dopamine transporter deficiency syndrome (DTDS) is an autosomal recessive 
disorder characterized by infantile/juvenile-onset parkinsonism dystonia (Kurian 
et al., 2009; Kurian et al., 2011; Ng et al., 2014). Patients express DAT point 
mutations (Leu368Gln, Pro395Leu, Val158Phe, Pro554Leu, Gly327Arg, 
Gln439X, Pro529Leu, Leu224Pro, Arg521Trp) that abolish DAT function due to 
reduced plasma membrane expression. Cellular studies revealed that loss of 
function arises from DAT mutant retention in the ER due to misfolding (Chiba et 
al., 2014; Beerepoot et al., 2016; Asjad et al., 2017). Recent studies using 
pharmacochaperoning provide insight as to possible therapeutics for these 
children. Pharmacochaperoning requires reversible, small molecule binding to 
folding intermediates, as a means to lower the free energy necessary to achieve 
the trajectory of a fully folded protein (Chiba et al., 2014). One such 
pharmacochaperone is noribogaine, which binds DAT in an inward facing 
conformation. In flies, expressing DTDS mutants causes reduced sleep; 
however, noribogaine treatment rescues this phenotype. These data suggest that 
molecular pharmacochaperoning approaches could serve as possible 
therapeutics for these patients (Beerepoot et al., 2016; Asjad et al., 2017).  
 
Adult Parkinsonism 
A patient, presenting with both early onset PD and ADHD, was identified as 
heterozygous for two distinct DAT missense alleles (I132F and D412N) (Hansen 
CHAPTER I 
	 31 
et al., 2014). The Gether group performed kinetic analysis of both mutant 
transporters. I132F showed significantly reduced DA uptake compared to WT 
DAT, and D421N showed no measurable Vmax. The complete absence of DA 
uptake in D421N cannot be attributed to surface expression loss. Rather, D421N 
expresses significantly more protein compared to WT DAT controls. The authors 
attribute the lack of DA uptake to deficient Na+ binding. Indeed, the mutated 
aspartate is predicted to be critical for the Na+ binding site (Penmatsa et al., 
2013). Further, D421N mutant cells undergo anomalous dopamine efflux (ADE), 
meaning they display an outward DA current at steady state. Cellular studies 
describing ADE show that this DA current occurs through DAT and is blocked 
with cocaine and methylphenidate (Mazei-Robison et al., 2008; Bowton et al., 
2010; Bowton et al., 2014). Hansen et al. show that D421E ADE can be rescued 
with AMPH treatment. The I321F mutation occurs in DAT’s sixth transmembrane 
region (TM6). While TM6 is critical for substrate binding and translocation, the 
mutated isoleucine is not predicted as required for substrate binding. Consistent 
with this prediction, I312F DAT has equal affinity for the DAT inhibitor  b-CFT. 
Rather, the authors predict that substituting isoleucine for phenylalanine may 
impact substrate translocation mechanisms, resulting in the observed reduction 
in Vmax.  
 
A rare DAT coding variant (V24M) was discovered in a PD patient in a screen for 
genetic variants possessing altered blood metabolite levels (Long et al., 2017). 
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The authors note that this individual had increased blood levels of dopamine 
sulfate; however, they speculate whether altered dopamine sulfate levels are a 
consequence of the mutation or due to L-DOPA treatment for PD. This mutation 
occurs at DAT’s N-terminal domain, which is required for protein interactions, 
posttranslational modifications, DA reverse transport, and substrate translocation 
(Vaughan and Foster, 2013).  
 
Attention deficit hyperactivity disorder (ADHD) 
ADHD is characterized by hyperactivity, disorganization, inattentiveness, and/or 
impulsivity (American Psychiatric Association, 2013b). Common therapies for 
ADHD include methylphenidate (Ritalin), a competitive DAT antagonist, and 
amphetamine (Adderall), a competitive DAT substrate (Pliszka, 2007). 
Polymorphisms in the DAT gene were found in ADHD patients (Cook et al., 1995; 
Yang et al., 2007). Further, DAT-/- mice display a hyperactive phenotype (Giros et 
al., 1996). Taken together, these observations provide evidence DAT is a risk 
allele for ADHD, and disrupted DAT function may contribute to ADHD pathology. 
Several functional DAT coding variants were identified in ADHD patients 
including A559V, R615C, V24M, and L164F; however, the latter two mutants 
have not been characterized (Mergy et al., 2014a). Interestingly, as previously 
noted, the V24M mutant was identified in an adult PD patient (Long et al., 2017). 
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A559V 
A559V mutation was found in patients with ADHD, bipolar disorder (BD), and 
autism spectrum disorder (Grunhage et al., 2000; Mazei-Robison and Blakely, 
2005; Bowton et al., 2014). This mutant undergoes ADE. A559V DAT’s ADE is 
attributed to enhanced sensitivity to intracellular Na+ levels, which results in a 
voltage dependent DA leak (Mazei-Robison et al., 2008). Further, data suggests 
that mechanistically, ADE may also arise from increased D2R activity. Cells, 
overexpressing A559V DAT and endogenously expressing D2R, demonstrate 
reduced ADE following treatment with the D2R antagonist, raclopride (Bowton et 
al., 2010). Downstream of D2R, cells expressing A559V have increased CaMKII 
activity, PKCb activity, and DAT N-terminal phosphorylation (Bowton et al., 2010; 
Bowton et al., 2014). These findings are consistent with reports that DAT-
mediated DA efflux requires PKCb, CaMKII, and N-terminal phosphorylation 
(Kantor and Gnegy, 1998; Khoshbouei et al., 2004; Johnson et al., 2005; Fog et 
al., 2006a; Chen et al., 2013; Zestos et al., 2016). Interestingly, AMPH treatment, 
which promotes DAT-mediated DA efflux in WT DAT, rescues A559V DAT’s 
ADE. The authors propose this finding as a possible mechanism to explain the 
paradox of using psychostimulants to alleviate hyperactivity in ADHD patients 
(Mazei-Robison et al., 2008).  
 
Above, describes cellular experiments for the A559V mutant; however, they do 
not explain how this point mutation affects DAergic phenotypes in vivo. To test 
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this, the Blakely group generated an A559V DAT KI mouse (Mergy et al., 2014a; 
Mergy et al., 2014b; Davis et al., 2018). This mouse has increased extracellular 
DA levels, which the authors attribute to previously reported ADE. Increased 
extracellular DA result in tonically active D2R activity, which inhibits vesicular DA 
release at steady state. Further, increased extracellular DA increases the 
duration of D2R-mediated sIPSCs (Mergy et al., 2014b). Taken as a whole, these 
data demonstrate that this DAT point mutation alters DAergic signaling.  
 
Interestingly, A559V DAT mice are not hyperactive, despite having increased 
extracellular DA levels. However, their locomotor response to AMHP and MPH is 
blunted (Mergy et al., 2014b). In a recent report with A559V DAT mice, Davis et 
al. demonstrate that this mutation results in enhanced motivation for sucrose 
reward, and increased impulsivity, which the authors attribute to their enhanced 
desire for reward (Davis et al., 2018). Therefore, altered DA regulation resulting 
from a DAT point mutation results in DAergic phenotypes. 
 
R615C 
R615C is a rare DAT coding variant, originally discovered in a cohort of Irish 
patients with ADHD (Bellgrove et al., 2009; Sakrikar et al., 2012). The mutated 
arginine is located at DAT’s distal C-terminus. This mutant displays a gain-of-
function endocytic phenotype in cells. It internalizes significantly faster than WT 
DAT at steady state levels. Further, PKC activation and AMPH treatment 
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stimulate WT DAT endocytosis; however, they have no effect on R615C 
endocytic rates suggestive of a ceiling effect in transporter endocytic rates 
(Sakrikar et al., 2012).  
 
Additionally, this mutant displays increased CaMKII association and consistent 
with this finding, R615C has increased N-terminal phosphorylation. Further, this 
mutant shows less association with Flot-1. Consistent with disrupted Flot-1 
association, R615C DAT localizes to different membrane compartments than WT 
DAT (Sakrikar et al., 2012).  
 
DAT plasma membrane expression is negatively regulated. A negative endocytic 
regulatory mechanism or endocytic brake stabilizes DAT at the plasma 
membrane. As stated previously, Ack1 inactivation releases the endocytic brake, 
and results in enhanced DAT endocytosis (Wu et al., 2015). Given the gain-of-
function endocytic trafficking phenotype displayed by R615C DAT, Wu et al. 
hypothesized that imposing negative endocytic regulation upon this mutant would 
rescue the endocytic phenotype. Using a constitutively active Ack1 (S445P), they 
rescued enhanced R615C internalization rates back to WT DAT rates. This 
finding raised the possibility that regulating DAT endocytic rates could have 
implications for ADHD treatment. All mechanistic characterization of R615C 
mutant has been in cellular expression systems; however, they suggest that 
dysregulated DAT trafficking could have profound phenotypic consequences. An 
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in vivo model of this mutant is necessary to test how this mutation, and 
downstream disrupted regulation of DAT and DA signaling, contributes to ADHD-
like symptoms.  
 
Autism Spectrum Disorder 
Autism spectrum disorder (ASD) is characterized by deficits in social interaction 
or communication, and restrictive and/or repetitive behavioral patterns (American 
Psychiatric Association, 2013a). Altered DA signaling is reported in ASD-like 
behavior (Ernst et al., 1997; Gunaydin and Deisseroth, 2014; Lee et al., 2017; 
Paval, 2017). Consistent with this idea, rare genetic variants for DAT have been 
identified in probands with ASD, suggesting that DA clearance deficits can 
contribute to ASD presentation. T356M, R51W, and A559V point mutations have 
been identified in ASD patients. As described previously, A559V mutation was 
originally identified in patients with ADHD and BPD, and whole exome 
sequencing identified this rare allele in two unrelated males diagnosed with ASD 
(Bowton et al., 2014).  
 
T356M 
T356M is a de novo DAT coding variant found in an ASD patient (Neale et al., 
2012; Hamilton et al., 2013). T356 is located in DAT’s seventh transmembrane 
domain, and is conserved across species including mammals, Drosophila, and C. 
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elegans. Hamilton et al. showed that the T356M mutation did not affect DA 
affinity, but significantly reduced Vmax, which is not due to loss of surface T356M 
DAT. They attribute Vmax reductions, in part, to the mutant’s ADE. Additionally, 
this mutant displayed reduced AMPH-stimulated DA efflux. Taken together with 
diminished uptake, these findings suggest that T356M has reduced capacity for 
transport in both forward and reverse directions. Additionally, Hamilton et al., 
showed that reduced uptake rates and blunted AMPH-stimulated efflux could be 
partially rescued with zinc (Hamilton et al., 2015). Zinc coordinates sidechains of 
extracellular DAT residues H193, H375, and E396, and it promotes an outward 
facing DAT conformation (Norregaard et al., 1998; Loland et al., 1999; Pifl et al., 
2009; Li et al., 2015). 
 
To assess the physiological impact of this mutation in vivo, they used the 
UAS/GAL4 system in Drosophila to express T356M DAT over a dDAT null 
background. Compared to flies overexpressing WT hDAT, the T356M flies are 
hyperactive, and they do not demonstrate increased locomotor activity following 
AMPH treatment. These data suggest that ADE results in a hyperactive state due 
to increased extracellular DA. Interestingly, A559V also displays ADE; however, 
in the KI mouse model, this mutant is not hyperactive (Mergy et al., 2014b). 
Taken together, these data suggest that increased extracellular DA resulting from 
ADE alone does not contribute to hyperactivity.  
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R51W 
Whole exome sequencing identified the rare DAT variant, R51W (Cartier et al., 
2015). The mutated arginine is located at the DAT N-terminus, which is a site for 
multiple protein-protein interactions. Syntaxin1a (Syn1A) associates with DAT’s 
N-terminus, and this interaction is required for AMPH-stimulated DA reverse 
transport (Binda et al., 2008). R51W reduces DAT/Syn1A interaction, and 
consistent with this finding, displays reduced AMPH-stimulated DA efflux. Cartier 
et al. used the UAS/GAL4 system in flies to express R51W in DA neurons over a 
dDAT null background. This fly shows normal baseline locomotor activity 
compared to flies expressing WT DAT; however, AMPH-stimulated increases in 
locomotor activity are blunted in R51W flies compared to hDAT controls (Cartier 
et al., 2015). This finding supports the hypothesis that AMPH-stimulated efflux is 
critical for AMPH-stimulated increases in locomotor activity, however, it does not 
point to the importance of this mutation in ASD-related behaviors.  
 
Taken as a whole, DAT mutants in DTDS, PD, ADHD, ASD, and BPD 
demonstrate DAT’s critical role in regulating DA signaling. While many of these 
mutations do not affect total DAT or surface DAT populations, the diminished 
DAT function and regulation significantly impact DA signaling and DAergic 
behavior. These mutants support the hypothesis that DAT regulation is required 
to maintain homeostatic DA signaling.  
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I.F Rin (Rit2) 
Our laboratory demonstrated that the small, neuronal Ras-like GTPase, Rin, 
binds directly to DAT and is required for PKC-stimulated DAT internalization 
(Navaroli et al., 2011). However, the following questions remain unanswered: 1) 
what is the physiological impact of PKC-stimulated DAT internalization? and 2) 
what is the significance of Rin signaling in vivo? In Chapter IV, I will test both of 
these questions. Here, I present what is known about Rin GTPase biology.  
 
Rin signaling 
The Ras GTPase superfamily is composed of small (~25 kD) proteins subdivided 
into families: Ras, Rho, Arf, Rab, Sar, and Ran (Colicelli, 2004). GTPases act as 
molecular switches that cycle between GTP-bound (active) and GDP-bound 
(inactive) states. In the GTP-bound state, they display high affinity for effector 
molecules. Following GTP hydrolysis, catalyzed by GTPase activating proteins 
(GAPs), they dissociate from effector molecules. GTPases are inactive in the 
GDP-bound state. The exchange of GDP for GTP is the rate limiting step in 
GTPase signaling cycle. A guanine nucleotide exchange factor (GEF) catalyzes 
the release of GDP, which allows for GTP loading, and downstream effector 
binding (Colicelli, 2004). Ras-like GTPases exert multiple functions in neurons, 
including axonal initiation, growth, guidance, and branching (Hall and Lalli, 2010).  
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Rin (Rit2), and its homolog, Rit, were initially identified in two independent 
screens. Lee et al., using degenerate primers for Ras-GTPases, screened retinal 
cDNA libraries for novel Ras-like GTPases (Lee et al., 1996). From this screen, 
they identified two novel GTPases, Rin and Rit. Rin (Ras-like in neurons) is 
expressed exclusively in brain and retina, whereas Rit (Ras-like in tissues) is 
expressed ubiquitously in all tissues. In an independent study, Wes et al. 
screened for calmodulin binding proteins in Drosophila retina (Wes et al., 1996). 
Their screen identified a novel GTPase, Ric (Ras-related protein which interacted 
with calmodulin), as a ubiquitously expressed Ras-like GTPase, which they 
identified as homologous to Rin and Rit.  
 
Rin, Rit, and Ric all lack the classical CAAX domain (where C is a cysteine, A is 
an aliphatic amino acid, and X is any amino acid) necessary for lipid modification 
(prenylation, myristoylation, and palmitoylation) and plasma membrane 
association. These three GTPases all contain a polybasic domain at their C-
termini which is believed to mediate plasma membrane association in the 
absence of lipid modification (Lee et al., 1996; Wes et al., 1996; Heo et al., 
2006).  
 
Both Lee et al. and Wes et al. identified Rin as a calmodulin (CaM) binding 
protein, and this finding was later confirmed in an in vitro binding assay 
performed by the Hoshino group (Lee et al., 1996; Wes et al., 1996; Hoshino and 
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Nakamura, 2003). CaM binds Ca2+, serving as an intermediate protein to mediate 
Ca2+ signaling in the cell. It is abundantly expressed in the neuron and is 
reported to bind over 100 proteins in the brain (Xia and Storm, 2005).  The 
physiological consequence of Rin-calmodulin interaction remains untested.   
 
Nerve growth factor (NGF) activates Rin (Spencer et al., 2002; Shi et al., 2005a). 
The Andres group showed that H-Ras is required for Rin activation downstream 
of NGF and EGF signaling. Further, they show that NGF-stimulated Rin 
activation occurs in neuronal expression systems (PC6 cells, a subline of the 
pheochromocytoma PC12 cells, and SK-N-MC-IXC, a subline of the parental SK-
N-MC cell) and not in non-neuronal systems (HEK and Vero cells) (Spencer et 
al., 2002). This finding suggests that neuronal specific factors are required for 
Rin activation, consistent with Rin localization limited to neurons.  
 
The neurotrophic peptide, pituitary adenylate cyclase (AC) activated polypeptide 
38 (PACAP38), activates Rin (Shi et al., 2008).  PACAP induces neurite 
outgrowth in PC12 cells (Somogyvari-Vigh and Reglodi, 2004; Vaudry et al., 
2009). This neuropeptide activates downstream signaling cascades required for 
survival, proliferation, neurite outgrowth, and trophic factor induction (Waschek, 
2002). Shi et al. demonstrated Gai -mediated PACAP signaling through Src 
kinase to activate Rin (Shi et al., 2008).  
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It should be noted that many studies investigating Rin activity relied heavily upon 
constitutively active and dominant negative Rin, Rit, and Ras mutants. Given the 
extensive homology in effector domains among these proteins, and among the 
superfamily of Ras-like GTPases, one cannot distinguish as to whether the 
results seen are indeed due to activated Rin-like proteins, or rather, due to 
sequestration of effectors proteins for other Ras-like GTPases necessary for 
queried signaling cascades. The specific GAPs and GEFs required for Rin and 
Rit GTPase activity remain unknown. The Hoshino group report that Rin binds to 
mSOS (GEF); however, they did not test whether mSOS exerts GEF activity on 
Rin either in vitro or in vivo (Hoshino and Nakamura, 2002). Gene silencing 
studies provide a more Rin-specific approach to ask questions regarding Rin-
related biology. The Andres group used Rin knockdown in PC6 cells to 
characterize the PACAP38-Src-Rin signaling cascade. Further, some Rin 
signaling studies were performed in non-neuronal heterologous expression 
systems. Spencer et al. reported NGF-induced Rin activation in neuronal 
expression systems but not in non-neuronal expression systems (Spencer et al., 
2002), necessitating the importance of  using in vivo systems to study 
endogenous Rin activity in situ. In unpublished data from our laboratory, I 
demonstrate that Rin-targeted shRNAs are efficacious for reducing Rin 
expression in heterologous expression systems and in mouse brain (Chapter IV). 
  
Rin in vivo 
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The gene that encodes Rin, RIT2, has been identified as a risk allele in 
numerous GWAS studies. RIT2 mutations or deletions have been identified in 
patients with Parkinson’s disease (Latourelle et al., 2012; Pankratz et al., 2012; 
Emamalizadeh et al., 2014; Labbe and Ross, 2014; Liu et al., 2015; Lu et al., 
2015; Nie et al., 2015; Wang et al., 2015a; Zhang et al., 2015; Emamalizadeh et 
al., 2017), schizophrenia (Glessner et al., 2010; Emamalizadeh et al., 2017), 
autism spectrum disorder (Liu et al., 2016; Emamalizadeh et al., 2017), bipolar 
disorder (Emamalizadeh et al., 2017), essential tremor (Emamalizadeh et al., 
2017), and speech delay (Bouquillon et al., 2011). As previously stated, Rin is 
required downstream of PACAP signaling in PC12 cells to induce neurite 
outgrowth, and reports show that that PACAP signaling is required for increased 
cell survival of midbrain DAergic neurons (Takei et al., 1998; Reglodi et al., 
2004). Whether Rin/RIT2 mediates this effect, and further, whether this pathway 
is disrupted in Rin-related neurodegenerative pathologies remains unknown.  
 
Rit2 was identified by the Nestler laboratory as having increased DFosB binding 
to its promotor in NAc from mice receiving chronic cocaine treatment (Renthal et 
al., 2009). Gene expression changes are a proposed mechanism for long-term 
changes in reward circuitry following chronic drug abuse (Hyman et al., 2006; 
Nestler, 2008). DFosB is a stable transcription factor that is upregulated following 
cocaine exposure, and its long lasting expression is hypothesized to mediate 
long-lasting effects of drugs of abuse (Nestler, 2008). Whether Rin is indeed 
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transcriptionally regulated through DFosB, and further, whether Rin activity is 
altered following chronic cocaine treatment, must be tested further. However, this 
study is the first to propose a link between Rin expression and drug abuse.  
 
Prior to unpublished work described in this thesis (Chapter IV), very little was 
known about Rin’s role in vivo. A published abstract by the Andres group reports 
that in Rin-/- mice, brain Akt signaling is increased, p38 MAPK signaling 
decreased, and these mice have improved outcomes in response to traumatic 
brain injury (Pannell et al., 2015). However, with the absence of published data to 
go on, we cannot ascertain what importance, if any, Rin plays in neurobiology. 
Additionally, a germline knockout is sensitive to compensatory mechanisms 
throughout development. Furthermore, multiple lines of evidence support that Rin 
activity may be critical in DAergic neurons, and a conditional Rin KD or KO is 
critical for investigating these DA-specific mechanisms. In Chapter IV I will test, 
for the first time, the physiological importance of Rin activity in DA neurons. 
 
Summary 
DA signaling cascades are tightly regulated to maintain homeostatic DAergic 
function. DAT regulates descending DA systems through DA reuptake, thereby 
spatially and temporally limiting DA signaling events. Small alterations in DAT 
function can critically impact DAergic systems. Single point mutations in DAT are 
associated with PD, ADHD, ASD, and BPD. DAT point mutations often do not 
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affect DA uptake rates (Vmax) or surface expression. However, having 
dysregulated function is sufficient to disrupt the DA network. DAergic neurons 
intrinsically regulate DAT availability through regulated trafficking events. 
However, the physiological consequences resulting from acute DAT endocytosis 
remains unknown. I hypothesize that disrupting regulated DAT endocytosis will 
impair DAT’s critical and delicate control on DA signaling events; therefore, 
disrupting DAergic homeostasis. Within this thesis, I will discuss DAT domains 
required for functional DA uptake (Chapter II) and regulated trafficking events 
(Chapter III). Further, I will test the hypothesis that regulated DAT trafficking is 
required for DAergic behavior (Chapter IV).  
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Chapter II 
Dopamine Transporter Amino and Carboxy Termini Synergistically 
Contribute to Substrate and Inhibitor Affinities 
 
Authors: Sweeney CG, Tremblay BP, Stockner T, Sitte HH, and Melikian HE 
 
II.A Summary 
Extracellular dopamine and serotonin concentrations are determined by the 
presynaptic dopamine (DAT) and serotonin (SERT) transporters, respectively. 
Numerous studies have investigated the DAT and SERT structural elements 
contributing to inhibitor and substrate binding. To date, crystallographic studies 
have focused on conserved transmembrane domains, where multiple substrate 
binding and translocation features are conserved. However, it is unknown what, if 
any, role the highly divergent intracellular amino and carboxy termini contribute to 
these processes. Here, we used chimeric proteins to test whether DAT and 
SERT amino and carboxy termini contribute to transporter substrate and inhibitor 
affinities. Replacing the DAT amino terminus with that of SERT had no effect on 
DA transport Vmax, but significantly decreased DAT substrate affinities for DA and 
amphetamine. Similar losses in uptake inhibition were observed for small DAT 
inhibitors, whereas substituting the DAT carboxy terminus with that of SERT 
affected neither substrate nor inhibitor affinities. In contrast, the N-terminal 
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substitution was completely tolerated by the larger DAT inhibitors, which 
exhibited no loss in apparent affinity. Remarkably, all affinity losses were rescued 
in DAT chimeras encoding both SERT amino and carboxy termini. The sensitivity 
to amino terminal substitution was specific for DAT, as replacing the SERT amino 
and/or carboxy termini affected neither substrate nor inhibitor affinities. Taken 
together, these findings provide compelling experimental evidence that DAT 
amino and carboxy termini synergistically contribute to substrate and inhibitor 
affinities. 
 
II.B Introduction 
Psychostimulant drugs include therapeutics for multiple psychiatric disorders, 
such as depression and ADHD, as well as drugs of abuse (Torres et al., 2003a; 
Kristensen et al., 2011; Vaughan and Foster, 2013; German et al., 2015). 
Determining how these drugs interact with their molecular targets is essential for 
understanding psychostimulant addiction as well as psychiatric treatment. The 
monoamine transporters DAT and SERT are the primary targets for a variety of 
psychostimulants, such as cocaine and amphetamines (AMPH, METH, MDMA), 
as well as the SSRI and NDRI classes of antidepressants (Kristensen et al., 
2011; Vaughan and Foster, 2013; Gaffaney et al., 2014; German et al., 2015). 
Cocaine and SSRI/NDRIs inhibit these transporters by directly blocking DA and 
5HT reuptake, whereas amphetamine and its congeners are competitive DAT 
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and SERT substrates. Once in the cytosol, amphetamines mediate monoamine 
release from vesicles in a VMAT-dependent manner (Freyberg et al., 2016) and 
drive their efflux via their respective plasma membrane transporters (Sitte and 
Freissmuth, 2015). 
 
DAT and SERT belong to the SLC6 family of Na+- and Cl--dependent solute 
carriers, which are topologically similar, having twelve transmembrane domains 
and intracellular N- and C-termini (Torres et al., 2003a; Kristensen et al., 2011; 
Vaughan and Foster, 2013; German et al., 2015). Crystal structures of the SLC6 
bacterial homologs LeuT (Yamashita et al., 2005), Drosophila DAT (dDAT) 
(Penmatsa et al., 2013), and more recently human SERT (Coleman et al., 2016) 
have confirmed the predicted topologies of SLC6 transporters, shed light on the 
mechanism of substrate translocation, and better mapped inhibitor/substrate 
binding sites. While critical in understanding transporter structure and function, 
these transporter crystallographic studies lack structural insights into the N-
terminus and much of the C-terminus, due to their highly disordered properties. 
Mutagenesis studies have revealed that DAT and SERT intracellular N- and C-
terminal domains contribute to transporter regulated internalization (Holton et al., 
2005; Miranda et al., 2007; Boudanova et al., 2008b; Sorkina et al., 2009; 
Rickhag et al., 2013b; Seimandi et al., 2013; Bermingham and Blakely, 2016), 
post-endocytic trafficking (Bermingham and Blakely, 2016; Vuorenpaa et al., 
2016), biosynthetic trafficking (Sitte et al., 2004; Farhan et al., 2007; Sucic et al., 
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2011; Sucic et al., 2013; Bermingham and Blakely, 2016), and amphetamine-
stimulated substrate efflux (Khoshbouei et al., 2004; Guptaroy et al., 2009; Sitte 
and Freissmuth, 2010; Sucic et al., 2010; Rickhag et al., 2013a). Moreover, DAT 
and SERT N- and C- terminal coding variants have been identified in ADHD and 
autism spectrum disorder patients (Prasad et al., 2005; Prasad et al., 2009; 
Sakrikar et al., 2012; Cartier et al., 2015; Wu et al., 2015), further implicating 
these regions as important for transporter function, and necessitating the need 
for greater understanding into how they may contribute to transporter 
mechanisms of action. Computational modeling of the DAT N-terminus 
(Khelashvili et al., 2015a; Khelashvili et al., 2015b) and both SERT N- and C-
termini (Fenollar-Ferrer et al., 2014) has shed light onto their secondary 
structure. Moreover, these studies have raised the possibility that these domains 
may interact with the plasma membrane and, potentially, each other. However, 
there remains a dearth of experimental data testing whether or not these 
domains contribute to substrate and inhibitor affinities. In the current study, we 
asked whether DAT and SERT N- and C-termini influenced substrate and 
inhibitor affinities. To address this question, we generated DAT/SERT chimeras 
in which the N-, C-, or both termini are exchanged between their respective DAT 
or SERT core proteins. DAT and SERT transmembrane cores share 52% 
sequence identity; however, their N- and C-termini are highly divergent (17% and 
27% sequence identity, respectively), thus providing an effective strategy to test 
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whether these intracellular domains differentially contribute to substrate or 
inhibitor affinities. 
 
II.C Materials and Methods 
Materials: Rat anti-DAT (MAB369) antibody was from Millipore and mouse anti-
SERT antibody was from MAb technologies. Horseradish peroxidase (HRP)-
conjugated anti-rat secondary and mouse anti-actin (SPM161) antibodies were 
from Santa Cruz and HRP-conjugated anti-mouse antibody was from Jackson 
Immunoresearch Laboratories (115-035-003). Sulfo-NHS-SS-biotin and 
streptavidin agarose were from Thermo Scientific. GBR12909, citalopram, and 
fluoxetine were from Tocris. All other chemicals and reagents were from Sigma-
Aldrich and Thermo Fisher Scientific and were of the highest grade available.  
 
cDNA constructs: Chimeric hDAT and hSERT cDNAs were generated using the 
PCR-Ligation-PCR (PLP) approach (Ali and Steinkasserer, 1995), using hDAT 
pcDNA3.1 (+) and/or hSERT pcDNA3.1 (+) as templates, corresponding to the 
following coding regions: N-SERT/DAT (hSERT[1-78]/hDAT[60-620], DAT/C-
SERT (hDAT[1-583]/hSERT[601-630]), SERT/DAT/SERT (hSERT[1-
78]/hDAT[60-583]/hSERT[601-630]), N-DAT/SERT (hDAT[1-59]/hSERT[79-
630]), SERT/C-DAT (hSERT[1-600]/hDAT[584-620]), DAT/SERT/DAT (hDAT[1-
59]/hSERT[79-600]/hDAT[584-620]). The resulting chimeric cDNAs were 
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digested and cloned back into their parental transporters at the following 
restriction sites: HindIII/PflMI (N-SERT/DAT, SERT/DAT/SERT), HindIII/AgeI (N-
DAT/SERT, DAT/SERT/DAT), or ClaI/XbaI (DAT/C-SERT, SERT/C-DAT, 
SERT/DAT/SERT, DAT/SERT/DAT). All chimeric constructs were confirmed by 
Sanger sequencing (Genewiz). 
 
Cell culture and generation of pooled stable cell lines: Human dopaminergic SK-
N-MC cells were obtained from American Type Culture Collection (Manassas, 
VA) and were maintained in MEM supplemented with 10% fetal bovine calf 
serum, 100 units/mL penicillin/streptomycin, 2 mM L-glutamine, 37°C, 5% CO2. 
Cells were transfected with wildtype or chimera cDNAs using Lipofectamine 2000 
according to manufacturer’s instructions with the following modifications: Cells 
were seeded into 6 well plates at a density of 1x106 one day prior to transfection, 
and were transfected with 3 µg plasmid DNA/well using a lipid:DNA ratio of 2:1. 
To generate stable cell lines, 48 hours following transfection, cells were selected 
using 0.5 mg/mL G418. Stably transfected cells were pooled and cell lines were 
maintained under selective pressure using 0.2 mg/mL G418.  
 
Uptake assays: [3H]DA and [3H]5HT uptake: 7.5x104 (DA uptake) or 5.0x104 
(5HT uptake) cells/well were seeded onto 96 well plates, one day prior to the 
assay. Cells were washed twice with room temperature Krebs-Ringers-HEPES 
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buffer (KRH: 120 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 2.2 
mM CaCl2, 10 mM HEPES, pH 7.4), and transport assays were conducted as 
described below. All transport reactions proceeded for 10 min, 37°C and were 
terminated by washing thrice with ice-cold KRH buffer. Cells were solubilized in 
scintillation fluid, 15 min, room temperature and [3H] accumulation was quantified 
using a Wallac Microbeta scintillation plate counter (Perkin Elmer). Triplicate 
points were measured for each data point and non-specific uptake was defined in 
the presence of either 10 µM GBR12909 (DA uptake) or 10 µM paroxetine (5HT 
uptake). Data were analyzed using Excel and GraphPad Prism software. Cocktail 
solutions were counted in parallel and accumulated [3H] was less than 10% of 
the total [3H] added for all assays. 
 
Kinetics: [3H]DA (dihydroxyphenylethylamine 3,4-[ring-2,5,6,-3H]; Perkin Elmer) 
and [3H]5HT (5-hydroxytryptamine [3H]-; Perkin Elmer) 10x cocktails were 
prepared by diluting a 1/20th volume radiolabeled substrate into 60 µM stock 
solutions of unlabeled DA or 5HT in KRH containing 0.18% glucose and 10 µM 
each pargyline and sodium ascorbate (KRH/g/p/a). 60 µM [3H]substrate solutions 
were serially diluted into KRH/g/p/a to generate [3H]DA or [3H]5HT cocktails at 
10X the indicated final substrate concentrations. Cells were preincubated (20 
min, 37°C) with KRH buffer supplemented with 0.18% glucose (KRH/g) and 
uptake was initiated by adding a 1/10th volume of 10x concentrated [3H] substrate 
cocktails.  
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Inhibitor dose response curves: Cells were pre-incubated in KRH/g (30 min, 
37°C) with the indicated drugs at the indicated concentrations. Uptake was 
initiated by adding a 1/10th volume of 500 nM [3H]DA or 250 nM [3H]5HT 10x 
cocktail, for final assay concentrations of 50 nM (DA) or 25 nM (5HT).  
 
AMPH and fenfluramine dose response: Cells were pre-incubated in 
KRH/glucose buffer (20 min, 37°C). Uptake was initiated by adding a 1/10th 
volume of either 500nM [3H]DA or 250 nM [3H]5HT 10x cocktails, containing 
AMPH or fenfluramine, respectively, at 10x the indicated final concentrations.  
 
Cell Surface biotinylation: Surface proteins were covalently labeled with sulfo-
NHS-SS-biotin as previously described (Loder and Melikian, 2003; Holton et al., 
2005). Briefly, cells were rapidly chilled by washing in ice-cold PBS, pH 7.4, 
supplemented with 1.0 mM MgCl2, 0.1 mM CaCl2 (PBS2+), and incubated with 1.0 
mg/ml sulfo-NHS-SS-biotin in ice-cold PBS2+, twice, for 15 min at 4°C. Residual 
reactive NHS groups were quenched by repeated washing and incubating twice 
in PBS2+/100 mM glycine, 15 min, 4°C. Cells were washed three times in ice-cold 
PBS2+, lysed in RIPA buffer containing protease inhibitors and protein 
concentrations were determined using the BCA protein assay (Pierce). 
Biotinylated proteins from equivalent amounts of cellular protein were isolated by 
CHAPTER II 
	 55 
batch streptavidin chromatography (overnight, 4°C) and bound proteins were 
eluted in 2X SDS-PAGE sample buffer, 30 min, room temperature. Either 
supernatants (WT DAT, DAT/C-SERT) or total cellular lysates (N-SERT/DAT, 
SERT/DAT/SERT) were used to normalize surface levels. Blots were probed with 
actin for normalization (N-SERT/DAT, SERT/DAT/SERT). Samples were 
resolved by SDS-PAGE and specific proteins were detected by immunoblotting 
with the indicated antibodies. Immunoreactive bands were detected with 
SuperSignal West Dura (Pierce) and were captured using a VersaDoc Imaging 
station (Biorad). Non-saturating bands were quantified using Quantity One 
software (Biorad). Relative surface expression was quantified as percent surface 
protein (WT DAT, DAT/C-SERT, N-DAT/SERT, DAT/SERT/DAT). Data were 
normalized to percent WT DAT (DAT/C-SERT), N-SERT/DAT 
(SERT/DAT/SERT), or N-DAT/SERT (DAT/SERT/DAT). 
 
II.D RESULTS 
SLC6 crystallographic studies have shed considerable light on both substrate 
translocation mechanisms and inhibitor binding sites (Yamashita et al., 2005; 
Penmatsa et al., 2013; Wang et al., 2015b; Coleman et al., 2016). However, it 
remains uncertain whether transporter intracellular N- and C-termini contribute to 
these fundamental transporter properties. To test the hypothesis that these 
cytoplasmic domains influence the transport mechanism and inhibitor binding, we 
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created DAT/SERT chimeras which retained either DAT or SERT 
transmembrane domains (i.e. “cores”), but differentially replaced DAT and SERT 
N- and C-termini with their homologous counterparts (see schematic, Fig. II-1A). 
We chose these domains because although DAT and SERT are highly 
homologous within their transmembrane domains, their N- and C-termini diverge 
significantly (17% and 27% amino acid conservation, respectively, Fig. II-1B). We 
first asked whether these domains contributed to substrate uptake kinetics for the 
DAT core chimeras. Each DAT core chimera exhibited saturable DA uptake 
(Figure II-2A), indicative of functional protein expressed at the plasma 
membrane. However, Vmax values for DAT/C-SERT and SERT/DAT/SERT were 
significantly lower than either WT DAT or N-SERT/DAT (Table II-1). Vmax is 
affected by both transporter surface expression and substrate translocation rates. 
To test whether reduced Vmax values were due to attenuated transporter surface 
expression, we performed surface biotinylation experiments comparing either WT 
DAT to DAT/C-SERT, or N-SERT/DAT to SERT/DAT/SERT. Note that the DAT 
and SERT antibody epitopes are localized on their respective N-termini, therefore 
allowing only for direct comparisons between transporters with identical N-
termini. In addition, we found that the N-terminally directed anti-SERT antibody 
recognized a non-specific band in the supernatant (intracellular), but not surface, 
fraction recovered from SK-N-MC cell lysates, with similar mobility as SERT (not 
shown). This precluded using total or intracellular SERT signals for 
normalization. Therefore, for assays using the anti-SERT antibody, we 
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normalized chimera surface levels to actin as a loading control. The percent of 
DAT/C-SERT expressed at the surface, relative to its own total protein 
expression, was not significantly different than WT DAT (p = 0.72, Fig. II-2B). 
However, the absolute amount of DAT/C-SERT was significantly reduced, thus 
the absolute amount of DAT/C-SERT expressed at the cell surface was likewise 
significantly reduced compared to WT DAT (51.4 ± 6.0% WT levels, Fig. II-2C), 
which accounts for the observed Vmax decrease. We also observed that 
SERT/DAT/SERT was expressed at significantly lower levels at the cell surface 
than N-SERT/DAT (10.3 ± 2.7% of N-SERT/DAT levels; Fig. II-2D), fully 
accounting for its decreased Vmax, as opposed to compromised catalytic activity. 
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Figure II-1. A. DAT/SERT chimera schematic. DAT “core” and SERT “core” 
chimeric proteins were designed as depicted. DAT regions are indicated in 
red, SERT regions are indicated in cyan. B. DAT and SERT N- and C-termini 
are highly divergent. Sequence alignments of DAT and SERT N- and C-
termini. Conserved residues (by identity, charge, or size) are indicated in red. 
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Figure II-2. DAT core chimera uptake kinetics and surface expression.  
A. [3H]DA uptake assays. Saturation uptake kinetics were measured as 
described in Experimental Procedures, in SK-N-MC cells stably expressing 
either WT DAT (black), N-SERT/DAT (cyan), DAT/C-SERT (blue), or 
SERT/DAT/SERT (red). Average data are presented ±S.E.M., n = 11-16. B-D. 
Surface Biotinylation Assays. Surface levels for the indicated constructs were 
determined by surface biotinylation, as described in Experimental Procedures. 
B. WT DAT vs. DAT/C-SERT surface levels. Average data ± S.E.M. are 
presented, relative to the total amount of DAT chimera expressed, p = 0.72, 
Student’s t test, n = 3-4. C. WT DAT vs. DAT/C-SERT total expression levels, 
calculated as the sum of biotinylated (surface) and supernatant (intracellular) 
fractions, *Significantly different from WT DAT, p < 0.04, Student’s two-tailed t 
test, n = 3-4. Inset: Representative immunoblot for B and C. D. N-SERT/DAT 
and SERT/DAT/SERT surface expression, normalized to actin. ***Significantly 
different from N-SERT/DAT, p < 0.001, Student’s two-tailed t test, n = 3. Inset: 
Representative immunoblots (Note: boxed bands were digitally extracted from a 
single blot exposure, probed for both the chimeras and actin, in parallel). 
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To test whether DAT’s N- and C-termini contribute to DA apparent affinity, we 
compared the WT DAT Km value with those measured for the DAT core chimeras 
(Table II-1). Replacing the DAT N-terminus with the SERT N-terminus 
significantly decreased the apparent substrate affinity, as reflected by an 
increased Km for DA (WT DAT: 1.1 ± 0.1µM; N-SERT/DAT: 2.2 ± 0.4 µM, n = 11-
16, Table I), whereas substituting the DAT C-terminus with that of SERT (DAT/C-
SERT) had no effect on apparent DA affinity compared to WT DAT (Table II-1, p 
= 0.99). Surprisingly, replacing both DAT N- and C- termini with those of SERT 
restored the Km back to WT DAT levels, thereby rescuing the loss of apparent 
affinity induced by substituting the DAT N-terminus alone (Table II-1). We next 
asked whether the N-terminus contributes to apparent substrate affinity in 
general, or to apparent DA affinity specifically, by measuring each chimera’s 
sensitivity to AMPH, a competitive DAT substrate. As illustrated in Table II-1, 
similar to our findings with DA, N-SERT/DAT exhibited a significant increased Ki 
for AMPH, compared to WT DAT, indicating loss of apparent substrate affinity, 
whereas DAT/C-SERT showed no change in AMPH sensitivity compared to WT. 
Moreover, SERT/DAT/SERT exhibited a significant decrease in Ki for AMPH 
(52.1 nM ± 11.4 nM, n = 11, p < 0.05), indicating an increased apparent affinity. 
 
Given that DAT N- and C-termini differentially impacted apparent substrate 
affinity, we next extended our analyses to test whether these domains also 
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contribute to competitive inhibitor affinities. We first focused on cocaine and other 
tropane-derived congeners. Despite the impact that N-terminal substitution 
imposed upon apparent substrate affinity, none of the DAT core chimeras 
exhibited a significant difference in Ki values for cocaine, as compared to WT 
DAT (Table II-1). In contrast, similar to what we observed for DAT substrates, N-
SERT/DAT exhibited significantly lower apparent affinity than WT DAT for the 
high-affinity DAT inhibitor b-CFT (WIN35,428; n = 4). Moreover, substituting the 
SERT C-terminus had no effect on apparent b-CFT affinity, and substituting both 
the DAT N- and C- terminus rescued the loss in apparent affinity observed with 
the N-terminal substitution (Table II-1). We further tested whether the apparent 
affinity of another high affinity tropane, b-CIT (RTI-55), was similarly impacted by 
the DAT N-terminal substitution. Interestingly, despite the structural similarity 
between b-CIT and b-CFT, N-SERT/DAT exhibited no difference in apparent 
affinity for b-CIT as compared to WT DAT (Table I, Student’s two-tailed t-test, p = 
0.33, n = 3-7). Cocaine is a relatively low affinity inhibitor with equimolar potency 
across monoamine transporters, whereas both b-CFT and b-CIT are non-
selective, high affinity inhibitors for both DAT and SERT. Therefore, we next 
tested whether methylphenidate (MPH) and GBR12909, high affinity inhibitors 
with selectively for DAT over SERT, were similarly affected by DAT N- and C-
terminal substitutions. Similar to what we observed with DAT substrates, N-
SERT/DAT exhibited significantly decreased sensitivity to MPH, whereas MPH 
apparent affinities for DAT/C-SERT were not significantly different from WT DAT 
CHAPTER II 
	 63 
(p = 0.99) and SERT/DAT/SERT rescued the loss in sensitivity observed for N-
SERT/DAT (Table II-1). In contrast, substituting DAT N- and C-termini with SERT 
termini had no effect on DAT core chimera sensitivity to the high affinity DAT 
inhibitor, GBR12909 (p = 0.37). 
 
We next tested whether reciprocal DAT substitutions onto the SERT core would 
similarly impact apparent substrate and inhibitor affinities. WT SERT and SERT 
core chimeras exhibited robust, saturable 5HT uptake when expressed in SK-N-
MC cells (Fig. II-3A) and no significant differences in Vmax values were observed 
among the chimeras as compared to WT SERT, although N-DAT/SERT exhibited 
a trend towards decreased 5HT transport Vmax (p = 0.07).  
 
Assessment of 5HT Km values revealed no differences between WT SERT and 
any of the SERT core chimeras (Table II-2), suggesting that, unlike DAT, the 
SERT N-terminus does not contribute to apparent substrate affinity. To test 
whether this is specific to 5HT, or applies to other SERT substrates, we 
measured the apparent affinity for fenfluramine, a SERT-selective amphetamine 
derivative. As seen in Table II-2, substituting the DAT N-, C-, or both termini had 
no effect on the SERT core chimera fenfluramine Ki values, as compared to WT 
SERT. We similarly tested a panel of chemically diverse SERT inhibitors, 
including the tropane compounds cocaine and b-CIT, the SSRI escitalopram, and 
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the tricyclic antidepressant, imipramine. Replacing the DAT N- and/or C-termini 
onto SERT had no effect on the potency of these compounds, as compared to 
WT SERT (Table II-2), suggesting that while the DAT N-terminus contributes to 
apparent substrate affinity and potency for a subclass of inhibitors, SERT can 
tolerate N-terminal substitutions without compromising either apparent substrate 
or inhibitor affinities. 
  
CHAPTER II 
	 65 
  
 
  
Figure II-3. A. SERT-core chimera uptake kinetics. [3H]5HT uptake assays. 
Saturation uptake kinetics were measured as described in Experimental 
Procedures, in SK-N-MC cells stably expressing either WT SERT (black), N-
SERT/DAT (cyan), SERT/C-DAT (blue), and DAT/SERT/DAT (red). Average 
data are presented ±S.E.M., n = 5-6. B-C. DAT substrate and inhibitor 
chemical structures. Chemical structure of compounds whose affinities were 
(B) or were not (C) affected by DAT N-terminal substitution with the SERT N-
terminus. 
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II.E DISCUSSION 
Monoamine transporter N- and C-termini encode multiple motifs critical for 
biosynthesis (Sitte et al., 2004; Farhan et al., 2007; Sucic et al., 2011; Sucic et 
al., 2013; Koban et al., 2015), surface regulation (Holton et al., 2005; Boudanova 
et al., 2008b; Sorkina et al., 2009), and AMPH-stimulated substrate efflux 
(Khoshbouei et al., 2004; Guptaroy et al., 2009; Sitte and Freissmuth, 2010; 
Sucic et al., 2010; Rickhag et al., 2013a). Given that coding variants in both the 
DAT and SERT terminal domains have been independently reported in patients 
with neuropsychiatric disorders (Prasad et al., 2005; Prasad et al., 2009; Sakrikar 
et al., 2012; Cartier et al., 2015), understanding how these domains may also 
influence substrate and inhibitor binding is critical. DAT N-terminal residues 
interact with intracellular domains that contribute to an intracellular transport 
gating mechanism, which modulates substrate translocation (Yamashita et al., 
2005; Guptaroy et al., 2009; Sucic et al., 2010; Guptaroy et al., 2011; Khelashvili 
et al., 2015b). In particular, R60 (Kniazeff et al., 2008) T62 (Guptaroy et al., 
2009), and R51 (Khelashvili et al., 2015b) interact with intracellular loops to help 
stabilize the DAT outward (R60, T62) and inward (R51) facing conformations. 
R60 and T62 are maintained in our chimeras, as they are conserved between 
DAT and SERT. However, R51 is not conserved between DAT and SERT, and 
observed differences in substrate/inhibitor apparent affinities may be due to loss 
of R51 influence on gating. This putative change in gating may be translated to 
the substrate binding pocket, and thereby result in decreased apparent affinities 
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for certain DAT substrates and inhibitors. An R51W coding variant identified in 
autism spectrum patients was recently reported (Cartier et al., 2015), which 
results in reduced DA efflux capacity, consistent with a role for R51 in 
transitioning between inward and outward facing conformations. Such results 
further raise the possibility that altered N-terminal mobility may have broader 
functional implications in neuropsychiatric disorders. 
 
Our results using DAT/SERT chimeric proteins revealed that the DAT N-terminus 
influences the apparent affinity of substrates and a subset of DAT inhibitors, 
whereas SERT function and inhibition was insensitive to N- and C-terminal 
substitutions. N-SERT/DAT exhibited reduced apparent affinity for DAT 
substrates DA and AMPH, as well as the inhibitors MPH and b-CFT. 
Interestingly, the N-terminus did not contribute to apparent affinities for cocaine, 
GBR12909, or b-CIT. In contrast, a recent study using DAT/NET chimeras, found 
that replacing the DAT N-terminus with that of NET enhanced the DAT affinity for 
DA, whereas replacing the NET N-terminus with that of DAT reduced NET affinity 
for DA (Vuorenpaa et al., 2016). Consistent with our results, they also observed 
that C-terminal exchanges had no effect on DA affinity. Further, a study from 
Vaughan and colleagues found that N-terminal point mutations (S4A, C6A, S7A, 
S7D) in rat DAT exhibited reduced b-CFT binding (Moritz et al., 2013), further 
supporting that the DAT N-terminus contributes to the affinity of select inhibitors. 
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Taken together with our findings, these data are consistent with a model in which 
the DAT N-terminus may influence the stability of the ligand-bound conformation 
Interestingly, we observed that this occurred over a broad range of structurally 
diverse compounds (see chemical structures, Figs. II-3B, C). However, although 
cocaine, b-CFT and b-CIT are all tropane-derivatives, only b-CFT apparent 
affinity was affected by the DAT N-terminal substitution. A previous report 
identified a DAT point mutation (D345N) that is insensitive to b-CFT, but retains 
sensitivity to cocaine inhibition (Chen et al., 2001), suggesting that binding of 
tropanes derivatives within DAT is not identical. Moreover, a dDAT crystal 
structure encoding point mutations that mimic hDAT displayed enhanced cocaine 
and β-CFT, but not b-CIT binding (Wang et al., 2015b), consistent with a model 
in which these compounds have differential binding properties for DAT. Cocaine 
and b-CIT are larger molecules than b-CFT. Cocaine’s ester linkage (absent in b-
CIT and b-CFT) increases its size compared to b-CFT, while the substitution of 
the larger halide, iodide, in b-CIT increases its size compared to b-CFT. This 
raises the possibility that the molecular size of these compounds exerts a large 
influence on their ability to bind within the S1 binding pocket. Consistent with this 
premise, DA, AMPH, and MPH, which are all small DA-related compounds, were 
all sensitive to the N-terminal substitution, whereas GBR12909, which is a large, 
extended piperazine derivative, was not impacted by the DAT N-terminal 
substitution.  
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The potential explanation for the observed different shifts in inhibitory potency is 
an energy change for reaching the inhibitor-transporter complex state, which 
does not affect every inhibitor in the same way. Thus, the intracellular termini 
substitution may have caused structural changes in the outer vestibule or 
changed the free energy hypersurface of the translocation process. Most 
inhibitors bind competitively to DAT and prevent the transition from outward-
facing to inward-facing. It is conceivable that larger compounds interfere already 
in the initial part of the transition, while smaller inhibitors block the transporter 
movement along the transition path. The geometry of the outward facing 
conformation is most likely unchanged, as the Ki of the largest compounds did 
not change. More intensive structural and/or computational interrogations will be 
necessary to discern among these possibilities. 
 
How does the N-terminus influence the coordination of substrates and inhibitors 
in the DAT binding pocket? DAT’s adaptation to molecule size within its pocket 
was demonstrated by Gouaux and colleagues (Wang et al., 2015b) using the 
same dDAT crystal structures bound to substrates and inhibitors. In their study, 
they posit that the small substrates sit precisely within the pocket in appropriate 
position. The larger inhibitors, like tropanes and antidepressants, lock DAT in an 
outward facing conformation to exert their effects. A notable difference between 
their findings and ours is that, as stated previously, they do not find any 
CHAPTER II 
	 71 
difference between inhibitor binding sites for cocaine and b-CFT; however, their 
study focused on dDAT whereas ours investigated hDAT. Although the binding 
sites of hDAT and dDAT share approximately 80% identity, dDAT exhibits ten-
fold lower affinity for cocaine than hDAT (Porzgen et al., 2001). Another potential 
difference between our findings and the previous results is that although their 
constructs bind DA and inhibitors, they lack DA uptake function. The dDAT 
crystal structures omit much of EL2 and the N-terminus. Complete N terminal 
truncation (residues 1-66) results in a loss of DA uptake (Sorkina et al., 2009), 
truncation of residues 1-60 results in marked loss of transporter uptake velocity 
(Torres et al., 2003b), and a previous DAT truncation mutant lacking residues 1-
59 exhibits some measurable uptake, although neither the kinetic constants nor 
expression levels were reported for D1-59 DAT mutant (Gu et al., 2001). Work 
from our laboratory likewise suggests that truncations within the N-terminus 
significantly impair transporter expression and function (data not shown). Our 
current study has the benefit of using N-and C-terminal substitutions on an 
otherwise complete WT background, such that DA uptake could be assessed in 
robustly expressing transporters.  
 
Another factor that may contribute to role of the DAT N-terminus in 
substrate/inhibitor affinities is the interaction of the DAT N-terminus with PIP2 and 
IL4 (Hamilton et al., 2014; Khelashvili et al., 2015b). A recent molecular 
dynamics study examining the hDAT N-terminus on the dDAT background 
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reported a PIP2-mediated interaction with hDAT N-terminal residues (K3, K5, and 
R51) with IL4 (Khelashvili et al., 2015b). This interaction appears to break salt 
bridges necessary for the conserved intracellular gate. These findings contrast 
with simulation studies examining hSERT, where the N-terminus moves further 
away from intracellular domains following transition to the inward-open state 
(Fenollar-Ferrer et al., 2014). It should be noted that PIP2 binds to SERT at its 
intracellular loops (Buchmayer et al., 2013), but whether PIP2 affects SERT N-
terminal mobility remains untested. We did not detect differences in 
substrate/inhibitor apparent affinities among the SERT-core chimeras. The 
reported differential trajectories for DAT and SERT N-terminal domains during 
transition to the inward-open state may result in differential effects on 
substrate/inhibitor binding sites. These opposing trajectories may explain why we 
see differences in effects between DAT-core and SERT-core chimeras. 
 
In summary, we have identified a putative role for the DAT N-terminus in 
influencing the substrate/inhibitor binding site, and a possible synergistic role for 
the DAT N- and C-termini to coordinate accessibility to the binding site. These 
findings will provide critical information to future structural studies that 
incorporate DAT intracellular domains in structural analyses.  
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Chapter III  
 Dopamine transporter amino- and carboxy-termini are synergistically 
required for Ack1-dependent endocytosis 
 
Sweeney CG, Alejandro B, and Melikian HE 
 
III.A Introduction 
DAT’s regulation over synaptic DA clearance is directly related to DAT availability 
at the plasma membrane, as evidenced by DAT genetic deletion with DAT-/- mice 
(Giros et al., 1996; Gainetdinov et al., 1998) and DAT pharmacological blockade 
with numerous drugs, including the psychostimulants cocaine and AMPH 
(Kristensen et al., 2011; Vaughan and Foster, 2013; German et al., 2015). DAT 
function and surface expression are acutely regulated by PKC. PKC activation 
results in rapid DAT internalization coupled with reduced recycling rates (Daniels 
and Amara, 1999; Melikian and Buckley, 1999). Multiple reports from our lab and 
others independently implicate domains within both DAT intracellular N- and C-
termini as required for constitutive and PKC-mediated DAT endocytosis (Holton 
et al., 2005; Boudanova et al., 2008b; Sorkina et al., 2009). Our laboratory 
reported that a C-terminal motif, FREKLAYAIA (587-596), is both necessary and 
sufficient for PKC-stimulated DAT endocytosis (Holton et al., 2005; Boudanova et 
al., 2008b). Alanine substitution of the FREK sequence, (4A mutant), 
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demonstrated enhanced basal internalization rates like those seen following PKC 
activation (Boudanova et al., 2008b). This study posed the idea that a negative 
regulatory mechanism, or “endocytic brake”, exists to stabilize DAT surface 
expression. Following PKC activation, the brake is released, and the transporter 
internalizes rapidly. The Sorkin laboratory reported that DAT’s N-terminal domain 
(residues 1-65) is required for negatively regulating DAT surface expression, and 
that the juxtamembrane residues (60-65) are most critical for maintaining DAT 
surface expression (Sorkina et al., 2009). Taken together, these studies 
demonstrate that both N- and C-termini are required for negatively regulating 
DAT surface expression. It remains unknown whether independent endocytic 
mechanisms exist at both termini or whether DAT uses one synergistic endocytic 
mechanism that requires both domains. To test the hypothesis that DAT N- and 
C-termini are synergistically required for regulated DAT endocytosis, I used 
DAT/SERT chimeras in which I replaced DAT N-, C-, or both termini with SERT 
terminal domains (Sweeney et al., 2017). These chimeras were previously used 
to demonstrate that DAT’s N- and C-termini synergistically mediate substrate and 
certain inhibitor affinities. DAT and SERT are homologous transporters, yet they 
share little sequence identity at their terminal domains. DAT and SERT N- and C-
termini contain multiple phosphorylation sites, and serve as domains for protein-
protein interactions (Eriksen et al., 2010; Zhong et al., 2012; Bermingham and 
Blakely, 2016). Both transporters undergo PKC-stimulated endocytosis, but only 
DAT requires Ack1 inhibition, downstream of PKC activation, for this process 
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(Wu et al., 2015). Additionally, our laboratory reported that the small, neuronal, 
Ras-like GTPase, Rin directly binds to DAT but not SERT, and it is required for 
regulated DAT endocytosis (Navaroli et al., 2011). Here, we tested internalization 
rates for each DAT-core chimera following PKC activation and Ack1 inhibition to 
test whether the N- and C-termini synergistically mediate PKC-stimulated 
endocytosis. Our findings demonstrate that both domains are collectively 
required for enhanced endocytosis following Ack1 inhibition. Further, our data 
suggest that DAT’s N-terminus mediates a functional step between PKC-
activation and Ack1-inactivation to drive regulated endocytosis. Additionally, we 
show that Rin acts downstream of PKC activation to mediate Ack1 
dephosphorylation, however neither DAT’s N- nor C-terminus is required for the 
DAT/Rin interaction. Further, we propose a novel strategy to identify proteins 
associated with DAT’s N- and C-termini. 
 
III.B Materials and Methods 
cDNA constructs: DAT/SERT chimeras were generated as previously described 
(Sweeney et al., 2017).  Bungarotoxin-binding site (BBS) DAT-core chimeras 
were generated as described in Wu et al. (Wu et al., 2017), with the following 
amino acid sequence inserted: GSSGSSGWRYYESSLEPYPDGSSGSSG. 
Underlined sequence refers to the BBS sequence, as flanked by linker sequence. 
All chimeric BBS-constructs were confirmed by Sanger sequencing (Genewiz). 
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Cell culture, transfection, and generation of pooled stable cell lines: Cells were 
maintained in either MEM (SK-N-MC cells) or DMEM (HEK293T and SK-N-DZ 
cells) supplemented with 10% fetal bovine calf serum, 100 units/mL 
penicillin/streptomycin, 2 mM L-glutamine, 1X non-essential amino acids (SK-N-
DZ cells), 37°C, 5% CO2.  Cells were transfected with WT, chimera, or BBS-DAT 
cDNAs using Lipofectamine 2000 according to manufacturer’s instructions with 
the following modifications: Cells were seeded into 6 well plates at a density of 
1x106 (SK-N-MC) or 5x105 (HEK293T) one day prior to transfection, and were 
transfected with 3 µg (SK-N-MC) or 2µg (HEK293T) plasmid DNA/well using a 
lipid:DNA ratio of 2:1. To generate stable cell lines, 48 hours following 
transfection, cells were selected using 0.5 mg/mL G418. Stably transfected cells 
were pooled and cell lines were maintained under selective pressure using 0.2 
mg/mL G418 (SK-N-MC).  
 
Uptake assays: [3H]DA uptake: All uptake assays were conducted as previously 
described in Chapter II (Sweeney et al., 2017).  
 
Internalization assay: Relative internalization rates were measured by reversible 
biotinylation as previously described (Loder and Melikian, 2003; Gabriel et al., 
2013; Wu et al., 2015).  Briefly, cells were rapidly chilled by washing in ice-cold 
PBS, pH 7.4, supplemented with 1.0 mM MgCl2, 0.1 mM CaCl2 (PBS2+), and 
incubated with 1.0 mg/ml sulfo-NHS-SS-biotin in ice-cold PBS2+, twice, for 15 min 
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at 4°C. Residual reactive NHS groups were quenched by repeated washing and 
incubating twice in PBS2+/100 mM glycine, 15 min, 4°C. Cells were washed four 
times with warmed PBS2+ supplemented with 0.18% glucose and 0.2% BSA 
±1µM PMA or 20µM AIM-100, and incubated 10min, 37oC to allow for 
internalization. Internalization was stopped by immediately moving the cells to ice 
and washing three times with ice cold NT buffer (150 mM NaCl, 20mM Tris, pH 
8.6, 1.0mM EDTA, pH 8.0, 0.2% BSA). Remaining surface biotin was stripped 
from internalization samples and strip controls with two incubations of 100mM 
TCEP in NT buffer, 25min, 4oC.  Cells were washed four times with PBS2+ and 
then lysed, and biotinylated proteins were isolated with streptavidin agarose 
beads and analyzed by SDS-PAGE followed by immunoblotting with anti-DAT 
(WT DAT and DAT/C-SERT) or anti-SERT (N-SERT/DAT and SERT/DAT/SERT) 
antibodies.  
 
BBS-DAT/chimera pulldowns: HEK cells transiently expressed BBS-DAT/chimera 
and HA-Rin at a ratio of 1:4. Cells were washed thrice with ice cold PBS and 
labeled with 120µM biotinylated α-bungarotoxin (BTX-b, Thermo Fisher), 2 hours, 
4oC. Bungarotoxin was removed from the cells and disposed of in the satellite 
accumulation area. Next, cells were washed thrice with ice cold PBS to remove 
any excess BTX-b. Cells were lysed with cold co-immunoprecipitation lysis 
buffer, also known as “Magic Lysis Buffer”, (50 mM Tris, pH 7.4, 100 mM NaCl, 
1% Triton X-100, 10% glycerol, and 1 mM EDTA) containing protease inhibitors 
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(1.0 mM PMSF and 1.0 g/ml each leupeptin, aprotinin, and pepstatin) and 
Phosphatase Inhibitor Mixture V (EMD Millipore). Following a 30min lysis, lysates 
were transferred to centrifuge tubes, and spun down at max speed for 10min in 
the cold room. Lysate protein concentrations were assessed with BCA assay 
(ThermoFisher), and equal amounts of BTX-b labeled protein were rotated 
overnight with streptavidin M280 dynabeads at 4°C. The next day, beads were 
washed, gently, with cold Magic Lysis Buffer. Pulled-down proteins were resolved 
by SDS-PAGE, and immunoblotted with antibodies for DAT, SERT, and HA.  
 
RT-qPCR: Total RNA was isolated using RNAqueous kit (Thermo) per 
manufacturers protocol. Following DNAase treatment (30 min, 37°C), cDNA was 
generated (Retroscript; Thermo) and mRNA levels were quantified by RT-qPCR, 
using an Applied Biosystems 7500 Real-Time System and TaqMan assays 
(Applied Biosystems). Each mRNA sample was analyzed in triplicate, and 
expression levels were normalized to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) expression, using 2-ΔCt method (Schmittgen and Livak, 
2008).  
 
Materials: Rat anti-DAT (MAB369) antibody was from Millipore, mouse anti-
SERT antibody was from MAb technologies, and Rat anti-HA (3F10) was from 
Roche. Horseradish peroxidase (HRP)-conjugated anti-rat secondary and mouse 
anti-actin (SPM161) antibodies were from Santa Cruz and HRP-conjugated anti-
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mouse antibody was from Jackson Immunoresearch Laboratories (115-035-003). 
Biotinylated bungarotoxin and M280 dynabeads were from Thermo Scientific. 
PMA and AIM-100 were from Tocris.  All other chemicals and reagents were from 
Sigma-Aldrich and Thermo Fisher Scientific and were of the highest grade 
available.  
 
III.C Results 
To test whether DAT’s N- and C-termini synergistically mediate PKC-stimulated 
endocytosis, we measured endocytic rates in WT DAT and DAT-core chimeras 
(Sweeney et al., 2017) following PKC activation, using PMA, or downstream 
Ack1 inactivation using the Ack1-specific inhibitor AIM-100 (Fig. III-1). The DAT-
core chimeras have DAT’s N-, C-, or both termini replaced with SERT terminal 
domains. SERT is a homologous transporter, but shares little sequence identity 
with DAT at the intracellular terminal domains. We measured a significant 
increase in WT DAT internalization rates following PKC activation and Ack1 
inhibition (Fig. III-1A), consistent with previous studies (Wu et al., 2015). DAT/C-
SERT, where DAT’s C-terminus is replaced with SERT’s, displayed a significant 
increase in endocytic rates following both PKC activation and Ack1 inhibition, 
similar to WT DAT (Fig. III-1B). Surprisingly, substituting SERT’s N-terminus onto 
DAT (N-SERT/DAT, Fig. III-1C) abolished PKC-stimulated DAT endocytosis, but 
maintained enhanced endocytic rates following Ack1 inhibition. Replacing both 
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intracellular termini with SERT’s (SERT/DAT/SERT, Fig. III-1D) abolished 
enhanced endocytosis following both PKC activation and Ack1 inhibition. Taken 
together, these data suggest that DAT’s N-terminus is required for PKC-
stimulated endocytosis and that both N- and C-termini synergistically coordinate 
enhanced endocytosis following Ack1 inhibition. This interpretation initially 
seemed counterintuitive, given that previous reports from our lab and others 
demonstrate that PKC activation leads to Ack1 dephosphorylation (Linseman et 
al., 2001; Wu et al., 2015), and that Ack1 dephosphorylation is required for 
regulated DAT endocytosis (Wu et al., 2015). These findings raised the 
hypothesis that there is a molecule, which associates with DAT’s N-terminus and 
acts downstream of PKC activation, to mediate Ack1 inactivation.  
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Figure III-1. DAT N-terminus is required for PKC-stimulated 
internalization and both N- and C-termini are required for the Ack1 
endocytic brake. A-D. Internalization assays. Stable SK-N-MC cells 
expressing (A)WT DAT, (B)DAT/C-SERT, (C)N-SERT/DAT, or 
(D)SERT/DAT/SERT. Relative internalization rates were measured by 
reversible biotinylation over 10 minutes ± 10µM PMA or ±20µM AIM-100, 37oC 
as described in III.B Materials and Methods.  Top, representative immunoblot 
showing total surface transporter at time 0 (T), strip control (S), internalized 
transporter under vehicle treated (V), PMA treated (P), and AIM-100 treated 
(A) conditions. Bottom, averaged internalization rates± S.E.M., normalized to 
transporter’s own vehicle treatment. **p<0.01, *p<0.05, significantly different 
from vehicle treated control, one way ANOVA, Dunnett’s multiple comparisons 
test, n=7-13.  
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Our laboratory previously reported that Rin GTPase is required for PKC 
stimulated DAT endocytosis (Navaroli et al., 2011) and the Hoshino laboratory 
reported that PKC activates Rin (Hoshino and Nakamura, 2002), posing Rin as a 
possible candidate for promoting Ack1 inactivation downstream of PKC 
activation. To test this hypothesis, we overexpressed empty vector, HA-Rin, 
constitutively active HA-Rin(Q78L), and dominant negative HA-Rin(S34N) in 
HEK293T cells. We treated them ±10µM PMA, 37oC, 30 minutes, and assayed 
Ack1 dephosphorylation (Fig. III-2). Dominant negative Rin significantly reduced 
PKC-stimulated Ack1 dephosphorylation compared to vector controls, indicating 
that Rin activity is required downstream of PKC to inactivate Ack1.  
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Figure III-2. Rin mediates Ack1 inactivation downstream of PKC 
activation. Ack1 inactivation. HEK293T cells were transiently transfected with 
Vector, HA Rin, HA Q78L Rin, or HA S34N Rin for 48 hours. Cells were 
treated ± 10µM PMA, 37°C, 30 minutes. (A) Representative blot. (B) Average 
pAck1 expression relative to actin ± S.E.M., normalized to own vehicle 
treatment.  *Significantly different from vector control, p<0.05, one way 
ANOVA, Dunnett’s multiple comparisons test, n=9.  
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Given our findings that DAT’s N-terminus is required for PKC-stimulated 
endocytosis, and that Rin acts downstream of PKC to mediate Ack1 
dephosphorylation, we hypothesized that Rin associates with DAT’s N-terminus. 
Previous studies investigating DAT binding proteins rely upon co-IPs using large 
antibodies targeted against DAT’s N- and C-terminus (Table I-1). These 
preparations isolate total cellular DAT populations, rather than specifically the 
surface population. To pulldown surface DAT protein, while keeping intracellular 
protein-protein interactions intact, we engineered WT DAT and DAT-core 
chimeras with a bungarotoxin binding site (BBS) in the second extracellular loop 
(EL2) (Fig. III-3A). The BBS-site was placed in EL2 because insertions into this 
domain do not disrupt DAT function and trafficking (Sorkina et al., 2006; Navaroli 
and Melikian, 2010; Wu et al., 2017). BBS-DAT displays functional [3H]DA 
uptake, and downregulates in response to PKC activation (Fig. III-3B), and BBS-
DAT binds to Rin (Fig III-3C,D). Next, we tested whether DAT’s N-terminus is 
required for the DAT-Rin interaction. Each BBS-DAT-core chimera expressed 
and came down following labeling with biotinylated bungarotoxin; albeit, BBS-
SERT/DAT/SERT did not express well, consistent with our previous report 
(Sweeney et al., 2017). Interestingly, each BBS-DAT-core chimera pulled down 
HA-Rin, indicating that neither DAT’s N- nor C-terminus is required for the DAT-
Rin association, or that homologous domains within the SERT termini are 
sufficient to maintain the DAT-Rin interaction.  
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Figure III-3.  Bungarotoxin binding site DAT (BBS-DAT) pulls down 
surface DAT and helps to maintain intracellular protein-protein 
interactions. (A) BBS-DAT schematic. Traditional DAT co-IP experiments use 
a large antibody targeted against DAT’s intracellular N-terminus, which may 
disrupt intracellular interactions (left). BBS-DAT (right) uses an bungarotoxin 
binding site (BBS) inserted into DAT’s second extracellular loop to exclusively 
pulls down surface DAT populations while keeping intracellular interactions 
intact. (B) BBS-DAT downregulates in response to PKC activation. [3H]DA 
uptake assay. SK-N-MC cells stably expressing BBS-DAT were treated 
±10µM PMA, 30 min, 37°C and uptake assay was performed as described in 
III.B Materials and Methods. PKC activation significantly reduced [3H]DA 
uptake compared to vehicle controls. **significantly different compared to 
vehicle control, p<0.01, t-test, n=3. (C) BBS-DAT specificity control. BBS-DAT 
pulldown. HEK293T cells transiently transfected with HA Rin and either BBS-
DAT or WT DAT as described in III.B Materials and Methods. BTX labeling 
pulls down HA Rin with BBS-DAT but not WT DAT. (D) DAT’s N- and C-
termini are not required for DAT-Rin interaction. BBS-DAT core chimera 
pulldown with cells transiently transfected with respective BBS-chimera and 
HA Rin as described in III.B Materials and Methods. Each BBS-chimera pulled 
down HA Rin. Neither DAT N- nor C-terminus is required for the DAT/Rin 
interaction.  
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It should be noted that over the course of these studies, we discovered that SK-
N-MC cells do not express endogenous Rin (Fig. III-4). While Navaroli et al., 
reported that every cell line they investigated contained Rin (Rit2) mRNA 
(Navaroli et al., 2011), this finding was in contrast with Zhang et al., who did not 
detect Rin mRNA in HEK293 or SK-N-MC cells. However, they did detect 
endogenous Rin mRNA expression in SK-N-DZ cells (Zhang et al., 2013). To test 
what cell lines contain endogenous Rin, we performed RT-qPCR using cDNAs 
isolated from human cell lines, HEK293T, SK-N-MC, and SK-N-DZ (Fig. III-4). 
We only detect Rin mRNA in SK-N-DZ cells, consistent with the findings of 
Zhang et al.  
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Figure III-4. SK-N-DZ but not HEK293 nor SK-N-MC cells express Rin. RT-
qPCR from cDNA isolated from HEK293, SK-N-MC, and SK-N-DZ cells as 
stated in III.B. Materials and Methods. Relative Rin (Rit2) mRNA expression 
normalized to GAPDH levels and represented as 2-DCt. HEK293 and SK-N-MC 
cells do not express endogenous Rin, whereas, SK-N-DZ cells express 
measureable quantities of Rin.  
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III.D Discussion 
Our laboratory reported that an “endocytic brake” negatively regulates DAT 
surface expression, and the DAT C-terminal domain, FREKLAYAIA (587-596), is 
both necessary and sufficient for PKC-stimulated endocytosis (Holton et al., 
2005). Further, the FREK sequence (587-590) is required for the endocytic brake 
(Boudanova et al., 2008b). The Sorkin laboratory also reported a DAT endocytic 
negative regulatory mechanism, that requires juxtamembrane residues (60-65) at 
the N-terminus (Sorkina et al., 2009). These data suggest that DAT’s N- and C-
termini each independently coordinate an endocytic brake or rather that both 
domains synergistically mediate the endocytic brake. In this chapter, I tested the 
hypothesis that both domains are synergistically required for regulating DAT 
surface expression.  
 
Reports from our laboratory and others support that N- and C-terminal synergy is 
required for DAT regulatory mechanisms. AMPH-stimulated DA efflux requires 
coordination between DAT N- and C-termini. CaMKII (calcium/calmodulin-
dependent protein kinase II) associates with the DAT C-terminus to mediate N-
terminal phosphorylation (Khoshbouei et al., 2004; Fog et al., 2006a). Our 
laboratory recently reported that DAT N- and C-termini synergistically contribute 
substrate and select inhibitor affinities using the same DAT/SERT chimeras 
utilized in this chapter (this topic is discussed in depth in Chapter II)  (Sweeney et 
al., 2017). Additionally, DAT is palmitoylated at its membrane-proximal C-
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terminus (Foster and Vaughan, 2011; Moritz et al., 2015). Following PKC 
activation, palmitoylation decreases and N-terminal phosphorylation increases, 
and there is a reciprocal relationship between these two events. Taken together, 
these studies demonstrate that N- and C-terminal domains are synergistically 
required for AMPH-stimulated efflux, substrate affinity, and functional regulation; 
therefore, suggesting that other DAT functional mechanisms may require 
terminal synergy as well.  
 
In this chapter, we demonstrate that DAT N- and C-termini synergistically 
coordinate regulated endocytosis. While N-SERT/DAT and DAT/C-SERT both 
showed enhanced endocytosis following Ack1 inhibition, swapping both DAT 
intracellular termini for SERT domains abolished enhanced endocytosis following 
PKC activation and Ack1 inactivation (Fig III-1D). This finding demonstrates that 
DAT uses both N- and C-termini for Ack1-dependent endocytosis.  
 
WT SERT undergoes PKC-stimulated endocytosis (Qian et al., 1997; Samuvel et 
al., 2005), and its mechanism is distinct from DAT regulated endocytosis 
(Navaroli et al., 2011; Wu et al., 2015). When both SERT intracellular domains 
were swapped onto DAT, we abolished PKC-stimulated endocytosis. Although it 
is known that WT SERT undergoes PKC-stimulated endocytosis (Qian et al., 
1997), having two “matching” SERT intracellular domains was not sufficient to 
drive PKC-stimulated endocytosis in a putatively SERT-dependent manner. 
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Rather, it appears that the SERT terminal domains may require intact SERT 
protein in order to drive PKC-stimulated internalization. Future studies using 
SERT-core chimeras may shed light as to the role of these domains in SERT 
endocytic mechanisms.  
 
Interestingly, our N-SERT/DAT chimera did not internalize rapidly in response to 
PKC activation; however, it demonstrated significantly enhanced endocytic rates 
following Ack1 inhibition. We found this result surprising in light of reports from 
our group and others demonstrating that PKC activation inactivates Ack1, and 
Ack1 inactivation is required for PKC-stimulated DAT endocytosis (Linseman et 
al., 2001; Wu et al., 2015). How is the DAT N-terminus required for PKC-
stimulated endocytosis but not enhanced endocytosis following the downstream 
Ack1 inactivation? We hypothesize that a molecule associated with the DAT N-
terminus is required for PKC-stimulated Ack1 inactivation, and that it accelerates 
Ack1 dephosphorylation. We tested whether Rin, a protein which 1) associates 
with DAT but not SERT, 2) is activated by PKC, and 3) whose activity is required 
for PKC-stimulated DAT endocytosis, is required for Ack1 inactivation 
downstream of PKC. HEK293 cells overexpressing dominant negative Rin 
displayed significantly less Ack1 inactivation following PKC activation compared 
to vector controls. This result suggests that Rin activity is required downstream of 
PKC to inactivate Ack1.  
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Additionally, we found that neither the DAT N- nor C-terminus was required for 
Rin association with DAT. The most likely explanation for this finding is that 
DAT’s intracellular loops are sufficient for the DAT/Rin interaction. However, Rin 
was initially discovered to be a DAT binding protein through a yeast 2-hybrid 
screen using the C-terminal sequence, FREKLAYAIA, as bait (Navaroli et al., 
2011). Taken together, these data suggest that the DAT C-terminus is sufficient 
but not necessary for the DAT/Rin interaction. However, a limitation to the BBS-
DAT pulldown is that it isolates DAT associated protein complexes rather than 
solely proteins directly interacting with DAT. Using this method, we cannot rule 
out the possibility that Rin, which binds to the plasma membranes via a polybasic 
domain (Heo et al., 2006), remains part of a DAT-associated complex even if 
potential direct interactions with N- or C-terminal domains is disrupted. Future 
FRET studies using CFP-tagged DAT-core chimeras will test this hypothesis. 
Further, additional studies, using the BBS-DAT chimeras will test additional 
candidates for N-terminally associated proteins required for Ack1 inactivation 
downstream of PKC activation. One such candidate is RACK1 (Receptor of 
activated protein kinase C 1). RACK1 associates with DAT’s N-terminus (Lee et 
al., 2004; Franekova et al., 2008), and acts as an adapter protein to link PKC 
with its substrates (Adams et al., 2011). While RACK1 association with DAT was 
reported by two independent groups, the functional implications remain untested.  
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Our new BBS-DAT construct demonstrated that neither the DAT N- nor the C-
terminus is required for the DAT/Rin interaction. However, in spite of this 
negative result, BBS-DAT will be a critical tool in identifying novel DAT binding 
partners. Previous studies testing DAT-associated proteins rely upon DAT co-
immunoprecipitation using large antibodies targeted against the DAT N- or C-
terminus. A limitation to this approach is that it requires bulky antibodies that can 
disrupt sensitive and dynamic protein-protein interactions. Additionally, these 
approaches investigate entire cellular DAT populations. Here, we are interested 
in proteins that interact with DAT specifically at the plasma membrane, and BBS-
DAT will only pull down the surface DAT population. These studies are not the 
first to insert a bungarotoxin binding site in the DAT’s EL2 (Hong and Amara, 
2013). However, a notable difference between our construct and the Amara 
laboratory’s construct is the use of our previously published linker sequence (Wu 
et al., 2015), which allows for epitope access at a wide range of temperatures. 
This access at 4°C is an important difference between our BBS-DAT and HA-
EL2-DAT, which has the HA-tag only accessible at temperatures above 18°C 
(Sorkina et al., 2006).  
 
Upon completion of our studies, we discovered that our SK-N-MC cells do not 
express endogenous Rin (Fig. III-4). While this finding suggests that Rin may not 
be in fact required for PKC-stimulated DAT internalization, we report that in intact 
DA nerve terminals, Rin is absolutely required for this process (Chapter IV, 
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Fig.IV-9). Therefore, we predict that another protein, perhaps the homologous 
GTPase Rit, compensates in the absence of Rin in certain heterologous 
expression systems; however, this remains untested. Future studies using 
heterologous expression systems to test DAT endocytic mechanisms should 
utilize cells that express endogenous Rin, such as the SK-N-DZ human 
neuroblastoma line. 
 
In this chapter, we identified that DAT N- and C-termini synergistically mediate 
regulated endocytosis following Ack1 inactivation, Rin activity is required 
downstream of PKC to inactivate Ack1, and DAT’s N-terminus mediates PKC 
inactivation of Ack1, but not through association with Rin. Further, we 
demonstrated use of a new BBS-DAT construct which can be used to test for 
future DAT interacting protein. 
 
CHAPTER IV 	
	 95 
Preface to Chapter IV 
Conditional, inducible gene silencing in dopamine neurons  
reveals a critical role for Rin GTPase in anxiety, presynaptic  
dopaminergic function, and response to cocaine 
These data are unpublished and in preparation for manuscript submission 
 
Author contributions: 
Carolyn Sweeney, Gilles Martin, Andrew Tapper, and Haley Melikian designed 
experiments 
 
Carolyn Sweeney, Patrick Kearney, Iris Rivera, and Gilles Martin performed 
experiments 
 
Carolyn Sweeney, Patrick Kearney, Jenya Kolpakova, Gilles Martin, and Haley 
Melikian analyzed data 
 
Jun Xie and Guangping Gao designed AAV-TRE-shRNA vector 
 
University of Massachusetts Viral Vector Core packaged viral vectors for 
expression 
  
CHAPTER IV 	
	 96 
 
Chapter IV 
Conditional, inducible gene silencing in dopamine neurons  
reveals a critical role for Rin GTPase in anxiety, presynaptic  
dopaminergic function, and response to cocaine 
 
Authors: Sweeney CG, Kearney PK, Rivera IV, Kolpakova J, Xie J,  
Guangping G, Tapper AR, Martin GE, and Melikian HE 
 
IV.A Introduction 
Dopamine (DA) is a critical modulatory neurotransmitter required for learning, 
motivation, movement, anxiety, and rewarding behaviors (Wise, 2004; Russo and 
Nestler, 2013). DA signaling dysfunction has profound clinical consequences, as 
evidenced by multiple neurological and neuropsychiatric disorders, including 
Parkinson’s disease, ADHD, schizophrenia, and anxiety (Calhoon and Tye, 2015; 
Faraone et al., 2015; Grace, 2016; Poewe et al., 2017). The neuronal, Ras-like 
GTPase, Rin (Rit2) is highly enriched in DA neurons (Zhou et al., 2011); 
however, its role in DAergic signaling remains entirely unknown. GWAS studies 
implicate Rin as a risk allele for Parkinson’s disease, autism spectrum disorder, 
essential tremor, schizophrenia, and bipolar disorder (Emamalizadeh et al., 
2017). Rin is required for neurotrophic signaling and causes neurite outgrowth in 
PC6 cells (Shi et al., 2005b). Rin binds directly to the presynaptic, cocaine- and 
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AMPH-sensitive DA transporter (DAT), and Rin activity is required for regulated 
DAT endocytic trafficking in PC12 cells (Navaroli et al., 2011). Despite the 
putative linkage between Rin and DAergic activity, it is currently unknown 
whether Rin activity directly impacts DAergic physiology. To test the hypothesis 
that Rin expression in DA neurons is required for DAergic function, we used 
conditional, inducible Rin knockdown in DA neurons of adult mice, and assessed 
locomotor, anxiety, and cocaine-induced behavior.  
 
IV.B Materials and Methods 
Mice. Pitx3IRES-tTA/+ were the generous gift of Dr. Huaibin Cai (National Institute 
on Aging), and were continually backcrossed to C57Bl/6(Lin et al., 2012). Mice 
were maintained in 12hr light/dark cycle at constant temperature and humidity. 
Food and water was available ad libitum, and mice were maintained on either 
standard or doxycycline-supplemented chows (S3888, BioServ). Studies were 
conducted in accordance with UMASS Medical School IACUC Protocol A-1506 
(H.E.M). 
 
Stereotaxic viral delivery. Adult mice (minimum 5 weeks old) were anesthetized 
with an i.p. injection of 100mg/kg ketamine (Vedco Inc.) and 10mg/kg xylazine 
(Akorn Inc.). 20% mannitol (NeogenVet) was administered i.p. 15 minutes 
(minimum) prior to viral delivery, to increase viral spread (Burger et al., 2005). 
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Mice heads were shaved and placed in the stereotaxic frame (Stoelting Inc.). 
Heads were disinfected by washing three times with betadine followed by 70% 
ethanol. A small incision was cut to expose the skull, and a 30%H2O2 solution 
was used to clean the skull surface and visualize Bregma. 1µl indicated viruses 
were administered bilaterally into the VTA (Bregma: anterior/posterior: -3.08mm, 
medial/lateral: ±0.5mm, dorsal/ventral: -4.7mm) at a rate of 0.2µL/min over 5 
minutes. Syringes were left in place for a minimum of 3 minutes post-infusion 
prior to removal. Mice were individually housed, for a minimum of six weeks 
before experiments were performed. Dox-treated mice were placed on dox-
supplemented chow at minimum 4 days prior to stereotaxic injection and were 
maintained on +dox chow throughout recovery and experimental procedures.  
 
Mouse Behavior. Open field test. Male and female mice were habituated to 
experimental room for a minimum of 30 minutes before conducting experiment. 
The room was kept in dim light, and white noise was used to maintain constant 
ambient sound. During test, a single mouse was placed in a 38.5x40cm box. 
Activity was recorded using a video camera for ten minutes. EthoVision software 
(Noldux) was used to determine total distance traveled and time spent in center 
versus periphery of the arena. Two-way ANOVA revealed no gender differences 
detected for either total distance (p=0.94) or time in center p=0.81, therefore data 
from both sexes were pooled. Elevated Plus Maze (EPM). Male and female mice 
were habituated to experimental room for a minimum of 30 minutes before 
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conducting the experiment. The room was kept in dim light throughout 
habituation and experimental procedures. The EPM apparatus consists of four 
arms- two open and two closed- 45cm above the floor. During the test, a single 
mouse was placed in the center of apparatus. The animal was allowed to explore 
open and closed arms of apparatus for 5 minutes. Time spent in open and closed 
arms and total number of entries into both sets of arms was recorded by MED-
PC IV software (MED Associates, Inc.). Two-way ANOVA revealed no gender 
differences detected for time in open arms (p=0.63), therefore data from both 
sexes were pooled. Cocaine induced locomotor activity. Animals were placed in 
locomotor activity chamber (San Diego Instruments), and locomotor activity was 
recorded during a 45 minute habituation period. Next, each animal received a 
saline injection (10mL/kg), and locomotor activity was recorded for 90 minutes. 
This initial test served as a baseline for each mouse. Two days later, mice 
habituated to test chamber 45 mins, during which their locomotor activity was 
recorded. Next, each mouse received cocaine injection at either 15mg/kg or 
30mg/kg, and we recorded their activity for 90 minutes.  
 
Immunohistochemistry. Mice were transcardially perfused with ice-cold 
phosphate-buffered saline, pH 7.4 (PBS), followed by ice cold 4% 
paraformaldehyde/PBS (w/v). Brains were removed and dehydrated in 30% 
sucrose/PBS (w/v), 3-7 days, and 25µm sections were prepared using 
microtome. Tissue was blocked and permeabilized in IHC blocking solution (5% 
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normal goat serum, 1% H2O2, 0.1% Triton-X 100 in PBS), 1 hour, at RT. All 
antibodies were diluted in IHC blocking solution. Slices were incubated in 
indicated primary antibodies, 1 hr, RT, washed and incubated with the indicated 
secondary antibodies, 45 minutes, RT. Slices were washed, mounted on glass 
slides and allowed to air dry prior to mounting on glass coverslips using Prolong 
Gold Anti-fade with DAPI (Invitrogen). Slides dried overnight and widefield 
epifluorescent images were captured with a Zeiss Axiovert 200M scope using 
Retiga-R1 CCD camera (QImaging) and Slidebook 6 software (Intelligent 
Imaging Innovations).  
 
Midbrain tissue isolation and RT-qPCR. Animals were sacrificed, brains were 
rapidly removed and either flash frozen on dry ice or sectioned (200µm) fresh on 
a Vibratome in ice cold cutting solution (2.5mM KCl, 1.25mM NaH2PO4, 20mM 
HEPES, 2mM thiourea, 5mM sodium ascorbate, 3mM sodium pyruvate, 92mM 
N-methyl-D-glucamine, 30mM NaHCO3, 25mM D-glucose). 1mm diameter tissue 
punches were made in VTA/SNc or SNr, under magnification. For frozen tissue, 
10µm coronal sections were made using cryostat (Leica Microsystems Inc.). A 
Veritas Microdissection System Model 704 (Arcturus Bioscience) was used to 
microdissect SNc/VTA- or SNr-enriched regions. Total RNA was isolated using 
RNAqueous kit (Thermo) per manufacturers protocol. Following DNAase 
treatment (30 min, 37°C), cDNA was generated (Retroscript; Thermo) and mRNA 
levels were quantified by RT-qPCR, using an Applied Biosystems 7500 Real-
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Time System and TaqMan assays (Applied Biosystems). Each mRNA sample 
was analyzed in triplicate, and expression levels were normalized to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression, using 2-ΔCt 
method(Schmittgen and Livak, 2008).  
 
Western blot. Protein was solubilized in RIPA (10mM Tris base pH 7.4, 150mM 
NaCl, 1mM EDTA, 0.1% (v/v) SDS, 1% (v/v) Triton-X 100, 1% (w/v) sodium 
deoxycholate) with protease inhibitors (1mM PMSF, 1µg/mL leupeptin, 1µg/mL 
pepstatin, 1µg/mL aprotinin) for a minimum of 30 minutes at 4°C. Protein 
concentrations were determined by Pierce BCA protein assay. Indicated amounts 
of protein were incubated with sample buffer (1.0M Tris, pH 6.8, 5%SDS, 10% 
glycerol, 1% bromophenol blue, 50mM DTT) and rotated, 30 minutes at RT. 
Samples were analyzed by SDS-Page and immunoblot using indicated 
antibodies. Immunoreactive bands were quantified using Quantity One software 
(BioRad).  
 
Cell transfection and cDNA. 5x105 HEK293T cells/well were seeded one night 
prior to transfection in 6 well plates. Cells were transfected with Lipofectamine 
2000 (Thermo Fisher) per manufacturers protocols. Briefly, we used 4µg 
Lipofectamine/well at a ratio of 2:1 lipid to cDNA. For Rin knockdown 
experiments we used 0.66µg shRNA containing cDNA and 0.33µg RFP-mRin 
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reporter cDNA, and 1 µg rtTA plasmid. Mouse Rin in pGEX2T was a gift from 
Julian Downward (Addgene plasmid #55663)(Fritsch et al., 2013). It was PCR 
amplified and subcloned into TagRFP vector using HindIII and XbaI. Rin shRNAs 
and pGIPZ controls were obtained from Dharmacon. Mature antisense 
sequences for each shRNA are as follows: mRin837 (clone V3LMM_441839) 
TTATCTTCTTCCACAGGCT and mRin794 (clone V3LMM_441840) 
TCATAGGTGTGACGGACCT. pscAAV-TRE-eGFP and pscAAV-TRE-miR33-
shRNA-eGFP plasmids. pTre3G promoter was isolated from pTre3G (Clone 
tech) plasmid using EcoRI and SalI. The CB6 promoter in the pscAAV-CB6-
eGFP was removed by MluI and BstXI digestion and replaced with the pTre3G 
promoter to generate pscAAV-TRE3g-eGFP plasmid. pscAAV-TRE3g-eGFP 
plasmid was digested with BglII and PstI as backbone, miR-33-shRNA was 
synthesized as insert to generate pscAAV-TRE3g-miR33-shRin-eGFP. 
 
Slice preparation: Three-week-old male Pitx3IRES-tTA/+ mice or Pitx3IRES-tTA/ 
D1r.Td-tomato mice were given bilateral VTA injections of either AAV9-TRE-
eGFP or AAV9-TRE-shRin-eGFP and allowed 3-4 weeks to recover and for viral 
expression. Mice were deeply anesthetized with isoflurane, and killed by 
decapitation. To cut 200 µm (electrophysiology) or 300 µm (slice biotinylation)-
thick coronal slices with a Vibroslicer (VT1200, Leica MicroInstrutments; 
Germany), we rapidly removed and transferred the brain in a cold (~ +0.5oC) 
oxygenated (95% O2 and 5% CO2) cutting solution of the following composition: 
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92 mM NMDG, 2.5 mM KCl, 1.25 mM NaH2PO4 , 30 mM NaHCO3 , 20 mM 
HEPES, 25 mM glucose,  2 mM thiourea, 5 mM Na-ascorbate, 3 mM Na-
pyruvate, 0.5 mM CaCl2·4H2O, and 10 mM MgSO4·7H2O. Then, slices were 
immediately transferred in an incubation chamber containing aCSF (in mM): 119 
mM NaCl, 2.5 mM KCl, 1.25 mM, NaH2PO4 , 24 mM NaHCO3 , 12.5 mM 
glucose, 2 mM CaCl2·4H2O, and 2 mM MgSO4·7H2O. Electrophysiology:  
Following a minimum recovery time of 1 hr at room temperature, we transferred 
slices to a recording chamber where they were submerged and perfused with a 
carbogenated aCSF, at a constant rate of 1–2 mL/min. We visualized nucleus 
accumbens medium spiny neurons in infrared differential interference contrast 
video microscopy using a fully motorized microscope (Scientifica, Uckfield, UK) 
mounted with Olympus objectives (10x and 60x; Olympus Microscopy, Japan). 
Slice biotinylation: Striatal slices were collected and hemisected along the 
midline before recovering 40min at 31°C in oxygenated ACSF.  
 
Electrophysiology. When recording spontaneous excitatory postsynaptic 
potentials (sEPSPs), we acquired 2 min gap-free current and voltage traces 
using borosilicate glass electrodes (1.5 mm OD, 4–6 MΩ resistance) filled with an 
internal solution containing (in mM): 120 Cs-methanesulfonate, 20 KCl, 10 
HEPES, 2 K2ATP, 2 K2GTP, and 12 phosphocreatine. We acquired and filtered 
EPSPs at 10 kHz and 2 kHz, respectively, with an EPC-10 amplifier and 
Patchmaster, an acquisition software (HEKA, Elektronik, Germany). We analyzed 
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sEPSPs amplitude and frequency with Mini 6.0 software (Synaptosoft Inc, USA). 
The threshold was determined by the formula  rms x 3 (~ 0.4 mV). We 
monitored series resistance by comparing EPSCs decay time before and after 
induction. We rejected recordings with changes of resting potential larger than 1 
mV.  
 
Slice biotinylation. Hemislices were treated ±1μM PMA or 10μM AMPH in ACSF 
for 30min at 37°C with constant oxygenation, using contralateral hemisections as 
controls. Following drug treatment, slices were moved to ice and biotinylated with 
membrane-impermeant sulfo-NHS-SS-biotin (1mg/ml) for 45min. Residual biotin 
was quenched with two washes of ice-cold ACSF supplemented with 100mM 
glycine for 20min. Slices were then washed with ice-cold ACSF and lysed in 
RIPA buffer containing protease inhibitors by triturating sequentially through a 
200μL pipet tip, 22G and 26G tech-tips and rotating 30min at 4°C. Protein 
concentrations were determined using a BCA protein assay. Biotinylated proteins 
were isolated by pull down of 20μg lysate with 30μL of streptavidin agarose 
beads overnight. A total 20μg lysate fraction of each lysate was also reserved. 
Isolated proteins were eluted from beads in denaturing SDS/PAGE sample buffer 
for 30min at room temperature with rotation. Samples were analyzed by 
SDS/PAGE and DAT was detected by immunobloting. Surface DAT levels were 
determined by comparing biotinylated DAT to total DAT fractions. 
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Viral production. pscAAV-TRE-shRin-eGFP and pscAAV-TRE-eGFP were 
packaged into AAV9 viral particles by the University of Massachusetts Medical 
School Viral Vector Core.  
 
Antibodies. Rat anti-DAT 1:2000 (MAB369, Millipore), mouse anti-actin 1:5000 
(Santa Cruz), mouse anti-RFP 1:2000 (Thermo), rabbit anti-TH 1:500 (Millipore), 
goat anti-rat HRP 1:5000 (Santa Cruz), goat anti-mouse HRP 1:5000 (Jackson 
Laboratories).  
 
IV.C Results 
Conditional and inducible Rin knockdown with the Tet-OFF/ON system. 
Conditional and inducible, rAAV-mediated gene delivery has proven an 
indispensable tool for pinpointing molecular mechanisms that operate within 
specific neuronal circuits. However, AAV-mediated gene-silencing studies have 
not progressed as rapidly as have transgene overexpression and gene ablation 
studies. Short, inverted repeat DNA sequences cause instability within the viral 
genome (Xie et al., 2017). This precludes effectively using Cre-lox technology 
due to the inverted sequences in both the shRNA and within lox sites. AAV 
packaging size constraints further eliminate many large, neuronal promoters to 
conditionally drive shRNAs (Wu et al., 2010). This obstacle is particularly difficult 
to circumvent in DA neurons, which are phenotypically distinguished by TH and 
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DAT, both of which have large promoters that are incompatible with AAV. Here, 
we circumvented these obstacles, by designing an rAAV vector that expresses 
an shRNA under the TRE promoter, facilitating use of the TET-OFF system (Das 
et al., 2016) to drive conditional Rin-directed shRNA expression in tetracycline 
transactivator (tTA)-expressing cell populations (Fig. IV-1).  
 
First, we tested commercially available mouse Rin (mRin)-targeted shRNAs. We 
identified two mouse-specific, Rin-directed shRNA candidates (shRin#1 and 
shRin#2) using an RFP-mRin reporter in transfected HEK293T cells (Fig. IV-2A). 
Both shRNAs significantly knocked down RFP-Rin levels, and we continued our 
studies with the more efficacious shRNA (shRin#1, further referred to as shRin). 
shRin was cloned into pscAAV-TRE-eGFP vector. To test that shRin is 
efficacious in this vector, we coexpressed RFP-mRin, TRE-shRin, and rtTA 
(TET-ON) in HEK cells ±doxycycline. In this system, shRin significantly reduced 
RFP-mRin levels in a dox-dependent manner (Fig. IV-2B), thus shRNAs cloned 
into the pscAAV-TRE-eGFP vector are both efficacious and inducible. 
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Figure IV-1. Tet-OFF/ON system for conditional and inducible shRNA 
expression. rAAV (TET-OFF/ON) vector uses a tetracycline responsive 
element (TRE) to drive Rin-targeted shRNA expression selectively in cells 
expressing the Tet transactivator (tTA). (A) For in vivo experiments, we drive 
TRE-shRIN-eGFP expression in Pitx3IRES-tTA/+ mice (TET-OFF). shRNA 
expression was suppressed by maintaining mice on a doxycycline (dox) diet. 
(B) For in vitro cell experiments, we use rtTA-expressing vector to drive 
expression of TRE-shRin-eGFP (TET-ON). shRNA expression was driven in 
the presence of dox in cell media.  
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Figure IV-2. Testing Rin-targeted shRNAs. (A) Screen for efficacious mRin-
directed shRNA. HEK293T cells were transiently transfected with RFP-Rin 
reporter and either vector (pGIPZ) or Rin-directed shRNAs and RFP-Rin 
protein levels were assessed 48 hours post-transfection by immunoblot, 
normalized to actin. Both shRin#1 and shRin#2 significantly reduced Rin 
expression as compared to vector controls. *Significantly different from vector 
control, P<0.04, one way ANOVA, Dunnett’s multiple comparisons test, n=3. 
(B) Test for inducible shRNA expression. Cells were co-transfected with RFP-
Rin reporter, rtTA, and TRE-shRIN#1 cDNAs, and were treated ±500ng/mL 
dox for 48 hours. RFP-mRin expression was assessed by immunoblot, 
normalized to actin. The TRE-shRin construct exhibited significant inducibility. 
*Significantly different from (-)dox control, P=0.02, one tailed t test, n=4. 
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Rin expression increases throughout postnatal development and stabilizes 
around 3-4 weeks post birth (Lee et al., 1996; Spencer et al., 2002). We did not 
want Rin knockdown to interfere with Rin development. Therefore, we tested Rin 
mRNA expression in WT mice at 4, 7, and 11 weeks old. We saw no significant 
difference in Rin expression in mice from 4-11 weeks in age, (Fig, IV-3, p=0.79, 
One way ANOVA, n=4-6) indicating that midbrain Rin expression is stable in 
adolescent and adult mice, and that knockdown experiments should not interfere 
with the reported Rin developmental period 
  
 
  
Figure IV-3. Midbrain Rin mRNA levels do not change after 4 weeks of 
age. (qPCR Analysis. Mouse midbrain was isolated and Rin expression was 
measured by qPCR, normalized to GAPDH internal controls. We saw no 
significant difference in Rin expression at 4, 7, and 11 weeks of age. One way 
ANOVA, P=0.78, n=4-6.  
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AAV-mediated Rin knockdown in Pitx3IRES-tTA/+ mouse dopaminergic 
neurons. Pitx3 is a transcription factor exclusively expressed in postnatal DA 
neurons (Smidt et al., 1997; Maxwell et al., 2005). Pitx3IRES2-tTA/+ mice were 
previously demonstrated to express a tetracycline transactivator (tTA) in TH+ 
VTA and SNc midbrain neurons (Lin et al., 2012). We bilaterally injected AAV9-
TRE-shRin-eGFP into Pitx3IRES2-tTA/+ VTA, and maintained mice ±200mg/kg 
doxycycline for 6 weeks post-injection. GFP reporter expression was clearly 
visible in TH+ cell bodies in the VTA and SNc in (-)dox mice (Fig. IV-4). GFP 
expression was noticeably higher in VTA compared to SNc, consistent with 
reports that Pitx3 expression is 6X greater in VTA than in SNc (Korotkova et al., 
2005). In contrast, GFP expression was markedly suppressed in mice kept on 
(+)dox diet (Fig. IV-4). Rin mRNA expression was significantly decreased in SNc-
enriched tissue from (-)dox mice, as compared to (+)dox mice (Fig. IV-5A), and 
no change in Rin expression was detected in  the neighboring, non-DAergic SNr 
(Fig. IV-5B, p=.92). Decreased Rin expression was not likely due to 
compromised DA neuron viability, as there was no significant change in TH or 
DAT mRNA expression in SNc enriched tissue (Fig. IV-5C,D, p=0.86 and 0.53 
respectively). 
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Figure IV-4. Conditional gene expression in Pitx3IRES-tTA/+ DA neurons. 
Pitx3IRES-tTA/+ mouse VTA was bilaterally injected with AAV9-TRE-GFP and 
mice were maintained ±dox. Brains were sectioned 6 weeks post-injection, 
stained for TH (red) and imaged for TH and GFP (green) co-localization. Dox 
diet suppressed GFP expression in TH+ cells. Intrachannel exposure times 
and post hoc image manipulations are identical. 
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Figure IV-5. Rin knockdown in SNc does not impair DAT or TH 
expression. qPCR Analysis. AAV9-TRE-miR33-shRin was bilaterally injected 
into Pitx3IRES2-tTA/+ VTA, and mice were maintained ±dox diet, 6 weeks. 
The indicated brain regions were harvested by tissue punch and laser capture 
microscopy, and Rin expression was measured by qPCR, normalized to 
GAPDH internal controls. Note significant Rin knockdown in SNc (A), but not 
in the neighboring, non-DAergic, substantia nigra pars reticulata (SNr) (B), 
one tailed t-test, P=0.92. Rin knockdown had no effect on (C)TH (TH-SNc, 
one tailed t-test, P=0.87) or (D)DAT (DAT-SNc, one tailed t-test, P=0.52). 
*Significantly different from (+)dox control, P<0.02, one tailed t test, n=10-12. 
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DAergic Rin expression impacts baseline anxiety, but not locomotion. The 
DAergic system is central to a variety of rodent behaviors including locomotion 
(Beninger, 1983). To test whether Rin expression in DAergic neurons impacts 
baseline locomotor behavior, we used an open field test (OFT) in which mice 
explore a novel arena for ten minutes. We measured total distance traveled in 
male and female mice injected with AAV9-TRE-shRIN-eGFP ±dox. There was no 
significant effect on sex (Two way ANOVA, sex effect, F1,26=0.058, P=0.94) 
therefore we grouped both sexes together for analysis. Rin KD in DA neurons did 
not affect total distance traveled (Fig. IV-6A, t-test, P=0.67); however, Rin KD 
mice spent significantly more time in the field center (Fig. IV-6B). Mice avoid 
open spaces, and increased time spent in an open field is indicative of reduced 
anxiety, suggesting that Rin KD in DAergic neurons results in an anxiolytic 
phenotype. As a complementary approach to the OFT, we used the elevated plus 
maze (EPM) to test whether Rin KD in DAergic neurons reduces baseline 
anxiety. The elevated plus maze is the gold standard for studying anxiety-related 
phenotypes in rodents. Mice are free to explore two opposing open arms or two 
opposing closed arms. Mice prefer to spend time in closed arms; therefore, an 
increase in time spent in open arms is indicative of an anxiolytic-like response in 
the animal. Once again, sex had no effect on time spent in open arms (Two way 
ANOVA, sex effect, F1,26=0.24, P=0.63); therefore, we grouped the two sexes 
together for analysis. Rin KD mice spent significantly more time in the open arms 
as compared to (+)dox controls (Fig. IV-6C), consistent with an anxiolytic-like 
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phenotype. To test whether the dox diet increases anxiety in mice, Pitx3IRES2-tTA/+ 
mice were maintained ±dox for four weeks prior to test in the elevated plus maze. 
Once again, we saw no effect on sex (Two way ANOVA, sex effect, F1,28=2.60, 
P=0.13) so we grouped males and females together. We saw no significant 
difference in time spent in open arms between (+)dox and (-)dox mice (data not 
shown, t-test, n=14-16, P=0.75), demonstrating that our observed anxiety effects 
are not due to the dox diet. Taken together, these data demonstrate that Rin 
expression in DA neurons influences baseline anxiety-like behaviors, but does 
not impact baseline locomotor activity. 
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Figure IV-6. Rin knockdown in DA neurons does not affect baseline 
locomotor activity but reduces generalized anxiety. AAV9-TRE-miR-
shRin-eGFP was injected into Pitx3IRES2-tTA/+ VTA, and mice were maintained 
±dox diet, 6 weeks. Locomotor behavior and anxiety were assessed in males 
and females equivalently. Open field test. (A) Total distance traveled was not 
impacted by Rin KD, two tailed t-test, P=0.67, n=15. (B) Mice spent 
significantly more time in the center of the field following Rin KD as compared 
to (+)dox controls. *Significantly different from (+)dox control, two tailed t-test, 
P=0.02, n=15. (C) Elevated plus maze. Rin KD mice spent more time in open 
arms compared to (+)dox controls. *Significantly different from (+)dox mice, 
two tailed t-test, p<0.01, n=15. 
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DAergic Rin expression differentially impacts male and female locomotor 
response to acute cocaine injection. Cocaine is a potent DAT inhibitor, and 
acute cocaine treatment increases extracellular DA levels. Additionally, the 
Nestler laboratory found increased DFosB binding to the Rin promotor in mouse 
NAc following chronic cocaine treatment, suggesting that cocaine may impact 
Rin expression levels and/or signaling (Renthal et al., 2009). To test the 
hypothesis that Rin expression in DA neurons impacts locomotor response to 
acute cocaine injection, we tested male and female mouse locomotor activity in a 
beam break assay. On day one, mice habituated to the locomotor chamber for 45 
minutes, and then received a saline injection (10mL/kg). Two days later, mice 
habituated to the locomotor chamber for 45 minutes and then received either 
15mg/kg or 30mg/kg cocaine injection, and locomotor activity was recorded for 
90 minutes. In (+)dox control male mice, a 15mg/kg injection was subthreshold, 
but they displayed significantly increased locomotor activity following a 30mg/kg 
cocaine dose (Fig. IV-7A,C). In contrast, following DAergic Rin KD, male mice 
displayed significantly increased locomotor activity following 15mg/kg and 
30mg/kg cocaine injection (Fig. IV-7B,C). These data indicate that in male mice, 
Rin KD in DA neurons enhances sensitivity to cocaine. Female (+)dox control 
mice showed significant increase in locomotor activity at both 15 and 30mg/kg 
cocaine injection (Fig. IV-8A,C). This finding is consistent with previous reports 
that females are more sensitive to cocaine than males (Becker and Koob, 2016). 
Following Rin KD in DA neurons, female mice did not display enhanced 
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locomotor activity to either 15 or 30mg/kg cocaine (Fig. IV-8B,C). To test whether 
the observed effects are not due to the dox diet alone, Pitx3IRES2-tTA/+ were 
maintained on ±dox for four weeks, and were tested at 15mg/kg cocaine. We 
saw no significant difference between males ±dox (Two tailed t-test, P=0.82) and 
females ±dox (Two tailed t-test, P=0,85). Therefore, the dox diet does not 
contribute to the observed effects on cocaine-induced locomotor activity. These 
data indicate that DAergic Rin KD in female mice abolished locomotor response 
to acute cocaine injection.  
  
CHAPTER IV 	
	 118 
 
Figure IV-7. Rin KD in DA neurons enhances sensitivity to cocaine 
locomotor effects in males. AAV9-TRE-shRin-eGFP was bilaterally injected 
into male Pitx3IRES2-tTA/+ VTA, and mice were maintained ±dox diet, 6 weeks. 
(A,B) Locomotor activity time course. Mice, maintained (A) (+)dox and (B) (-
)dox, habituated to locomotor chambers for 45min before injection with saline, 
and then activity was recorded for 90min. The assay was repeated two days 
later and mice received either (C) 15mg/kg cocaine, or (D) 30mg/kg cocaine 
during the test period. Rin knockdown in DA neurons (-dox) significantly 
increased sensitivity to 15mg/kg cocaine (Two way ANOVA, drug effect, 
F(1,13)=25, Bonferroni’s multiple comparisons test, ***P<0.001) while both 
groups (+dox and -dox) had increases in locomotor activity following injection 
with 30mg/kg cocaine (Two way ANOVA, drug effect, F(1,12)=19.61, 
**P<0.01). 
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Figure IV-8. Rin KD in DA neurons reduces cocaine locomotor effects in 
females. AAV9-TRE-shRin-eGFP was bilaterally injected into female 
Pitx3IRES2-tTA/+ VTA, and mice were maintained ±dox diet, 6 weeks. (A,B) 
Locomotor activity time course. Mice, maintained (A) (+)dox and (B) (-)dox, 
habituated to locomotor chambers for 45min before injection with saline, and 
then activity was recorded for 90min. The assay was repeated two days later 
and mice received either (C) 15mg/kg cocaine, or (D) 30mg/kg cocaine during 
the test period. 15mg/kg cocaine significantly increased locomotor activity in 
control (+dox) (Two way ANOVA, drug effect, F(1,14)=5.54, Bonferroni’s 
multiple comparisons test, *P<0.05) as did 30mg/kg (Two way ANOVA, drug 
effect, F(1,14)=9.09, Bonferroni’s multiple comparisons test, *P<0.05). Rin KD 
in DA neurons reduced female cocaine-induced locomotor response at 
15mg/kg (Two way ANOVA, drug effect, F(1,14)=5.54, Bonferroni’s multiple 
comparison test, P=0.94) and 30mg/kg (Two way ANOVA, drug effect, 
F(1,14)=9.09, Bonferroni’s multiple comparisons test, P=0.36).  
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Rin knockdown in DA neurons blocks protein kinase C stimulated DAT 
endocytosis, and reduces total DAT content. We found that Rin knockdown in 
DA neurons reduces baseline anxiety in male and female mice, and it produces 
dimorphic phenotypes in response to acute cocaine treatment. We wanted to test 
what mechanisms are required for these observed effects. Our laboratory 
previously reported that Rin binds to DAT, and its activity is required for PKC 
stimulated DAT endocytosis in PC12 cells. To test whether Rin is required for 
PKC-stimulated DAT endocytosis in bona fide DA nerve terminals, we expressed 
AAV9-TRE-shRin-eGFP or AAV9-TRE-eGFP control in Pitx3IRES2-tTA/+ mice. We 
performed a slice biotinylation assay in acute, coronal striatal slices ±PKC 
activation with PMA. In NAc, DAergic Rin KD blocked PKC-stimulated DAT 
internalization compared to eGFP controls (Fig. IV-9A). DAT rapidly internalizes 
following AMPH exposure; however, it is unknown whether this mechanism 
requires Rin activity. Following Rin knockdown in DA neurons, both eGFP control 
and Rin knockdown mice demonstrate AMPH-stimulated DAT internalization in 
NAc, indicating both that Rin is not required for AMPH-stimulated DAT 
internalization, and that Rin KD in DA neurons does not globally block all 
endocytic mechanisms (Fig. IV-9A). In DS, we see a trend (t-test, p=0.08) for 
blocked PKC-stimulated internalization following Rin knockdown in DAergic 
terminals; however, the effect is not significant (Fig. IV-9B). Consistent with our 
findings in the NAc, Rin KD had no effect on AMPH-stimulated DAT endocytosis 
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(Fig. IV-9B). Taken together, Rin in DA neurons is required for PKC-stimulated 
endocytosis but not AMPH stimulated endocytosis in NAc. 
 
We next asked how blocking PKC-stimulated DAT endocytosis affects total DAT 
populations. We hypothesized that while PKC-stimulated DAT trafficking was 
blocked during a six-week Rin KD, the neuron might compensate for loss of 
regulated trafficking by altering total DAT levels in a post-transcriptional 
mechanism. To test this hypothesis, we isolated the striatum from male mice 
expressing AAV9-TRE-shRin-eGFP, (±)dox, and probed for total DAT content. 
Following DAergic Rin KD, we observed significantly less DAT in striatal tissue 
(Fig. IV-10). Given that we observed no change in DAT mRNA levels in mouse 
midbrain following Rin knockdown, these data suggest that loss of total DAT in 
Rin knockdown animals happens post transcriptionally, and may indicate a 
compensatory mechanism in the absence of PKC-stimulated DAT endocytosis. 
  
CHAPTER IV 	
	 122 
  
 
  
Figure IV-9. Rin KD in DA neurons blocks PKC-stimulated DAT 
endocytosis in NAc. Striatal slice biotinylation assay. Acute striatal slices 
were made from mice expressing AAV9-TRE-eGFP or AAV-TRE-shRin-eGFP 
for 4 weeks. (A) NAc. Above, representative blots from slices treated ±1µM 
PMA or 10µM AMPH. Below, quantification of NAc data. (B) Dorsal Striatum. 
Above, representative blots from PMA or AMPH treated slices. Below, 
quantification of dorsal striatum data. Rin expression in DAergic nerve 
terminals is required for PKC- stimulated internalization but not AMPH-
stimulated DAT trafficking in NAc. *p<0.05, Student’s t test, n=2-7. 
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Figure IV-10. Rin KD in DA neurons reduces total striatal DAT. Total 
striatal DAT. Mice expressed AAV9-TRE-shRin-eGFP for a minimum 6 weeks 
±dox. Total striatal protein was isolated and assayed by SDS-PAGE followed 
by quantitative immunoblot. Rin KD mice (-dox) expresses less DAT in the 
striatum. *p<0.05, Student’s t test, n=5. 
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DAergic Rin KD reduces spontaneous EPSP in NAc. We next asked what is 
the physiological output following Rin KD in DA terminals. DAT expression is 
required for regulating extracellular DA levels, and further, spontaneous 
glutamatergic activity in the striatum is modulated by DA (Cepeda et al., 1993; 
Nicola and Malenka, 1998). We hypothesized that Rin KD and loss of PKC-
stimulated DAT endocytosis impacts excitatory transmission in the NAc. We 
measured sEPSP in MSNs in current clamp from mice injected with either AAV9-
TRE-eGFP or AAV9-TRE-shRin-eGFP in VTA. Cocaine did not affect the sEPEP 
amplitude following cocaine treatment in either control or Rin KD mice (Fig. IV-
11A). However, in eGFP control mice, cocaine significantly increased the sEPSP 
interevent interval following cocaine exposure. Rin KD mice displayed no 
difference in sEPSP interevent interval following cocaine exposure (Fig. IV-11B). 
When examining the cumulative distribution of interevent intervals from eGFP 
animals and Rin KD mice, we observed a rightward shift in measurements from 
Rin KD mice (Fig. IV-11C). This finding suggests that Rin KD in DA nerve 
terminals reduces the sEPSP frequency.  
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Figure IV-11. Rin KD in DA neurons reduces spontaneous excitatory 
postsynaptic potentials (sEPSP) frequency in NAc. Pitx3IRES-tTA/Drd1a-
tdTomato mice expressed AAV9-TRE-eGFP or AAV9-TRE-shRin-eGFP for 4 
weeks. MSNs were kept in current clamp, and sEPSPs were measured 
±10µM cocaine. (A) Amplitude of sEPSPs. (B) Interevent interval of sEPSPs. 
(C) Cumulative distribution of sEPSP frequency from eGFP controls vs. Rin 
KD mice. *P<0.05, Wilcoxon test, n=5-7.  
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IV.D Discussion 
DAergic transmission is integral to locomotor behavior both in rodents (Marshall 
and Berrios, 1979; Starr and Starr, 1986), and in humans, where DA neuronal 
death underlies the movement anomalies in PD (Lotharius and Brundin, 2002). 
Moreover, a recent report revealed that NMDA-mediated DA neuron phasic 
bursting is required to elicit anxiety in response to aversive conditioning (Zweifel 
et al., 2011). Rin was reported as a risk allele for several DA-associated 
disorders, including PD, ET, ASD, schizophrenia, and bipolar disorder 
(Emamalizadeh et al., 2017), many of which have a significant anxiety 
component. However, whether Rin impacts DAergic function and contributes to 
disease pathogenesis remains completely unknown. We found that Rin 
expression in DA neurons is involved in baseline anxiety-related behavior, but 
had no effect on baseline locomotor activity (Fig. IV-6). Additionally, we report 
that Rin KD in DA neurons enhances cocaine’s locomotor effects in males (Fig. 
IV-7) but eliminates cocaine’s locomotor effects in females (Fig. IV-8) Although 
Rin is required for NGF-mediated signaling via MAP kinase (Shi et al., 2005b), it 
is unlikely that the observed phenotypes were due to changes in DA neuron 
viability, as TH and DAT expression were unaffected by Rin KD (Fig. IV-5). DA 
neurons are heterogeneous, and have distinct target areas that drive these 
behaviors (Parker et al., 2016). Thus, Rin knockdown may preferentially impact a 
DA neuron subpopulation, leading to the differential phenotypes we observed.  
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Rin is required for PKC-stimulated DAT endocytosis in PC12 cells (Navaroli et 
al., 2011), and here we demonstrate that it is also required for regulated DAT 
endocytosis in intact DAergic nerve terminals in NAc, however not in DS (Fig. IV-
9). This result suggests that these two DAergic nuclei have distinct regulatory 
DAT trafficking mechanisms. This hypothesis is consistent with the differential 
DAT trafficking regulation in NAc vs DS, reported in Vav2-/- mice (Zhu et al., 
2015). AMPH stimulated DAT trafficking was unaffected following Rin KD in 
DAergic terminals (Fig. IV-9). This finding demonstrates that Rin is not required 
for AMPH-stimulated DAT endocytosis, which is consistent with previous reports 
that PKC-stimulated and AMPH-stimulated DAT endocytosis are distinct 
mechanisms (Saunders et al., 2000; Boudanova et al., 2008a). Moreover, this 
result demonstrates that Rin KD did not broadly disrupt all endocytic mechanisms 
within the neuron.  
 
Rin KD and loss of regulated DAT endocytosis resulted in reduced total DAT 
within the striatum of male mice (Fig. IV-10). Increased cocaine sensitivity is 
correlated with reduced DAT availability at the plasma membrane (Nelson et al., 
2009), suggesting that increased cocaine hyperactivity at a 15mg/kg dose in Rin 
KD mice may result from reduced DAT availability. Interestingly, we observed 
that in female mice, Rin KD reduced hyperactivity following both 15 and 30mg/kg 
cocaine (Fig. IV-8). It is unknown whether Rin KD reduced DAT levels in female 
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striatum. Females are more sensitive to cocaine (Calipari et al., 2017). Further, 
female mice in estrous are more sensitive to cocaine’s rewarding effects and 
have increased DAT N-terminal phosphorylation compared to females in 
dioestrous (Calipari et al., 2017). This finding suggests that hormonal signaling in 
females not only contributes to increased cocaine sensitivity, but also that this 
sex hormone effect impacts DAT regulation. Therefore, loss of DAT regulation in 
Rin KD mice might account for the differences we observed cocaine-induced 
hyperlocomotion between males and females (Fig. IV-7,8). It is unknown whether 
females undergo regulated DAT endocytosis. Future studies testing PKC-
stimulated trafficking in female mice will test whether DAT endocytic mechanisms 
differ between males and females.  
 
We observed that Rin KD resulted in decreased sEPSP frequency with no 
change in amplitude (Fig. IV-11), suggesting that Rin KD in DAergic neurons 
modulates presynaptic excitatory signaling. Given that Rin KD was restricted to 
DA neurons, I predict that the changes in excitatory signaling arise from changes 
in DA signaling within the NAc. Both D1 and D2-like receptor activation 
decreases glutamate release onto MSNs within the NAc (Tritsch and Sabatini, 
2012). Therefore, I hypothesize that reduced sEPSP frequency arises from 
increased extracellular DA. In support of this hypothesis, Rin KD mice express 
reduced DAT levels (Fig. IV-10), which may result in reduced DA reuptake. 
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Future studies using FSCV will test whether Rin KD impacts DA release and 
clearance. 
 
Additionally, control mice show increased sEPSP interevent interval following 
cocaine treatment, but Rin KD mice show no change in interevent interval 
following cocaine exposure (Fig. IV-11). Interestingly, a similar trend was seen in 
a previous report using DAT KD mice, which express 90% less DAT (Wu et al., 
2007). DAT KD mice show no change in sEPSC frequency following cocaine 
treatment, whereas WT mice showed decreased sEPSC frequency with cocaine 
treatment. These studies provide further support that reduced DAT expression 
impacts excitatory signaling in NAc following cocaine treatment. Additional 
parallels between Rin KD mice and DAT KD mice is observed following acute 
cocaine injection. DAT KD mice display increase hyperactivity in response to 
cocaine injection, consistent with our Rin KD mice (Tilley et al., 2007).  In 
contrast to the hypothesis that our observed behaviors arise from increased 
extracellular DA in the NAc, we observed that Rin KD resulted in reduced anxiety 
in male and female mice (Fig. IV-6). Increased DA signaling and reduced 
glutamatergic firing within the NAc is associated with increased anxiety (Russo 
and Nestler, 2013). How can we observe increased cocaine sensitivity and 
reduced anxiety in Rin KD mice? I predict that the effect we observe on anxiety 
arises from a brain region other than the NAc. The VTA projects to multiple brain 
regions including the amygdala, which is commonly associated with anxiety-
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related behaviors (Calhoon and Tye, 2015; Zarrindast and Khakpai, 2015). 
Future studies using retrograde AAV serotypes will be informative in isolating 
VTA-NAc pathway dependent behaviors versus amygdala-VTA behaviors.  
 
Conditional and inducible gene expression control has proved an indispensable 
approach to interrogate the nervous system, and to elucidate the neuronal basis 
for normal and pathological physiology and behavior. Our successful application 
of TET-OFF technology, in combination with higher integrity shRNA-encoding 
AAV, is likely to have broad utility in neurobiological studies, and there are 
multiple conditional tTA mice available with which to apply this approach. 
Although we observed a striking and significant ability to suppress Rin 
expression in DA neurons, it should be noted that we occasionally observed GFP 
reporter expression in TH+ cells of dox-treated mice (not shown). This is 
reflected in the significantly more variable Rin expression values obtained by 
qPCR (Fig. IV-5A) compared to (-)dox mice, and may be due to the short half-life 
of dox, and inability to control mouse dox dosing via ad libitum route. 
Alternatively, it may reflect a longer GFP protein half-life, in comparison to Rin 
mRNA. Nevertheless, the dox regimen was sufficient to suppress the observed 
anxiolytic phenotypes and acute cocaine responses. 
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Taken as a whole, these studies are the first to demonstrate Rin GTPase’s role in 
vivo. Further, we confirm that in bona fide DA neurons, Rin is required for PKC-
stimulated DAT endocytosis. This finding correlates PKC-stimulated DAT 
trafficking with baseline anxiety and locomotor response to cocaine, making this 
study the first to investigate the physiological impact of PKC-stimulated DAT 
endocytosis.  
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Chapter V 
Discussion and Future Direction 
DA neurotransmission is critical for movement, reward, cognition, and anxiety 
(Wise, 2004; Schultz, 2007; Russo and Nestler, 2013). DAergic dysregulation 
results in numerous neuropsychiatric diseases such as PD, ADHD, and ASD. 
Therefore, understanding DAergic regulation is necessary to understand complex 
behaviors and to create novel therapeutics for neuropsychiatric disease. DA 
reuptake through DAT is the primary mechanism for terminating DA signaling 
events. Therefore, DAT is a critical regulator of DAergic signaling cascades. DAT 
availability at the plasma membrane is required for DA reuptake and is tightly 
regulated through presynaptic signaling pathways, which affect DAT function and 
surface expression through endocytic regulation. DAT is the molecular target for 
AMPH and cocaine. Further, point mutations in DAT are linked to DTDS, PD, 
ADHD, BPD, and ASD, suggesting that changes within DAT function can have 
profound consequences in DAergic behavior. Within this thesis I discuss how 
DAT terminal domains regulate DA uptake (Chapter II) and regulatory trafficking 
pathways (Chapter III). Further, taking advantage a known DAT endocytic 
mechanism, I blocked PKC-mediated DAT endocytosis in vivo to test the 
physiological impact of regulated endocytosis.  
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V.A DAT N-terminus is required for substrate and small inhibitor affinity 
Multiple lines of evidence demonstrate that DAT’s N-terminus is required for 
many DAT mechanisms including AMPH-stimulated efflux (Khoshbouei et al., 
2004), regulated phosphorylation (Bermingham and Blakely, 2016), negative 
endocytic regulation (Sorkina et al., 2009), and protein binding (Table I-1). 
Further, a point mutation in DAT’s N-terminus (R51W) was identified in a patient 
with ASD (Cartier et al., 2015). Therefore, the DAT N-terminus is critical for DAT 
regulation, and may play an important role in DAergic behavior. We identified that 
the DAT N-terminus is required for substrate (DA, AMPH) and certain inhibitor 
(bCFT, MPH) affinities but not affinity for cocaine, GBR12909, or bCIT (Table II-
1). These data point to the N-terminus’ role in shaping the substrate/inhibitor 
binding pocket. The DAT N-terminus serves as an intracellular gate, which 
moves in relation to DAT intracellular loops during the translocation process, to 
expose the translocated DA to the cytosol (Cheng and Bahar, 2015). The 
juxtamembrane N-terminal domain required for N-terminal gating (RETWK, 60-
65) is conserved between DAT and SERT, and therefore conserved in our N-
SERT/DAT chimera (Fig. II-1). Therefore, affinity loss from N-terminal 
substitution is not due to changes in the N-terminal intracellular gate. 
Additionally, when we replaced both SERT intracellular domains onto DAT 
(SERT/DAT/SERT), we rescued the affinity losses displayed by N-SERT/DAT. 
These data suggest that DAT and SERT N- and C-termini may “recognize” one 
another within the cytoplasm, and therefore work together to stabilize the DA 
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binding pocket. DAT and SERT’s N-terminal domains are mobile during the 
substrate translocation process (Fenollar-Ferrer et al., 2014; Khelashvili et al., 
2015a; Khelashvili et al., 2015b); however, it is unknown how DAT’s N- and C-
termini interact with one another during this process. Molecular dynamic 
simulations and intramolecular FRET were used to determine how the SERT N- 
and C-termini move with respect to one another during the substrate 
translocation process (Fenollar-Ferrer et al., 2014). Whether DAT’s terminal 
domains interact with one another when DAT is in an open conformation, as is 
predicted for SERT, remains untested. Future studies modeling both terminal 
domains together will be informative in asking this question, and will reveal DA 
translocation mechanisms, and perhaps provide mechanistic insight into other N- 
and C-terminal synergistic mechanisms such as substrate efflux.  
  
V.B DAT N-terminus is required for PKC-stimulated DAT endocytosis 
As stated previously, DAT’s N- and C-termini are required for negative endocytic 
regulation (Holton et al., 2005; Boudanova et al., 2008b; Sorkina et al., 2009). 
Reports from our lab and others independently implicate DAT’s N- and C-termini 
as required for stabilizing DAT surface expression. Therefore, I wanted to test 
whether these two domains synergistically work together to support regulated 
DAT endocytosis. It is known that DAT rapidly internalizes following PKC 
activation, and Ack1 inactivation is required downstream of PKC to stimulate 
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enhanced DAT endocytosis (Wu et al., 2015). Using DAT/SERT chimeras (Fig. I-
1) (Sweeney et al., 2017), I tested endocytic rates following PKC activation and 
Ack1 inhibition. WT DAT, N-SERT/DAT, and DAT/C-SERT all showed increased 
endocytic rates following Ack1 inhibition; however, SERT/DAT/SERT did not. 
These data demonstrate that individually, neither DAT’s N- nor C-terminus is 
required for rapid endocytosis following Ack1 inhibition. This raises two 
hypotheses: 1) that Ack1 inactivation independently stimulates mechanisms 
associated with N- and C-termini for rapid endocytosis or 2) that Ack1 
inactivation stimulates a molecule(s) that associates with both N- and C-termini 
to stimulate rapid endocytosis. Given that N- and C-termini synergistically 
mediate substrate affinity (Sweeney et al., 2017), AMPH-stimulated efflux (Fog et 
al., 2006b), and the reciprocal relationship between palmitoylation and 
phosphorylation (Moritz et al., 2015), I hypothesize that both terminal domains 
synergistically work together to mediate enhanced endocytic rates following Ack1 
inhibition. An intriguing hypothesis is that Ack1 itself mediates N- and C-terminal 
synergy, and once dephosphorylated, it disassociates from DAT. However, 
preliminary results from our lab refute this hypothesis. Ack1 does not co-IP with 
DAT (Sweeney and Melikian, unpublished data), and Ack1 and DAT do not 
colocalize as measured through immunocytochemistry (Marshall and Melikian, 
unpublished data). Therefore, I predict that another molecule mediates this N- 
and C-terminal synergy. I tested whether Rin is the mediating molecule. Given 
the fact that 1) Rin is required for PKC-stimulated DAT endocytosis, 2) Rin is 
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activated by PKC, and 3) Rin activity is required for PKC-stimulated Ack1 
dephosphorylation, it appeared to be a strong candidate to mediate N- and C-
terminal synergy. However, Rin associated with each DAT-core chimera (Fig. III-
3), demonstrating that neither DAT’s N- nor C-terminus is required for DAT/Rin 
interaction. However, we did not test whether Rin’s association with DAT-core 
chimeras is differentially affected by PKC activation or Ack1 inhibition. It may be 
that at steady state, Rin associates with each DAT-core chimera, and that 
stimulating regulated endocytosis affects the association. Future studies testing 
DAT/Rin association in the presence of PMA or AIM-100 will provide further 
mechanistic insight to the DAT/Rin interaction. Additionally, other factors may 
mediate the hypothesized DAT terminal synergy. BBS-DAT-core chimeras will 
serve as an excellent tool to screen for DAT N- and C-terminal binding proteins 
at the cell surface. Previous studies screening for DAT associated proteins have 
relied upon GST-tagged peptides or yeast 2-hybrid screens with DAT terminal 
peptides as bait (Table I-1). While these approaches have been critical for 
identifying DAT associated proteins, they do not take into account the entire DAT 
protein. Further, they preclude the possible identification of proteins that require 
both N- and C-termini for DAT association. BBS-DAT can be used both in cellular 
systems and in vivo to identify novel DAT binding partners in the future.  
 
V.C DAT microdomain localization and regulated endocytosis 
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DAT localizes to distinct microdomains within the plasma membrane. Further, 
localization to these domains and/or mechanisms associated with DAT 
microdomain targeting correlate with mechanisms associated with regulated 
endocytosis. Our lab previously reported that DAT interacts with Rin, and that 
DAT/Rin colocalization is enhanced in lipid rafts (Navaroli et al., 2011). 
Additionally, Rin is required for PKC-stimulated DAT downregulation (Fig. IV-9, 
Navaroli et al., 2011). These findings raise two questions: 1) Does Rin target 
DAT to lipid raft microdomains? and 2) is DAT’s presence within these 
microdomains domains required for PKC-stimulated internalization? To test the 
former, one can compare DAT localization within lipid rafts in mice ±Rin KD. A 
loss of DAT localization to lipid rafts in Rin KD mice would suggest that Rin is 
required to target DAT to these domains. Data from the Yamomoto lab correlate 
DAT microdomain localization to regulated DAT endocytosis. They showed that 
DAT associates with the lipid raft-enriched, integral membrane protein, Flot-1, 
and that Flot-1 is required to maintain DAT within membrane microdomains. 
Further, they demonstrated that Flot-1 is required for PKC-stimulated 
endocytosis (Cremona et al., 2011). These findings support the hypothesis that 
PKC-stimulated DAT internalization requires DAT to be localized within lipid raft 
domains. Additional support linking membrane localization to DAT trafficking 
mechanisms comes from studies with the ADHD-associated DAT mutant, 
R615C. 615C DAT is enriched in non-raft compartments, and it does not undergo 
PKC-stimulated internalization (Sakrikar et al., 2012). It should be noted that the 
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absence of PKC-stimulated internalization is due to increased basal endocytic 
rates. In fact, our lab reported that a constitutively active Ack1 mutant, S445P, 
can rescue the enhanced basal endocytic rates associated with the 615C mutant, 
and therefore restores PKC-stimulated internalization. Does S445P-Ack1 restore 
basal DAT endocytic rates by restoring 615C DAT localization to lipid rafts? This 
hypothesis remains untested.  
 
In Chapter III, I demonstrate that N-SERT/DAT does not undergo PKC-stimulated 
endocytosis, but maintains Ack1-dependent endocytosis. Further, I predicted that 
a molecule associated with the DAT N-terminus must mediate this effect. 
However, given what we know about DAT localization to lipid rafts, it raises the 
alternative hypothesis that N-SERT/DAT is mislocalized, and expression in 
different compartments within the plasma membrane may result in the loss of 
PKC-stimulated endocytosis. To test this hypothesis, one can first test whether 
N-SERT/DAT colocalize with a lipid raft marker, such as CTxB, and whether is 
localization is different from WT DAT.  
 
Ultimately, the studies linking DAT membrane localization to regulated 
endocytosis are correlations. It remains unknown whether loss of regulated 
endocytosis following Rin KD or Flot-1 KD arise due to loss of direct interaction 
with these proteins, or rather due to loss of localization. Does DAT need to be in 
the right place at the right time to undergo regulated endocytosis, or rather, does 
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it need to directly interact with raft-associated proteins for regulated endocytosis? 
These two ideas are not mutually exclusive, and further studies linking known 
DAT regulatory mechanisms to DAT membrane localization will provide further 
insight regarding how membrane localization impacts DAT function and 
regulation.  
 
V.D Rin is not expressed in certain heterologous expression systems – 
Implications for data interpretation 
Our laboratory previously reported that Rin directly binds to DAT, and that Rin is 
required for PKC-stimulated DAT endocytosis (Navaroli et al., 2011). This study 
used RT-PCR to demonstrate that Rin is expressed in multiple heterologous 
expression systems, including non-neuronal cell lines, which was surprising 
given that Rin is only expressed in neuronal tissue. However, throughout the 
course of my graduate work, I found that 1) I could not detect Rin in SK-N-MC 
cells and HEK293T cells using RT-qPCR and 2) the Rin antibody we were using 
(27G2 clone) detected an immunoreactive band that is not Rin. These findings 
raised questions regarding Rin’s putative role in DAT endocytic regulation. When 
reevaluating Navaroli et al.’s work, several findings remain true in light of this 
new information. 1) Rin binds to DAT but not SERT. Rin was originally identified 
as a DAT binding protein through a yeast 2-hybrid screen using FREKLAYAIA 
(587-596) as bait. Additionally, FRET analysis using YFP-Rin and CFP-DAT 
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showed significant interaction between the two proteins, but no interaction 
between Rin and SERT nor Rin and GAT1. 2) Rin activity is required for PKC-
stimulated DAT endocytosis. Internalization assays in PC12 cells expressing 
constitutively active and dominant negative Rin mutants showed that Rin activity 
is required for PKC-stimulated DAT internalization. However, Rin is a Ras-like 
GTPase, and within this family, there is significant homology within effector 
domains. Therefore, we cannot rule out that a dominant negative Rin sequesters 
effectors necessary for other GTPases that are required for DAT endocytic 
regulation. Ultimately, we are interested in DAT endocytic mechanisms in 
DAergic terminals rather than cellular expression systems. When we knockdown 
Rin in DAergic nerve terminals, we block PKC-stimulated DAT endocytosis (Fig 
IV-9). Therefore, Rin is absolutely required for PKC-stimulated DAT endocytosis. 
However, if Rin is not expressed in all cell systems, how can we say that it is truly 
required? Rin shares significant homology with the ubiquitously expressed Rit. 
We do not know whether Rit is required for PKC-stimulated internalization, or that 
Rit can compensate for Rin in cellular systems. Our laboratory has efficacious 
Rit-targeted shRNAs (Sweeney and Melikian, unpublished data), which can be 
used to test this possibility. Alternatively, DAT may use different regulatory 
endocytic pathways in different neuronal populations. In our studies, Rin KD 
blocked PKC-stimulated DAT internalization in NAc but not DS (Fig. IV-9). 
Similarly, Vav2 is required for regulating DAT surface expression in NAc but not 
DS (Zhu et al., 2015). Taken together, these data demonstrate that DAT requires 
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different endocytic regulatory mechanisms in nigrostriatal pathways than in 
mesolimbic pathways. Therefore, more studies are needed to study DAT 
regulatory mechanisms in DA terminals to test the hypothesis that different forms 
of regulation exist within different DAergic neuronal populations. 
 
V.E PKC-stimulated DAT endocytosis in vivo 
Initial reports that DAT functionally downregulates in response to PKC activation 
were published over 20 years ago (Bermingham and Blakely, 2016). This led to 
numerous papers investigating the functional downregulation and endocytic 
trafficking mechanisms following PKC activation. However, to date, the 
endogenous source of PKC activation in DA terminals remains unknown. 
Previous studies relied heavily upon direct PKC activation with phorbol ester 
treatment (PMA). However, this approach directly bypasses endogenous 
receptor activation, and therefore bypasses other secondary messenger 
cascades associated with receptor activation. PKC is activated by Gq-coupled 
receptor activation. Gq signaling activates phospholipase C (PLC), which in turn 
cleaves PIP2 to generate DAG and IP3, which respectively activate PKC and 
increase intracellular Ca2+. What are the endogenous Gq-coupled receptors on 
DAergic terminals and does their activity regulate DAT surface expression? 
Muscarinic acetylcholine receptors (mAChRs, M1-M5) are distributed throughout 
the striatum. Both M1, M3, and M5 subtypes are Gq-coupled; however, only M5 is 
expressed on DAergic terminals (Vilaro et al., 1990; Weiner et al., 1990; Shin et 
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al., 2015), making it a strong candidate for endogenous PKC activation to drive 
DAT endocytosis. Preliminary data from our laboratory, using a nonselective 
mAChR activator at a subthreshold concentration in conjunction with an M5 
positive allosteric modulator, suggest that M5 activation stimulates regulated 
DAT trafficking in DAergic terminals (Kearney and Melikian, unpublished data). 
mGluR5 is another Gq-coupled candidate to activate DAT endocytic signaling. 
mGluR5 is a Group I metabotropic glutamate receptor. Page et al. nonselectively 
activated Group I mGluRs in striatal synaptosomes, which caused decreased DA 
uptake, and this effect was blocked with co-incubation with a mGluR5 specific 
antagonist (Page et al., 2001). These data demonstrate that DA uptake velocity 
is sensitive to mGluR5 activation. While these data must be repeated in intact 
striatal preparations, it points to an mGluR5-dependent mechanism for reducing 
DA uptake.  
 
If M5 and mGluR5 are the endogenous sources of regulated DAT endocytosis, it 
raises interesting hypotheses regarding the physiological importance of PKC-
stimulated DAT endocytosis. For example, M5-induced DAT trafficking would 
suggest that DAT is critical for regulating DAergic tone during cholinergic 
signaling events in the striatum. To this same extent, mGluR5-stimulated DAT 
endocytosis would point to DAT’s importance in regulating homeostatic DA levels 
during glutamatergic signaling. Both cholinergic and glutamatergic DAT 
regulation can be tested using channelrhodopsin conditionally expressed in 
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cholinergic neurons or glutamatergic terminals in the striatum. Using blue light to 
stimulate either ACh or Glu release, we can test whether cholinergic or 
glutamatergic stimulation stimulates DAT surface redistribution. Moreover, if 
these studies point to M5- and mGluR5-mediated regulated DAT endocytosis, I 
propose blocking this pathway with our Rin KD model to further test the 
physiological pathway and impact behind PKC-stimulated DAT endocytosis.  
 
V.F What is the physiological importance of 
PKC-stimulated DAT endocytosis? 
DAergic signaling is critical for key brain functions including movement initiation, 
learning, and reward. DAT regulates DA signaling events through reuptake into 
the presynaptic neuron. DAT must be available at the plasma membrane in order 
to regulate DA signaling. PKC-stimulated DAT endocytosis dynamically regulates 
DAT surface expression, and therefore regulates DAT availability at the plasma 
membrane. However, the physiological consequence of PKC-stimulated DAT 
endocytosis remains entirely unknown. To test the hypothesis that PKC-
stimulated DAT endocytosis is required for DAergic behavior, we knocked down 
Rin conditionally in adult DA neurons. Our laboratory previously identified Rin as 
a DAT binding protein that is required for PKC stimulated endocytosis (Navaroli 
et al., 2011), and here we demonstrated that Rin is required for PKC-stimulated 
endocytosis in NAc DAergic terminals (Fig. IV-9). We also demonstrated that 
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PKC-stimulated DAT endocytosis is not required for baseline locomotor behavior 
(Fig. IV-6A); however, it contributes to baseline anxiety as measured by EPM 
and OFT (Fig. IV-6B,C). Additionally, we showed that PKC-stimulated DAT 
endocytosis differentially affects male and female locomotor response to acute 
cocaine injection. Blocking regulated DAT internalization enhanced sensitivity to 
cocaine in males (Fig. IV-7); however, it eliminated cocaine-induced locomotor 
response in females (Fig. IV-8). This study design relies on Rin knockdown to 
block PKC-stimulated DAT endocytosis. While I can correlate regulated DAT-
trafficking to the observed behaviors, I cannot say that it is absolutely causative. 
To directly assess the physiological importance of PKC-stimulated DAT 
endocytosis in vivo, we require knock in mice expressing regulated DAT 
trafficking deficient mutants. N-SERT/DAT does not internalize rapidly in 
response to PKC activation (Fig. III-1), lending itself as an interesting endocytic 
loss-of-function mutant. Additionally, R615C DAT displays and endocytic gain-of-
function phenotype in cells. It internalizes rapidly in the absence of PKC 
activation (Sakrikar et al., 2012). These two mutants will provide the opportunity 
to test the physiological impact of DAT endocytosis on DAergic behaviors. I 
predict that if these mutants phenocopy our behavioral data following Rin KD, it 
will help to support the conclusion that regulated DAT endocytosis is required for 
locomotor response to acute cocaine injection and generalized anxiety.  
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V.G Rin and Behavior 
Rin is a Ras-like GTPase expressed solely in neurons (Lee et al., 1996; Wes et 
al., 1996). It is activated in response to growth factor signaling, and it binds CaM 
(Lee et al., 1996; Wes et al., 1996; Shi et al., 2005b). We know very little about 
Rin function, and all Rin functional studies have been performed in vitro or in 
heterologous expression systems. Rin signaling in vivo remains untested, and 
the physiological importance of Rin signaling in the brain is entirely unknown. 
Multiple lines of evidence suggest that Rin activity is key in DAergic neurons. 
GWAS studies implicate Rin as a risk allele for DAergic neurological disorders 
(PD, schizophrenia, ASD, essential tremor, BPD, and speech delay) 
(Emamalizadeh et al., 2017). Further, Rin expression is enriched in DAergic brain 
regions (Zhou et al., 2011). Finally, our laboratory identified that Rin binds to 
DAT, and is required for regulated DAT endocytosis. Therefore, we conditionally 
knocked down Rin in DAergic neurons to test whether Rin is required for DAergic 
behavior.  
 
Rin KD and anxiety 
Anxiety is characterized by apprehension, sustained arousal, and risk avoidance 
(Tovote et al., 2015). In rodents it is often measured in avoidance assays, in 
which more anxious animals avoid open spaces (Carola et al., 2002). To test 
whether Rin KD in DAergic neurons affected anxiety-related behavior, we used 
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the EPM and OFT. We saw that Rin KD in male and female DAergic neurons 
produced an anxiolytic phenotype (Fig. IV-6). While amygdala, BNST, 
hippocampal, and cortical regions are classically associated with anxiety related 
behavior, increasing evidence demonstrates that midbrain DAergic neurons are 
key in modulating anxiety responses (Calhoon and Tye, 2015; Zarrindast and 
Khakpai, 2015). Optogenetic stimulation of DAergic VTA neurons causes animals 
to spend less time in open arms in EPM (Gunaydin et al., 2014). This effect was 
also seen by activating DAergic terminals within the PFC, suggesting that 
increased activity in VTA-PFC projections has an anxiogenic effect. Conditional 
NMDAR KO in DAergic neurons revealed that NMDA-mediated DA neuron firing 
is required to elicit anxiety in response to aversive conditioning (Zweifel et al., 
2011). Leptin receptor is expressed in VTA DAergic neurons. Conditional leptin 
receptor (Lepr) KO in DAT-Cre mice reduced open arm entries in EPM, and 
increased DA neuron burst firing (Liu et al., 2011). Further, microinjection of D1 
antagonist in amygdala attenuated this phenotype, demonstrating that a DAergic 
VTA-amygdala pathway contributes to anxiety behavior.  
 
VTA DAergic neurons express M5 mAChRs (Vilaro et al., 1990), which are Gq- 
coupled, and therefore activate PKC signaling cascades. Potentiating cholinergic 
signaling in the VTA by local physostigmine infusion resulted in anxiogenic 
response in rats (Small et al., 2016). It is tempting to hypothesize that cholinergic 
activation of PKC signaling in DA neurons causes both regulated DAT trafficking 
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and anxiogenic response. In Rin KD mice, PKC-stimulated DAT trafficking is 
blocked and these mice have an anxiolytic response. These data provide a 
correlation between DAT trafficking in midbrain DAergic neurons and anxiety 
related behavior. KOR is expressed in DAergic neurons, and KOR signaling 
increases DAT surface expression (Kivell et al., 2014). Interestingly, conditional 
KOR KO in DAT-cre mice has an anxiolytic effect as measured by increased time 
in the center during OFT and reduced latency to enter the lit compartment in a 
light/dark box (Van't Veer et al., 2013). These data further correlate a known DAT 
trafficking mechanism with an anxiety-related phenotype. Whether our observed 
anxiolytic phenotype following Rin KD is due to impaired DAT trafficking, and 
therefore impaired homeostatic DA regulation or, rather, due to other changes 
related to loss of Rin signaling remains unknown. As discussed previously, future 
studies with DAT trafficking-defective mutants will help to test whether regulated 
DAT trafficking is required for anxiety-response in mice.  
 
In our studies, we knocked down Rin in VTA and SNc DAergic neurons. These 
nuclei send projections throughout the basal ganglia and cortical regions. 
Therefore, we cannot determine the circuitry required for reduced anxiety in our 
Rin KD mice. To test whether Rin KD in DAergic VTA or SNc nuclei is required 
for anxiolytic response, I propose using AAV2 to infect specifically VTA or SNc. 
This viral serotype results in a more focal infection with reduced viral spread 
compared to the AAV9 used in our studies. Further, both VTA and SNc send 
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projections to multiple brain regions. I propose that future studies using 
retrograde viruses to infect the projection sites, such as NAc, PFC, amygdala, or 
hippocampus will be critical to interpret the brain circuitry mediating our findings.  
Rin and cocaine 
Sexual dimorphism within the DAergic system has been well documented 
(Becker et al., 2012). Cocaine is a powerful psychostimulant, and it affects 
females differently than males. Females binge more, escalate drug use more 
quickly, and progress to addictive behavior more rapidly (Becker et al., 2012). In 
our study, control females were sensitive to an acute 15mg/kg cocaine injection, 
whereas in males, this dose was subthreshold (Fig IV-7, IV-8). Further, Rin KD 
differentially affected male and female locomotor response to cocaine. In male 
mice, we observed enhanced sensitivity to cocaine-induced locomotor response 
at 15mg/kg (Fig. IV-7). In female mice, Rin KD abolished locomotor response to 
cocaine (Fig. IV-8). These data raise interesting questions as to how Rin 
regulates DAergic neuronal firing, and how this effect is different in male versus 
female mice. It is known that DA neuron firing rates fluctuate over the course of 
the estrous cycle, with increased firing in estrous and dioestrous females 
compared to proestrous (Becker et al., 2012). It should be noted, that we did not 
control for estrous cycle in our female mice. Further, we do not know how 
DAergic Rin KD impacts DA neuron firing. Future studies will test how Rin KD 
affects DA neuronal firing in both male and female mice.  
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Given that Rin KD blocked PKC-stimulated DAT endocytosis, and that cocaine is 
a potent DAT inhibitor, it raises the hypothesis that cocaine-dependent 
phenotypes may arise from loss of regulated DAT trafficking. Further, given the 
differential effect in cocaine response following Rin KD in males and females, I 
hypothesize that DAT endocytosis may be differentially regulated in males and 
females. The Nestler group recently reported increased DAT N-terminal 
phosphorylation in estrous females compared to males and dioestrous females, 
supporting the hypothesis that sex-dependent DAT regulatory mechanisms exist 
(Calipari et al., 2017). Here, we demonstrate that Rin is required for PKC-
stimulated DAT endocytosis in male NAc; however, we do not know if it is 
required for regulated DAT endocytosis in females. Future studies in females 
testing regulated DAT endocytosis ±Rin expression using our Rin KD model will 
provide insight as to whether DAT is regulated differently in males and females.  
 
Rin in NAc DAergic terminals 
Our electrophysiological studies demonstrate DAergic Rin signaling modulates 
excitatory transmission in NAc. We observed that DAergic Rin KD in NAc 
terminals resulted in reduced sEPSP frequency but not amplitude suggesting a 
presynaptic response (Fig. IV-11). It is known that DA modulates excitatory 
signaling from NAc glutamatergic terminals (Tritsch and Sabatini, 2012). 
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Therefore, I hypothesize that DAergic Rin KD impacts extracellular DA levels, 
and therefore, impacts DAergic modulation at glutamatergic presynaptic sites. 
Whether the hypothesized changes in extracellular DA result from loss of DAT 
availability resulting from impaired PKC-stimulated DAT endocytosis remains 
unknown. Ex vivo studies using fast scan cyclic voltammetry (FSCV) will directly 
test extracellular DA concentrations and clearance rates. Alternatively, alterations 
in DA signaling may result from changes in DA neuron firing following Rin KD. 
Studies testing the DAergic neuron firing properties in Rin KD mice will answer 
this question. Taken as a whole, we know that DAergic Rin KD blocks PKC-
stimulated endocytosis, and impacts spontaneous excitatory transmission. These 
findings support our original hypothesis that blocking PKC-stimulated 
endocytosis will prevent maintenance of DA homeostasis, and will impact striatal 
neurotransmission.  
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Appendix VI 
Is PKC-stimulated DAT internalization required for  
locomotor sensitization to amphetamine? 
 
VI.A Introduction 
DAT dynamically traffics to and from the plasma membrane. Following PKC 
activation, DAT’s internalization significantly increases, resulting in less DAT at 
the plasma membrane. PKC-stimulated DAT internalization requires Rin activity 
and Ack1 dephosphorylation (Navaroli et al., 2011; Wu et al., 2015); however, 
the physiological impact of this mechanism remains unknown. Work previously 
described in this thesis correlates PKC-stimulated DAT internalization with 
cocaine induced hyperlocomotion and anxiety-related behavior (Fig IV-6, 7, 8). 
While these studies implicate PKC-stimulated DAT internalization in regulating 
psychostimulant-induced behavior and anxiety, it is unknown whether PKC-
stimulated DAT internalization is required for locomotor sensitization to 
psychostimulants. Repeated exposure to drugs of abuse results in augmented 
motor effects. This effect is known as locomotor sensitization (Steketee and 
Kalivas, 2011) 
VI.B Materials and Methods 
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Stereotaxic viral delivery. DAT-cre mice were bilaterally injected with AAV2 as 
described in Chapter IV. Virus was allowed to express for four weeks before 
behavioral analysis.  
 
Virus and cDNAs. Ack1-HA (WT and S445P) were cloned into pcDNA3.1+ as 
described previously (Wu et al., 2015). To flank the sequence with loxP and 
lox2722 sites, they were subcloned into pAAV-EF1a-DIO-hChR2(H134R)-EYFP 
(gift of Karl Deisseroth. Addgene plasmid #20298) using AscI and NheI. Next, 
double floxed WT and S445P Ack1 were cut using AccI and EcoRI and blunted. 
They were then ligated into pAAV-CB6, which was blunted following linearization 
with EcoRI. These viral vectors were packaged into AAV2 by the University of 
Massachusetts Medical School viral vector core.  
 
Locomotor sensitization to amphetamine. Mice received daily injections of 
2mg/kg AMPH for 10 days. On days 1, 4, 7, and 10, the mice first habituated to a 
locomotor activity chamber for 45 mins before receiving AMPH injection. Upon 
receiving the AMPH injection, their locomotor activity was recorded for 90 
minutes. The mice the underwent a wash out period for two weeks. On day 25, 
we recorded the mice’s locomotor activity and injected them with saline as done 
previously on days 1, 4, 7, and 10. Typically, this assay would have saline 
controls run in parallel; however, this data set does not include saline controls 
(Fig. VI-1).  
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To test the hypothesis that PKC-stimulated DAT internalization is required for 
induction of locomotor sensitization to AMPH, I overexpressed constitutively 
Ack1 in NAc of DAT-cre mice. We et al. previously demonstrated that Ack1 
dephosphorylation is required for PKC-stimulated DAT internalization, and 
overexpression of a constitutively Ack1 (S445P) blocks PKC-stimulated DAT 
internalization (Wu et al., 2015). I bilaterally injected AAV2 expressing double 
floxed, inverted WT-Ack1, S445P-Ack1, or GFP control into VTA of DAT-cre 
mice. Following four weeks of viral expression, I tested mice for LMS to AMPH.  
 
VI.C Results and Discussion 
DAT-cre mice were bilaterally injected in the VTA with AAV2 expressing double-
floxed, inverted WT- or S445P-Ack1 or GFP, the virus expressed for 4 weeks 
before starting locomotor sensitization experiments. Mice received daily AMPH 
injections (2mg/kg) for ten days, and we measured their locomotor activity on 
days 1, 4, 7, and 10 as described in Fig VI-1. On day 25, the mice received a 
challenge AMPH dose. GFP, WT-Ack1, and S445P-Ack1 overexpressing 
showed no differences in locomotor activity during LMS induction on days 1, 4, 7, 
and 10 (Fig. VI-2). However, on day 25, following the two week washout, WT-
Ack1 overexpressing mice showed significantly reduced locomotor activity during 
the last thirty minutes of the locomotor assay (Two way ANOVA, Ack1 effect, 
F(2,297)=47.45). This finding raises an interesting possibility regarding Ack1 
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expression in DA neurons during maintenance of LMS. WT-Ack1 overexpression 
was significantly reduced in the final 30 minutes following AMPH injection 
compared to GFP infected mice. Therefore, WT-Ack1 overexpression alone, 
alters AMPH-stimulated locomotor activity following a sanitization protocol. 
Therefore, the Ack1 overexpression serves as a baseline for interpreting Ack1 
mutant overexpression. Constitutively active S445P-Ack1 showed significantly 
increased locomotor activity in the final 30 minutes following AMPH injection 
compared to WT-Ack1. These data suggest that Ack1 activity increases 
locomotor AMPH-stimulated locomotor effects following LMS. AMPH is a potent, 
competitive DAT substrate. As discussed in Chapter I, AMPH affects dopamine 
transporter activity in multiple ways including blocking DA reuptake, increasing 
DAT endocytic rates, and inducing DA reverse transport via DAT. Our lab 
previously reported that Ack1 inactivation is required for PKC-stimulated 
internalization, and that a constitutively active Ack1 (S445P) blocks PKC-
stimulated DAT internalization. Further, this Ack1 mutant rescues a gain-of-
function trafficking dysregulated DAT mutant (R615C). The data presented here 
suggest that blocking regulated DAT trafficking through S445P-Ack1 
overexpression amplifies locomotor activity following sensitization. Taken 
together with the findings in Chapter IV, it suggests that PKC-stimulated DAT 
trafficking is required for responding to psychostimulant induced behavior. It 
should be noted that the studies presented within this appendix are preliminary. 
Animal groups are small (n=5-7), and there may be additional AMPH-dependent 
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behavioral effects that are not reported due to lack of power. Further, saline 
controls were not conducted as depicted in Fig. VI-1. While additional 
experiments are necessary to complete this data set, it provides rationale for 
investigating the role of regulated DAT endocytosis in the sensitizing effects of 
psychostimulants.  
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Figure VI-1 Locomotor sensitization to AMPH paradigm. Animals receive 
daily injections of either AMPH (2mg/kg) or saline (10mL/kg) for ten days. Their 
locomotor activity is recorded on days 1, 4, 7, and 10. Then the animals 
undergo a two week washout period, after which all animals receive a single 
2mg/kg AMPH injection. An animal is considered sensitized to AMPH if it 
moves significantly more during day 25 compared to day 1. 
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Figure VI-2. Ack1 overexpression amplifies locomotor sensitization to 
AMPH. DAT-cre mice bilaterally injected with AAV2 expressing GFP or double 
floxed, inverted WT-Ack1 or S445P-Ack1 in the VTA. Mice underwent LMS 
AMPH protocol as described in Materials and Methods. On Day 25, WT-Ack1 
mice demonstrate significantly reduced AMPH-stimulated locomotor activity 
compared to GFP and S445P-Ack1 (Two way ANOVA, Ack1 effect, 
F(2,297)=47.45, Dunnett’s multiple comparison test, #P<0.05, ##P<0.01, GFP 
significantly different from WT-Ack1. *P<0.05, **P<0.01, ***P<0.001, S445P-
Ack1 significantly different from WT-Ack1. 
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